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Abstract
Replicating oncolytic viruses (OVs) that are able to selectively destroy malignant cells are
emerging as clinically relevant cancer therapeutics. Along with direct tumor cell lysis, ac-
tivation of specific anti-tumor immune responses contributes to efficacy of virotherapy, al-
lowing to consider it for a type of cancer immunotherapy. Combinations with different
immunomodulation strategies have been shown to enhance the immunostimulatory effects
of OVs and contribute to increased therapeutic efficacy. Based on the hypothesis that cer-
tain immunomodulation types might more efficiently contribute to efficacy of virotherapy
in a given tumor type, this study compared efficacy of oncolytic measles vectors encod-
ing immunomodulators from different classes. Furthermore, to identify immune effector
mechanisms associated with successful therapeutic strategies, analysis of the tumor immune
environment was performed following treatment with the most promising vectors.
Measles Schwarz vaccine strain vectors (MeVac) encoding immunomodulators to tar-
get the main phases in establishment of an anti-tumor immune response were developed.
Therapeutic efficacy of the novel vectors was compared in a fully immunocompetent murine
colon adenocarcinoma model, MC38cea. MeVac vectors encoding an antibody against the
negative T cell regulator PD-L1 (anti-PD-L1) and a fusion protein of murine interleukin-12
(FmIL-12), respectively, were identified as the most promising in terms of increased survival
of animals. Importantly, MeVac encoding FmIL-12 was the most effective, ensuring complete
tumor remissions in 90% of the treated animals. After MeVac therapy, long-term survivors
rejected secondary tumor engraftments, indicating establishment of a systemic anti-tumor
immune response. Profiling of the tumor environment four days after the last treatment with
the anti-PD-L1 encoding vector revealed a slight benefit for cell mediated immune responses,
as observed by a slight upregulation of the effector cytokines IFN-γ and TNF-α as well as an
increase in the intratumoral T cell population. More pronounced modulation of the tumor
immune environment was observed following treatment with the FmIL-12 encoding vector.
One day after treatment with MeVac encoding FmIL-12 an increase of effector cytokines
IFN-γ and TNF-α was observed, suggesting activation of a cell mediated immune response.
Analysis of tumor infiltrating lymphocytes revealed an increase in the T cell population, a
massive decrease in the natural killer (NK) cell population and upregulation of an activation
marker on NK cells. These results indicated early activation of the immune effector cells
following treatment with MeVac encoding FmIL-12, which in case of the NK cells could be
associated with activation induced cell death. Furthermore, immune cell depletion experi-
ments revealed that the CD4+ T cells and NK cells do not importantly contribute to the
therapeutic efficacy of the MeVac encoding FmIL-12 in this model, but that the cytotoxic
CD8+ T cells are essential.
This study presents MeVac encoding FmIL-12 as an effective therapeutic for activation
of cell mediated anti-tumor immune responses. Furthermore, the MeVac vector is estab-
lished as a flexible platform for targeted local delivery of immunomodulators. The tumor
immune profiling data provide a basis for further rational vector modifications to develop
immunomodulation strategies tailored to the individual tumor immune environment.
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Zusammenfassung
Replizierende onkolytische Viren (OVs), die selektiv maligne Zellen zersto¨ren, gewinnen
zunehmend klinische Bedeutung in der Behandlung verschiedener Tumorerkrankungen. Neb-
en der unmittelbaren Lyse von Tumorzellen tra¨gt die Aktivierung einer Tumor-spezifischen
Immunantwort zur therapeutischen Effizienz bei. Entsprechend kann die Virotherapie als
eine Form der Tumor-Immuntherapie betrachtet werden. Kombinationen verschiedener Im-
munmodulatoren mit OVs ko¨nnen die immunstimulatorischen Effekte versta¨rken und zu
einer besseren Wirksamkeit beitragen. Ausgehend von der Hypothese, dass bestimmte Im-
munmodulatoren in bestimmten Tumorarten sta¨rker zur Wirksamkeit der onkolytischen
Virotherapie beitragen, wurden in dieser Arbeit onkolytische Masernviren verglichen, die
verschiedene Klassen von Immunmodulatoren kodieren. Um immunologische Mechanismen
zu identifizieren, die mit einer erfolgreichen Behandlung assoziiert sind, wurde nach App-
likation der vielversprechendsten Vektoren das immunologische Mikromilieu der Tumoren
analysiert. Vom Schwarz-Impfstamm abgeleitete Masern-Viren (MeVac) wurden entwickelt,
um die wesentlichen Phasen der Induktion einer Anti-Tumor-Immunantwort zu versta¨rken.
Die therapeutische Effizienz der neuen Vektoren wurde in einem immunkompetenten Maus-
modell des Kolonadenokarzinoms, MC38cea, verglichen. MeVac-Vektoren, welche einen An-
tiko¨rper gegen den T-Zell-inhibitorischen Faktor PD-L1 (anti-PD-L1) beziehungsweise ein
murines Interleukin-12-Fusionsprotein (FmIL-12) kodieren, wurden als die vielversprechend-
sten Vektoren identifiziert, basierend auf einem verla¨ngerten U¨berleben der behandelten
Tiere. Der MeVac-Vektor, der FmIL-12 kodiert, zeigte eine herausragende therapeutische
Effizienz: Die Behandlung mit MeVac FmIL-12 fu¨hrte bei 90% der behandelten Tiere zu
einer kompletten Remission. Nach MeVac-Behandlung stießen u¨berlebende Tiere sekunda¨r
implantierte Tumoren ab, ein Hinweis auf die Induktion einer systemischen Anti-Tumor-
Immunantwort. Vier Tage nach Behandlung mit den anti-PD-L1 kodierenden Vektoren wies
das Tumor-Immunprofil auf eine leicht versta¨rkte zellula¨re Immunantwort hin, erkennbar
an einer Hochregulation der Effektor-Zytokine IFN-γ und TNF-α sowie einer Zunahme der
intratumoralen T-Zell-Population. Nach Behandlung mit dem FmIL-12 kodierenden Vek-
tor wurde eine durchgreifendere A¨nderung des Tumormilieus beobachtet. Einen Tag nach
der Behandlung mit MeVac FmIL-12 wurde ein Anstieg der Effektor-Zytokine IFN-γ und
TNF-α gemessen, ein Hinweis auf eine zellula¨re Immunantwort. Die Analyse der Tumor-
infiltrierenden Lymphozyten zeigte eine Zunahme der T-Zell-Population, eine drastisch ver-
ringerte Anzahl der natu¨rlichen Killer (NK)-Zellen sowie Hochregulation eines Aktivierungs-
Markers auf den NK-Zellen. Diese Ergebnisse weisen auf eine fru¨he Aktivierung dieser
Immun-Effektorzellen nach Behandlung mit MeVac FmIL-12 hin, wobei dies im Fall der
NK-Zellen mit einem Aktivierungs-induzierten Zelltod einhergehen ko¨nnte. Desweiteren
zeigte Depletions-Experimente, dass CD4+ T-Zellen und NK-Zellen nicht wesentlich zur
therapeutischen Effizienz von MeVac FmIL-12 in diesem Tumormodell beitragen, wa¨hrend
zytotoxische CD8+ T-Zellen essentiell sind. Diese Arbeit pra¨sentiert MeVac FmIL-12 als
effektive Therapie zur Aktivierung zellula¨rer Anti-Tumor-Immunantworten. Daru¨ber hinaus
wurden MeVac-Vektoren als flexible Plattform zur gezielten, lokalen Darreichung von Im-
munmodulatoren etabliert. Die Tumor-Immunprofil-Daten bilden die Basis fu¨r eine rationale
Vektor-Modifikation zur Entwicklung immunmodulatorischer Therapie-Ansa¨tze, die auf das
individuelle Tumormilieu zugeschnitten sind.
V

Kopsavilkums
Replice¯ties spe¯j¯ıgi onkol¯ıtiskie v¯ırusi (OV), kas specifiski izn¯ıcina l¸aundab¯ıgas sˇu¯nas, ien¸em
vietu starp jauniem, kl¯ıniski noz¯ımı¯giem ve¯zˇa terapijas veidiem. Viroterapijas efektivita¯te
ir balst¯ıta ne tikai uz tiesˇu ve¯zˇa sˇu¯nu izn¯ıcina¯sˇanu, bet ar¯ı uz specifiskas pretve¯zˇa imu¯na¯s
atbildes aktiva¯ciju, kas l¸auj to uzskat¯ıt par audze¯ju imu¯nterapijas veidu. Pe¯t¯ıjumi ra¯da,
ka dazˇa¯du veidu imu¯nmodulatori spe¯j paaugstina¯t OV imu¯nstimulatora¯s ı¯pasˇ¯ıbas, uzlabojot
terapijas efektivita¯ti. Balstoties uz hipote¯zi, ka konkre¯ti imu¯nmodula¯cijas veidi ir vaira¯k
pieme¯roti viroterapijas efektivita¯tes uzlabosˇanai konkre¯ta¯ audze¯ja veida¯, sˇaja¯ pe¯t¯ıjuma¯ tika
sal¯ıdzina¯ti onkol¯ıtiska masalu v¯ırusa vektori, kuros iekode¯ti imu¯nomodulatori no dazˇa¯da¯m
klase¯m. Turkla¯t, lai noteiktu imu¯na¯s siste¯mas efektoros meha¯nismus, kas saist¯ıti ar veiksmı¯ga¯-
kaja¯m terapijas strate¯gˇija¯m, tika veikta audze¯ja imu¯no profilu anal¯ıze pe¯c terapijas ar daudz-
solosˇa¯kajiem vektoriem.
Tika izveidoti masalu Schwarz vakc¯ınas v¯ırusa (MeVac) vektori, kuros iekode¯ti imu¯nmo-
dulatori, kas atbalsta dazˇa¯das pretve¯zˇa imu¯na¯s atbildes veidosˇana¯s fa¯zes. Jauno vektoru te-
rapeitiska¯ efektivita¯te tika sal¯ıdzina¯ta imu¯nkompetenta¯ pel¸u kolorekta¯la¯s adenokarcinomas
model¯ı MC38cea. Ka¯ daudzsolosˇa¯kie tika noteikti vektori, kuri spe¯ja palielina¯t dz¯ıvnieku
izdz¯ıvot¯ıbu. Tie bija vektori, kuros iekode¯ta antiviela pret T sˇu¯nu inhibitoro faktoru PD-L1
(MeVac anti-PD-L1), ka¯ ar¯ı pel¸u interleik¯ına-12 prote¯ına veids (MeVac FmIL-12). Noz¯ımı¯gi,
ka MeVac FmIL-12 para¯d¯ıja augsta¯ko efektivita¯ti, nodrosˇinot piln¯ıgu audze¯ju remisiju 90%
no terapiju san¸e¯musˇajiem dz¯ıvniekiem. Iza¯rste¯tie dz¯ıvnieki atgru¯da sekunda¯ru audze¯ju
veidosˇanos, nora¯dot uz siste¯miskas pretve¯zˇa imu¯na¯s atbildes kla¯tbu¯tni. Audze¯ja imu¯na¯s
vides anal¯ıze cˇetras dienas pe¯c pe¯de¯ja¯s anti-PD-L1 kode¯josˇa¯ vektora devas atkla¯ja nedaudz
paaugstina¯tu efektoro citok¯ınu IFN-γ un TNF-α koncentra¯ciju un nelielu T sˇu¯nu popula¯cijas
pieaugumu, nora¯dot uz vieglu sˇu¯nu medie¯ta¯s imu¯natbildes pastiprina¯sˇanos. Pe¯c terapijas ar
MeVac FmIL-12 tika nove¯rota izteikta¯ka audze¯ja imu¯na¯s vides modula¯cija. Vienu dienu
pe¯c pe¯de¯ja¯s MeVac FmIL-12 devas tika nove¯rots efektoro citok¯ınu IFN-γ un TNF-α kon-
centra¯cijas pieaugums, nora¯dot uz sˇu¯nu medie¯ta¯s imu¯natbildes aktiva¯ciju. Analize¯jot gal-
vena¯s audze¯jos infiltre¯jusˇos limfoc¯ıtu subpopula¯cijas, tika atkla¯ts T sˇu¯nu popula¯cijas pieau-
gums, liels dab¯ıgo gale¯ta¯jˇsu¯nu (NK) popula¯cijas samazina¯jums, ka¯ ar¯ı aktiva¯cijas mark¸iera
ekspresijas pieaugums NK sˇu¯nu popula¯cija¯. Sˇie rezulta¯ti nora¯da uz agr¯ınu imu¯no efektoru
aktiva¯ciju pe¯c MeVac FmIL-12 terapijas, kas attiec¯ıba¯ uz NK sˇu¯na¯m vare¯tu bu¯t saist¯ıta
ar aktiva¯cijas ierosina¯tu sˇu¯nu na¯vi. Ta¯la¯ki imu¯no sˇu¯nu popula¯ciju izsle¯gsˇanas eksperimenti
para¯d¯ıja, ka sˇaja¯ model¯ı CD4+ T sˇu¯na¯m un NK sˇu¯na¯m nav noz¯ımı¯gas ietekmes uz MeVac
FmIL-12 terapijas efektivita¯ti, bet ka CD8+ T sˇu¯nu kla¯tbu¯tne ir ı¯pasˇi bu¯tiska.
Sˇis pe¯t¯ıjums atkla¯j MeVac FmIL-12 ka¯ efekt¯ıvu terapijas veidu sˇu¯nu medie¯ta¯s pretve¯zˇa
imu¯natbildes aktive¯sˇanai un demonstre¯ MeVac vektora siste¯mu ka¯ elast¯ıgu platformu me¯rk¸e¯-
tai, loka¯lai imu¯nmodulatoru piega¯dei. Turkla¯t iegu¯tie audze¯ju imu¯na¯s profile¯sˇanas rezulta¯ti
veido pamatu turpma¯kai raciona¯lai vektoru izstra¯dei, lai att¯ıst¯ıtu imu¯nmodula¯cijas strate¯gˇi-
jas, kas ir individua¯li pieme¯rotas konkre¯ta¯ audze¯ja imu¯najai videi.
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1 Introduction
1.1 The Immune System — a Sentinel of Homeostasis
The existence of any developed multicellular organism relies on its ability to maintain a status
of relative stability, homeostasis, despite constant encounters with environmental threats.
Immune system is a set of complex defense mechanisms that provides an organism with
a protection against exogenous and endogenous threats, including foreign and potentially
harmful microorganisms, as well as altered and dying cells of the organism itself. The immune
system of a human body has evolved into an extremely powerful defense system that involves
mechanisms to respond to a given threat in a specific, adaptive manner and even form an
immunological memory1. The power of an activated immune response is immense, ensuring
a rapid and effective clearance of an invader, and is therefore constantly tightly regulated to
avoid harm for normal tissues in the body and allow restoration of the steady state2. Thus,
failures and errors in immune responses or their regulation disrupt the homeostatic balance
in the organism and can result in dangerous conditions, including persistent bacterial and
viral infections3, autoimmune responses4 and also development of cancer5.
1.2 Cancer — Evasion from Immune Surveillance
The idea that the immune system plays a role in protection against development of cancer
arose in the middle of the 20th century and became known as the cancer immmunosurveil-
lance hypothesis6. However, convincing proof for this concept was delivered not until decades
later, when appropriate mouse models with disrupted components of the immune system be-
came available. For instance, mice which lack the recombination activating gene 2 (RAG-2)
and are therefore unable to generate mature lymphocytes, have been shown to develop higher
rates of chemically induced as well as spontaneously arising tumors in comparison to wild-
type animals7. Later on, a dual role of the immune system in the development of cancer was
recognized and the immunosurveillance hypothesis was followingly expanded to the theory of
“cancer immunoediting”8. The cancer immunoediting theory proposes three stages during
the development of cancer in the presence of a functional immune system, also known as
the “three E’s” — “elimination”, “equilibrium” and “escape”8. During the “elimination”
phase the immune system is able to destroy transformed cells, hindering establishment of
a pre-malignant lesion. In “equilibrium” the immune response acts as a selective pressure,
promoting development of less immunogenic tumor cells. In the “escape” phase variants
of non-immunogenic tumor cells evade immune recognition and establish an aggressively
growing tumor8. A great amount of data supporting the cancer immunoediting theory has
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been obtained, establishing the concept of immunoediting as a paradigm in current cancer
research9.
1.3 Cancer Immunotherapy
1.3.1 Classification and Principles of Immunotherapies
The evidence for the crucial role of the immune system in the development of cancer formed
the basis for investigation of therapeutic interventions in anti-tumor immune response mech-
anisms. Cancer immunotherapy is the term used for therapeutic strategies that either involve
the use of immunological agents with intrinsic anti-tumor properties — passive immunother-
apy — or that aim at modulating and activating anti-tumor immune responses in the body
— active immunotherapy10. A classical example for passive immunotherapy is the use of
monoclonal antibodies (mAbs) that, for instance, block receptors providing survival sig-
nals for malignant cells11 or bind to and activate cell-death inducing receptors on tumor
cells12. Another intensely investigated strategy of passive immunotherapy is adoptive cell
transfer which aims at introducing a cell population that is enriched in potentially tumor
reactive immune effector cells into the body13. Although passive immunotherapy strategies,
mainly different anti-tumor mAbs, have demonstrated efficacy in certain tumor types and
have successfully entered routine clinical use14, active immunotherapy approaches offer more
possibilities to take advantage of the power of the immune system.
Active immunotherapeutic strategies can be classified as unspecific — aiming at im-
mune activation in general, and specific — aiming at inducing a response against defined
antigens15. However, such stringent classification is difficult as with both approaches, specific
and unspecific, ultimately an adaptive immune response, ergo, specific response against the
individual tumor, can be elicited. Stimulation of the innate immune response with agonists
of the pattern recognition receptors (PRRs) can be considered an example for an unspecific
active immunotherapy. PRRs are proteins that recognize various bacterial and viral products
that are collectively described as “danger signals”16. Activation of PRR signaling results
in an inflammatory response that can provide unspecific by-stander anti-tumoral effects, as
well as set the stage for activation of a specific adaptive anti-tumor immune response17.
Several PRR agonists which mostly include different bacteria-derived products or synthetic
molecules mimicking such products have been approved for treatment of cancer either as
standalone therapies or adjuvants to other immunotherapeutics17. One of the best-known
PRR agonists is an attenuated variant of Mycobacterium bovis, Bacillus Calmette-Gue´rin,
which is among the oldest cancer immunotherapies currently in use and is a therapy op-
tion for superficial bladder cancer since the middle of the 1980s18. In contrast, therapeutic
cancer vaccination with defined tumor-associated antigens (TAAs) represents a specific ac-
tive immunotherapy. The currently investigated vaccination approaches represent a wide
spectrum of methods, including use of cell-based strategies, whole proteins or peptides, of
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the specific TAAs, as well as gene therapy approaches for administration of DNA, RNA
or viral vectors encoding the respective TAA peptides along with some immunostimulatory
adjuvant19. If successful, these vaccination methods are able to provide TAAs to antigen
presenting cells (APCs) which are simultaneously activated by an adjuvant and can there-
fore present the peptides to effector cells to prime a TAA-specific immune response19. The
only therapeutic cancer vaccine that has been approved for clinical application up to now is
sipuleucel-T (trade name Provenge) for treatment of castration-resistant prostate cancer20.
Sipuleucel-T represents a personalized immunotherapeutic approach as it contains ex vivo
expanded APCs from the individual patient. After activation with a fusion protein con-
sisting of prostatic acid phosphatase and granulocyte macrophage colony-stimulating factor
the APCs are reinfused into the patient20. Although the approach seemed promising and
could provide survival benefit for patients20, this sophisticated procedure did not enter rou-
tine clinical application21. Active immunotherapeutic approaches that currently are more
clinically relevant will be discussed in the next sections. These include immunostimulatory
cytokine therapies and antibodies blocking the “immune checkpoints”.
1.3.2 Cytokine Therapies
Cytokines are a family of secreted or membrane-bound proteins that coordinate intercellular
communication in most physiological processes, including inflammation, cell differentiation,
chemotaxis, immune responses and cell death22. As intercellular messengers, cytokines have
a central role in the development of immune responses, including immune cell activation,
suppression, differentiation and migration23. Given their powerful immunoregulatory prop-
erties, the role of cytokines in the development of cancer and their potential for stimulating
anti-tumor immune responses have been investigated for a long time24. The first cytokine
to enter routine clinical use as a single agent for cancer therapy was interleukin-2 (IL-2).
IL-2 is a powerful T cell growth and activation factor, which was approved for treatment of
renal cell carcinoma (RCC) and melanoma in the United States of America (U.S.) in 1992
and 1998, respectively25. However, the overall benefit of IL-2 therapy for patients has been
modest. Although complete tumor regressions that can last for years have been achieved in
individual patients, a durable response after a high dose IL-2 therapy in both melanoma and
RCC is observed in 5 – 7% of cases26. The importance of IL-2 therapy is therefore more the
proof of concept for the potential of an immunostimulatory cytokine in treatment of cancer
and encouragement for further studies with other candidates.
IL-12 is a cytokine that, in the early 1990’s, was initially met with a great excitment for
its robust anti-tumor properties in different animal tumor models. In physiological conditions
IL-12 is mainly produced by activated APCs and induces a cell-mediated immune response
through activation of cytotoxic CD8+ T cells and natural killer (NK) cells and determines dif-
ferentiation of CD4+ T cells towards a T helper type 1 (Th1) phenotype
27. Accordingly, the
anti-tumor activity of the IL-12 in murine tumor models has been demonstrated to depend
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on activation of tumor-infiltrating immune cells28 and on additional anti-angiogenic effects
exerted through induction of the interferon-γ-inducible protein 10 (IP-10)29, 30. However,
up to now, attempts to translate IL-12 into clinical application have not been particularly
successful. Despite that, the history of clinical trials with IL-12 exemplifies gain of clinical
experience with cytokine therapies that is used for generation of promising sophisticated
cytokine-based immunotherapy approaches currently explored in pre-clinical and clinical
settings.
In most of the early clinical trials IL-12 treatment failed to demonstrate meaningful effi-
cacy and was associated with severe toxicities31, 32. Nevertheless, these studies also revealed
the crucial role of the dosing schedule, as pre-treatment with IL-12 was decisive to reduce
IL-12-induced IFN-γ production upon further consecutive IL-12 injections and to minimize
the adverse side effects32. Reduction of the treatment-associated toxicities and enhance-
ment of the therapeutic efficacy was necessary if the IL-12 was to remain a candidate for
clinical application, therefore clearly calling for more targeted application strategies than
the intravenous (i.v.)31, subcutaneous (s.c.)33 or intraperitoneal (i.p.)34 administration of
a recombinant IL-12 used in most of the early studies. Targeted IL-12 delivery approaches
that are currently being tested in clinical studies include intratumoral (i.t.) administration of
IL-12 encoding DNA plasmid via electroporation (NCT01502293∗, NCT01579318), i.t. injec-
tions with an adenovirus (AdV) vector encoding IL-12 (NCT02555397, NCT02026271) and
administration of an IL-12 conjugated with a tumor-antigen-specific mAb (NCT01417546).
These approaches have been successful at reducing the treatment-related toxicities. Also,
at least for the gene therapy approaches with electroporation and AdV, the therapeutic ef-
ficacy has been encouraging, demonstrating the possibility to induce sytemic responses in
non-injected lesions after local application35, 36.
There are many more cytokines that have been shown to stimulate anti-tumor immune
responses and are investigated pre-clinically or have already entered clinical studies. To
name just a few — the T and NK cell activation factors IL-15 (NCT01021059), IL-1837
and interferon-γ (IFN-γ)38, the APC maturation factor GM-CSF (granulocyte macrophage
colony-stimulating factor)39 and the chemotactic cytokines for recruitment of activated T
and NK cells, IP-10 and MIG (monokine induced by IFN-γ)40. The number of studies in-
vestigating potential therapeutic benefits of cytokines as cancer therapeutics has been and
continues to be tremendous. Yet, up to now, aside from IL-2, only two other cytokines have
been approved for cancer treatment as monotherapies. Both of these are closely related
molecules from the family of IFN-α which possess broad immunomodulatory properties, in-
cluding activation of cytotoxic T and NK cells, induction of dendritic cell (DC) maturation
and enhancement of tumor cell recognition by DCs and also have cytostatic and apoptotic
effects in tumor cells and tumor-supporting cells41. The current, relatively modest output in
clinically relevant therapeutics from the vast amount of the studied cytokines, as well limited
∗Here and further, “NCT” followed by an eight digit number is a registry number for a clinical trial on
ClinicalTrials.gov. https://clinicaltrials.gov/
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benefit from the ones already approved, is mainly associated with similar problems as those
described in the case of IL-12, namely much lower therapeutic efficacy than expected based on
pre-clinical studies and treatment-associated toxicities42. Therefore, identification of appro-
priate dosing schedules, administration routes and vehicles as well as biomarkers predicting
response to the therapy are the problems that will need to be addressed to guarantee success
of clinical translation of immunomodulatory cytokines for cancer treatment. Furthermore,
it is possible that with increasing understanding of the individual immunomodulatory prop-
erties, the activities of cytokines will be best taken advantage of in rational combinations
with one another, as well as with other immunotherapeutic strategies.
1.3.3 Immune Checkpoint Blockade
The power of an activated T cell response is so potent that, if uncontrolled, it can mani-
fest in autoimmune disorders43. Therefore, during all phases of the T cell-mediated immune
responses, the extent and duration of T cell activity is tightly regulated by a balance of stim-
ulatory and inhibitory signals that are collectively named “immune checkpoints”44. Many
human tumor types take advantage of this immunoregulatory system by dysregulating the
balance of the stimuli to favor the inhibitory signals and, thus, evade recognition and destruc-
tion by immune cells45. Disruption of this inhibitory signaling represents a novel strategy
in cancer immunotherapy that is known as “immune checkpoint” blockade44. In contrast
to most other immunotherapeutic strategies that aim at directly stimulating anti-tumor im-
mune response, the checkpoint blockade aims at indirectly releasing the power of the immune
response already in place by arresting the inhibitory signaling44.
Antibodies that aim at modulating the so-called “second signal” for T cell activation
are currently clinically the most relevant checkpoint blockade therapeutics. The “two sig-
nal” model (a simplified model for T cell activation) proposes that activation of a T cell
occurs when the T cell receptor (TCR) recognizes the respective antigen in the context of
major histocompatibility complex and receives a second, co-stimulatory signal through a
co-receptor46. A myriad of stimulatory and inhibitory co-receptors is actually present on the
surface of a T cell to allow context-dependent modulation of the fate of a T cell after antigen
recognition47. Antibodies that block signaling through two inhibitory T cell co-receptors, cy-
totoxic T-lymphocyte-associated protein 4 (CTLA-4 or CD152) and programmed cell death
protein 1 (PD-1 or CD279), have currently entered the clinic as cancer therapeutics. CTLA-4
and PD-1 both belong to the family of CD28 receptors48. CD28 itself is one of the best-
characterized stimulatory T cell co-receptors, which provides an activation signal to the TCR
through interaction with its ligands CD80 and CD86 that are expressed on the surface of
APCs48. CTLA-4 also binds CD80 and CD86 and therefore mainly opposes the stimula-
tory signals provided by CD2848. Expression of CTLA-4 is upregulated on T cells shortly
after initial antigen recognition, but it is constitutively expressed on the immunosuppres-
sive T regulatory cell (Treg) population and is crucial for the immunosuppressive capacity
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of Tregs
49, 50. Mice with a Ctla-4 knockout have a lethal phenotype due to severe systemic
autoimmune responses, demonstrating the central role of CTLA-4 in self-tolerance51. The
clinical relevance for CTLA-4 blockade was initially doubted due to the lethality of Ctla-4
knockout mice, but a partial CTLA-4 blockade with an antibody in murine tumor models
later demonstrated anti-tumor efficacy without significant toxicities52. A series of clinical
studies followed to demonstrate safety of CTLA-4 blockade in humans, until a fully human-
ized antibody against CTLA-4, ipilimumab, was finally approved for treatment of metastatic
melanoma in 2011. The approval was based on a randomized, three-arm phase III clinical
study which showed survival benefit for patients treated with either ipilimumab alone or in
combination with a peptide vaccine for the melanoma-specific antigen gp100 over the gp100
vaccine alone53.
In contrast to CTLA-4, PD-1 is involved in regulation of self-tolerance in peripheral
tissues. PD-1 expression is upregulated on activated T cells54, it is constitutively expressed
in conditions of persistent TCR activation and it is associated with an exhausted T cell
phenotype55. There are two PD-1 ligands, programmed death-ligand 1 and 2 (PD-L1 or
CD274 and PD-L2 or CD273), that upon engagement with PD-1 negatively regulate T cell
activation56, 57. The regulatory activities of PD-1 are much broader than those of CTLA-4,
as aside from T cells it is upregulated also on activated B and NK cells54, 58. The fact that
PD-1 can also bind CD80 further adds to the complexity of its signaling59. Thus, it is ad-
vantegous for tumor cells to upregulate expression of the PD-1 ligands as an immune evasion
mechanism. Although both, PD-L1 and PD-L2, can be upregulated in different tumor types,
PD-L1 expression is more relevant60, 61, 62. PD-L1 expression on tumor cells can be induced
by activated immune effector cells, mainly as a response to IFN-γ secretion63, 64. Alterna-
tively, PD-L1 expression can be also induced by constitutive oncogenic signaling65, 66. The
importance of PD-1 signaling in cancer immune evasion is further underlined by evidence
for correlation of PD-L1 expression with poor prognosis in different types of human can-
cer67, 68, 69. PD-1/PD-L1 blockade has therefore emerged as a very promising therapeutic
option in different tumor entities with both PD-1 and PD-L1 blocking antibodies. One of
the key studies supporting the clinical approval of PD-1 blockade was a randomised, dose
comparison cohort of a phase I study in heavily pre-treated metastatic melanoma patients
refractory to ipilimumab, in which anti-PD-1 at 2 mg/kg and 10 mg/kg demonstrated 26%
overall response rates70. Soon after publication of these results, two PD-1 blocking antibod-
ies, pembrolizumab and nivolumab, were granted an accelerated approval for treatment of
metastatic melanoma71. Since then, PD-1 blockade has also been approved for treatment of
non-small cell lung cancer (NSCLC), RCC, classical Hodgkin lymphoma as well as head and
neck squamous cell carcinoma71. Aside from the PD-1 targeting antibodies, also the first
PD-L1 blocking antibody, atezolimumab, was recently approved for treatment of urothelial
carcinoma and NSCLC71. Although treatment-associated-toxicities such as dermatitis, hep-
atitis, colitis and pneumonitis are observed with PD-1/PD-L1 blockade, these events are
less frequent than in the case of CTLA-4 blockade72. These differences are observed due
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to the distinct mechanisms of action of both approaches. As PD-1/PD-L1 is involved in
the regulation of peripheral tolerance, immune activation is more targeted than in the case
of anti-CTLA-4. Furthermore, besides a more favorable safety profile, in a direct head-to-
head comparison with ipilimumab in advanced melanoma patients, PD-1 blockade has been
also more effective in terms of higher response rates, extended progression free and overall
survival72.
Despite the rapid advancement of checkpoint blockade antibodies in the clinic, many
types of cancer remain unresponsive for this type of therapy and in the responsive tumor
types only a fraction of patients can experience the benefits. Therefore the main challenges
in further development of checkpoint blockade strategies will include identification of reliable
biomarkers to predict response to the therapy and allow selection of patients most likely to
benefit from the treatment73, as well as development of rational combination strategies to
increase the therapeutic efficacy74.
1.4 Oncolytic Viruses as a Type of Immunotherapy
1.4.1 Principles of virotherapy
Oncolytic viruses (OVs) are a class of cancer therapeutics that are able to selectively infect
and replicate in malignant cells while sparing normal tissues75. This property is referred to as
oncotropism76. The field of OV research has seen a renewed interest and major advancements
during the last two decades, but the idea of using viruses for cancer therapy can be considered
to be more than a century old, stemming from multiple case reports of tumor regressions after
acquisition of infectious diseases77, 78. Many wild-type as well as attenuated laboratory strain
viruses, for instance AdV79, herpesviruses (HSV)80, parvoviruses81, reoviruses82, measles
vaccine strain viruses (MV)83, Newcastle disease virus (NDV)84, vaccinia virus (VV)85 and
vesicular stomatitis virus (VSV)86, have been shown to possess oncotropic properties.
After recognition of a virus, a normal cell strives to induce an antiviral state, shutting
down the machinery of protein synthesis and inducing apoptosis to limit the replication and
spread of the virus87. However, during the process of malignant transformation a cell under-
goes major changes in its biology that frequently involve sacrifice of natural innate immune
response mechanisms to avoid induction of apoptosis and to sustain growth advantage for the
cancerous cells5. Mutations in pathways that prevent apoptosis, induce protein synthesis or
interfere with innate immune signaling have all been shown to provide replication advantages
for different OVs88. Thus, an enhanced and unrestricted replication of a virus is supported in
cancer cells, ultimately leading to destruction of the infected cells. Importantly, in addition
to direct tumor cell lysis through virus infection, bystander effects such as tumor vasculature
shutdown89, 90, 91 or activation of an anti-tumor immune response92 can greatly contribute
to the therapeutic effect of an OV. In particular, the immunostimulatory properties of OVs
have been recognized critical for therapeutic efficacy, allowing to consider virotherapy as a
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type of cancer immunotherapy76. Investigation of the immunostimulatory properties of OVs
to enhance the virus-induced anti-tumor immune response and development of combination
strategies with other cancer immunotherapies are currently among the major topics in the
field of virotherapy93.
1.4.2 Immunomodulatory Properties of Virotherapy
During their development, most human tumors establish an immunosuppressive environ-
ment to avoid recognition and destruction by the immune system94. In contrast, viruses,
through activation of PRRs, act as very potent stimulators of innate immune responses95.
Administration of a virus into the tumor therefore brings an immunostimulatory signal into
an otherwise mostly immunologically neglected environment. Destruction of the infected
tumor cells further releases TAAs under the established immunostimulatory conditions. The
TAAs can be taken up by activated APCs that ensure cross-presentation of the antigens to
T cells and prime a tumor-specific adaptive immune response96. Activation of a systemic
anti-tumor immune response after treatment with different OVs has been demonstrated in
many pre-clinical97, 98, 92 as well as in clinical studies99, 100. Therefore, virotherapy includes
aspects of PRR agonist immunotherapies and therapeutic vaccination approaches and can
therefore be classified as an active, unspecific type of cancer immunotherapy.
1.4.3 Combinations with Other Immunotherapies
Given the potent immunostimulatory properties of OVs, combinations with other cancer im-
munotherapy strategies are being explored to synergistically enhance the therapeutic poten-
tial. The strategies investigated for combination with OVs include approaches from generally
all classes of currently available immunotherapeutics – immunomodulatory cytokines101, 102,
checkpoint blockade antibodies103, 104, bispecific T cell engagers105, T cell costimulatory lig-
ands106, adoptive cell transfer107, 108 and vaccination approaches with oncolytic vectors en-
coding TAAs109. An approach that has received a particularly great attention has been
engineering of oncolytic vectors encoding different immunostimulatory molecules93. The
rationale for this strategy is on the one hand to support establishment of an anti-tumor
immune response and on the other hand a local expression of the encoded immunomodula-
tor only in the infected tumor cells to avoid toxicities that are frequently associated with
systemic administration of immunotherapeutics110. Immunomodulators from many classes,
including cytokines, T cell co-stimulatory molecules, immune checkpoint blockade antibodies
and bispecific T cell engagers, have been engineered for expression from different oncolytic
vectors (Table 1.1). In almost all of the studies listed in Table 1.1 the therapeutic efficacy
of the OV could be improved by combination with the chosen immunomodulators. Notably,
thus far GM-CSF has been used in combination with the most of the known OVs. GM-CSF
is a factor mainly known for its ability to promote expansion and maturation of dendritic
cells and is therefore able to support the TAA uptake and presentation phase111. Impor-
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tantly, a herpes simplex vector encoding GM-CSF known also as talimogene laherparepvec
(T-VEC)100 was approved for treatment of metastatic melanoma by the FDA in 2015.
Table 1.1: Oncolytic viruses encoding immunomodulators. List of immunomodulators
inserted into genomes of oncolytic viruses for local expression from infected cells. Main
functional properties of the respective immunomodulator are given under mode of action.
AdV — adenovirus; HSV — herpesvirus; MV — measles virus; NDV — Newcastle disease
virus; VV — vaccinia virus,; VSV — vesicular stomatitis virus; BiTE — bispecific T cell
engager. Adapted from Lichty et al.93
Immunmodulators Vectors Mode of action
GM-CSF AdV112; HSV-1113;
MV114; NDV115;
VV116; VSV117
Enhanced maturation of antigen-
presenting cells
IL-2 HSV118; NDV115 Activation of T cells
IL-4 AdV119; HSV120 Activation of T and NK cells
IL-12 AdV121; HSV122;
VSV123
Activation of T and NK cells
IL-15 HSV124;
Influenza A125;
VSV126
Activation of T and NK cells
IL-18 AdV127; HSV122 Activation of T and NK cells
TNF-α NDV115 Activation of T and NK cells
IFN-γ AdV128; NDV115;
VSV129
Activation of T and NK cells
Type I IFNs AdV130; MV131;
VV132; VSV133
Activation of antigen presenting cells and
T cells
CCL3 AdV134
Recruitment of polymorphonuclear
leukocytes
CCL5 AdV102 Recruitment of T cells
CCL21 HSV120 Recruitment of T cells
FLT3L AdV134; VSV135 Recruitment of T cells
CD80 AdV121; HSV122 T cell costimulation
CD137 (41BBL) AdV136; VV137 T cell costimulation
CD154 (CD40L) HSV120; VSV138 T cell costimulation
Anti-CTLA-4 MV104 Blockade of negative T cell signaling
Anti-PD-L1 MV104 Blockade of negative T cell signaling
BiTE VV105
Activation of target antigen specific
T cells
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1.5 Measles Virus
1.5.1 Biology of Measles Virus
Measles virus (MeV)∗ is a spherical virus with a non-segmented, single stranded, negative
sense RNA genome belonging to the Morbillivirus genus in the Paramyxoviridae family139.
The MeV viral particles are pleomorphic with a size in range of 100 – 300 nm139. The
genome of MeV is 15894 nt long and contains six genes140 which encode six structural141
and two non-structural proteins142, 143 (Figure 1.1). The genome starts and ends with non-
coding leader and trailer sequences containing transcription regulatory elements144. The
virus genome is encapsidated into a flexible, helical nucleocapsid formed by multiple copies
of MeV nucleoprotein (N), each binding exactly six nucleotides of the RNA genome145. The
nucleocapsid interacts with virus polymerase complexes formed by the large protein (L) and
the polymerase cofactor, phosphoprotein (P)146. The fusion protein (F), hemagglutinin (H)
and matrix protein (M) together with the lipid membrane from the host cell form the viral
envelope139. The F and H proteins on the surface of virus envelope exist in hetero-oligomeric
complexes147 and mediate fusion with the host cell membrane and interaction with the MeV
specific cellular receptors, respectively139. The F and H complexes are also transported to the
surface of an infected cell and cause fusion with the neighboring cell membranes, creating
large multinucleated cellular aggregates, syncytia139. The two non-structural proteins V
and C, which are alternatively translated from the P open reading frame (ORF) in infected
cells, are involved in the regulation of the host response against measles infection148, 149, 150.
Non-coding regions containing gene-end and gene-start transcription regulatory sequences,
which guide transcription termination and reinitiation as well as polyadenylation of mRNA,
are located between all ORFs of the viral proteins144. As the transcription reinitiation before
each ORF is not perfect, a transcription gradient exists in the MeV genome with the genes
encoded closer to the MeV trailer being transcribed less efficiently than those closer to the
MeV leader151. All replication stages of MeV take place in the cytoplasm of the host cell139.
Wild-type MeV is a human-restricted pathogen152 and mainly uses two receptors for
entry into human cells — poliovirus receptor-like 4 (PVRL-4) or nectin-4153, 154 and signaling
lymphocyte activation molecule (SLAM) or CD150155. The expression patterns of these pro-
teins determine the course of MeV infection in the host. MeV is transmitted via respiratory
droplets from an infected person which enter the upper airways of a new host, where the virus
infects airway epithelial cells via PVRL-4156, 153. Further, MeV infection spreads to alveolar
macrophages and DCs which transport MeV to local lymphatic tissue where SLAM-positive
lymphoid cells, including monocytes, T and B cells, are infected157, 158. Subsequently, MeV
is disseminated throughout the organism and can replicate in many organs including lungs,
skin, thymus, spleen, liver and stomach159. Clinical manifestation of measles starts after a
∗The abbreviation MeV is used for the wild-type measles virus, MV is used for measles vaccine strain
viruses and MeVac is used for measles Schwarz vaccine strain viruses.
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Figure 1.1: Schematic structure of the measles virus (MeV) virion and genome.
The viral envelope of MeV consists of the plasma membrane from the host cell and is
inlined by the measles matrix protein (M). The hemagglutinin (H) and fusion (F) proteins
decorate the outer surface of the viral envelope. The MeV genome is a single stranded,
negative sense RNA and is tightly packed in a nucleoprotein (N), viral polymerase (L)
and a polymerase cofactor, phosphoprotein (P). The P open reading frame additionally
codes for two alternatively transcribed non-structural proteins V and C. The MeV genome
starts and ends with non-coding regions, leader (ld) and trailer (tr), respectively, containing
transcription regulatory elements.
10 – 14 day incubation period and includes fever, cough, coryza and conjunctivitis, which is
followed by appearance of the characteristic maculopapular rash139. The onset of the rash
coincides with active adaptive immune responses, including the presence of measles-specific
antibodies and activated T cells which clear viremia within a few days160. After clearance
of the virus, measles-specific antibodies remain in the body and provide lifelong immunity.
In rare occassions a persistent measles infection of the nervous system develops, leading to
a neurodegenerative disorder, subacute sclerosing panencephalitis161. Measles can result in
a fatal disease and caused an estimated of 114 900 deaths globally in 2014162. The main
cause of measles-associated deaths are complications caused by secondary infections due
to measles-induced immunosuppression160. The mechanisms of immunosuppressive effects
caused by MeV are not completely understood, but can involve lymphopenia163, suppres-
sion of Th1 cytokine responses through upregulation of Th2 responses
164 and suppression of
lymphocyte proliferation165.
1.5.2 Measles Vaccine Strain Viruses
Wild-type MeV was first isolated in 1954 from the blood of David Edmonston166 and soon
development of a live attenuated vaccine against MeV followed167. The measles vaccine
turned out to be extremely effective and, although measles remains a health concern in
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regions with incomplete vaccination coverage, it is estimated that in the period between 2000
and 2014 alone the vaccine prevented about 17 million measles-associated deaths162. The
measles vaccine can also be considered one of the safest vaccines in the world, as it has been
given to more than one billion people since its development and a conversion to wild-type
MeV has never been observed139. Today, several different attenuated MeV vaccine strains
exist, some of which were derived from the original Edmonston isolate by further passaging in
different cell lines and some of which were derived from three other independent isolates168.
In Europe, the Schwarz measles vaccine strain is used, which was obtained by additional
passaging of the Edmonston isolate in chicken embryo fibroblasts169. It has been shown
that the genome sequence of the Schwarz vaccine strain is identical to that of the Moraten
strain which is used as a measles vaccine in the U.S., although both strains were obtained by
separate passaging168. In addition to CD150 and PVRL-4, the attenuated measles vaccine
strain viruses use CD46 as a cellular receptor170. This is due to acquisition of a mutation in
the H gene during virus passaging, changing the amino acid in position 481 of the H protein
from asparagine to tyrosine171. CD46 is a complement regulatory molecule which has the
ability to block the complement cascade at the stage of C3 activation, thereby preserving
autologous cells from the complement-induced cell lysis. CD46 is therefore expressed on the
surface of most human nucleated cells172. As a complement evasion mechanism, CD46 is
frequently overexpressed on cells of many different tumor types173, 174, 175, thus, as will be
discussed further, providing a natural oncotropism for measles vaccine strain viruses.
1.5.3 Measles as an Oncolytic Virus
In the 1970s several cases of tumor remissions in patients with hematological malignancies
after measles infection were reported176, 177, 178. These observations led to the idea to ap-
ply MeV in cancer therapy. Although these observations actually indicated that wild-type
MeV could be an appropriate agent for use in cancer therapy, application of attenuated
measles vaccine strains turned out to be a more promising approach regarding safety and
efficacy83. As mentioned before (subsection 1.5.2), the vaccine strain measles viruses infect
CD46-positive cells. However, a critical density of CD46 is necessary for efficient fusion
with the cell membrane and formation of syncytia179. As a complement evasion mechanism,
CD46 expression has been found to be upregulated in many different tumor types including
breast180, renal181, liver182, bladder183, gastrointestinal184 and hematological185 malignan-
cies. Taken together, these properties provide measles vaccine strain viruses with a natural
oncotropism. Effective tumor growth control of two hematological malignancies, multiple
myeloma and lymphoma, could also be demonstrated in the first pre-clinical studies of the
oncolytic properties of attenuated measles vaccine strain viruses186, 187.
Development of a reverse genetics system to allow generation of measles virus from
cloned DNA188 opened opportunities for further enhancement of attenuated MV to develop
oncolytic MV vectors with increased efficacy and safety. The major directions in MV engi-
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neering have focused on development of methods for non-invasive monitoring of virus spread
in vivo, modulation of viral tropism to enhance specificity of tumor cell infection and gener-
ation of viruses that induce more effective anti-tumor immune responses.
Several strategies have been used to modulate the tropism of MV. It was found that
the MV attachment protein H tolerates insertion of large polypetides without compromis-
ing assembly and replication of the virus189. Different tumor cell targeting strategies have
been explored since then, including display of tumor marker-specific single chain antibod-
ies190, 191, 192 and designed ankyrin repeat proteins (DARPins)193 or high affinity T cell recep-
tors194 on the C-terminus of MV H. The “retargeted” H allows MV to enter CD46 negative
cells, including non-primate cells, expressing the respective target receptor. Furthermore, to
ensure full “retargeting”, mutations ablating the H binding to the natural receptors CD46
and CD150 are introduced195, 196. Another strategy for modulation of MeV tropism includes
insertion of micro-RNA target sites into the MV genome, thereby suppressing viral repli-
cation in cells expressing the respective microRNA197. Multiple tissue-specific microRNA
target sites can be inserted into the MV genome to avoid measles replication after systemic
application in such sensitive organs as the brain, gastrointestinal tract and liver198.
MV vectors encoding different immunostimulatory transgenes have been developed to
improve vector-induced anti-tumor immunity. Enhanced anti-tumor efficacy in compari-
son to the parental vector has been demonstrated for an IFN-β encoding MV in a human
mesothelioma xenograft in immunodeficient mice131. MV encoding a neutrophil-activating
protein derived from the Helicobacter pylori has been shown to effectively control tumor
growth in an advanced human breast cancer xenograft model199. MV encoding murine gran-
ulocyte macrophage colony-stimulating factor (MV-mGM-CSF) has been shown to have an
increased efficacy in an immunodeficient lymphoma xenograft model200. Furthermore, ef-
ficacy and induction of a more potent anti-tumor immune response by MV-mGM-CSF in
comparison to a control vector has been demonstrated also in an immunocompetent murine
colon adenocarcinoma model114. MV expressing antibodies against the negative regulators
of T cells, CTLA-4 and PD-L1, have also been successfully developed and have elicited an en-
hanced anti-tumor response and a beneficial modulation of the tumor immune environment
in a fully immunocompetent murine melanoma model104. The immunostimulatory effects of
the encoded immunomodulators in the MeV genome synergize with the oncolytic effects of
MV, but also addresses delivery and safety issues of these immmunomodulators. Targeted
delivery of the immunomodulators to MV-infected cells allows local expression only at the
tumor site and avoids toxicities that are frequently associated with systemic administration
of immunotherapeutics201, 202.
Development of a feasible non-invasive method for monitoring of viral spread in vivo
supported advancement of the attenuated MV vaccine vectors into clinical application. Two
different strategies for tracking of MV replication have been used until now. The first
approach used MV expressing soluble, biologically inert marker peptides – the soluble extra-
cellular domain of the human carcinoembryonic antigen (hCEA) and the human chorionic
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gonadotropin β-subunit (βhCG)203. Replication of these viruses could be monitored by
measuring the concentration of the marker peptides in body fluids203. The second approach
focused on developing viruses that would allow to also monitor the physical distribution of
virus replication sites in the organism. A MV encoding the human thyroidal sodium iodide
symporter (NIS) (MV-NIS) was therefore developed204. NIS is an ion channel which trans-
ports iodide against its concentration gradient. NIS is expressed on the surface of MV-NIS
infected cells which are therefore able to concentrate radioactive iodide from the blood-
stream, allowing to monitor progress of the infection by single-photon emission computed
tomography or positron emission tomography205.
Several clinical trials for use of attenuated MV vaccine strain viruses for treatment of
different cancer types have already been concluded and more are currently ongoing. The
first clinical trial administering an unmodified Edmonston-Zagreb measles vaccine strain
virus (MV-EZ) in cancer patients was a phase I study for treatment of cutaneous T cell lym-
phoma. Five patients received intralesional MV-EZ injections which were preceded by IFN-α
injections as a safety measure to avoid uncontrolled virus spread. Regressions were observed
in five of six injected lesions and improvement of distant, non-injected lesions was observed in
two of the patients206. The first trial to administer an engineered MV, MV-CEA, was carried
out in patients with recurrent ovarian cancer. Twenty-one patients received i.p. injections
of escalating doses with MV-CEA up to 109 TCID50 (50% tissue culture infective dose). No
dose-limiting toxicities (DLTs) were observed and, importantly, the observed response rates
correlated with the received virus dose207. A phase I trial with administration of MV-NIS
i.p. in recurrent ovarian cancer patients followed. Also in this trial no significant DLTs were
observed and the best objective response was disease stabilization in 13 of 16 patients208. In
all of these first clinical trials only measles-immune patients were enrolled. In the following,
administration of MV-NIS in two measles-seronegative patients with disseminated multiple
myeloma has also been reported. Of note, complete remission of the disseminated disease
that lasted for nine months was observed in one of these patients209. Multiple phase I and
II clinical trials investigating MV-CEA or MV-NIS for treatment of different tumor entities,
including glioblastoma multiforme (NCT00390299), ovarian, fallopian or peritoneal cancer
(NCT02364713), refractory multiple myeloma (NCT00450814), malignant pleural mesothe-
lioma (NCT01503177), malignant peripheral nerve sheath tumor (NCT02700230), recurrent
or metastatic squamous cell carcinoma of the head and neck or metastatic breast cancer
(NCT01846091) are currently active or recruiting patients.
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Oncolytic viruses (OVs) are emerging as a novel, clinically relevant type of cancer im-
munotherapy. The ability of different OVs to induce immunogenic death of infected tumor
cells, eliciting tumor antigen specific immune responses, has been demonstrated in numerous
pre-clinical tumor models and more importantly validated in a clinical situation. Further-
more, it has been recognized that the immunostimulatory properties of OVs can be supported
by combination with different immunomodulators to synergistically enhance the therapeu-
tic efficacy. However, understanding of immune effector mechanisms determining success
of a particular combination approach and, thus, compatibility with the immunostimulatory
effects induced by a particular oncolytic vector remains limited.
Based on the hypothesis that certain immunomodulation types are more suitable for
combination with a given oncolytic vector to achieve therapeutic benefit in a given tumor
type, the aim of this study was to compare the therapeutic efficacy of oncolytic measles vec-
tors encoding immunomodulators targeting establishment of an anti-tumor immune response
at different phases (Figure 2.1).
Figure 2.1: Immunomodulation strategies for oncolytic measles virus therapy.
Transgenes for immunomodulators targeting establishment of anti-tumor immunity at differ-
ent stages were inserted into the genome of measles Schwarz vaccine strain virus. GM-CSF —
granulocyte macrophage colony-stimulating factor; IL-12 — interleukin-12; IP-10 (CXCL10)
— interferon-γ-induced protein 10; Anti-PD-L1, anti-CTLA-4 — antibodies against the neg-
ative T cell regulators PD-L1 and CTLA-4, respectively. Figure adapted from Mellman et
al., 201110.
Measles vectors encoding selected immunomodulators were generated: 1) granulocyte
macrophage colony-stimulating factor (GM-CSF) — to enhance maturation of antigen-
presenting cells; 2) IL-12 and IP-10 (CXCL10) — to enhance immune effector cell responses;
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3) antibodies against CTLA-4 and PD-L1 as well as a soluble form of CD80 (CD80-Fc) —
to counteract immunosuppression in the tumor microenvironment. The novel vectors were
characterized in vitro in terms of replication kinetics and cytotoxic potential, as well as
transgene expression and functionality. Subsequently, therapeutic efficacy was compared in
an immunocompetent murine colon adenocarcinoma model to identify the most promising
vectors or vector combinations. As a second objective, the study aimed at identification
of immune effector mechanisms associated with efficacy of the most promising novel im-
munomodulatory measles vectors. To this end, analyses of the tumor immune environment
following measles immunovirotherapy were performed. Intratumoral cytokine profiles and
the main tumor infiltrating lymphocyte subpopulations were analyzed and the role of the
main lymphocyte subpopulations for the therapeutic efficacy of the most promising vector
was validated in depletion experiments.
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3.1 Materials
3.1.1 Chemicals
Reagent Supplier and catalog number
Agarose, molecular biology grade Sigma-Aldrich, A9539
DAPI (4’,6-diamidino-2-phenylindole) Sigma-Aldrich, D8417
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, D2438
Ethidium bromide AppliChem, 1239-45-8
Ethylenediaminetetraacetic acid (EDTA) salt
solution
Sigma-Aldrich, E7889-100ML
Glycerol Sigma-Aldrich, G7757-1L
Ionomycin Cayman Chemical Company,
Cay-11932
Kanamycin Sigma-Aldrich, K0129
Methanol, > 99.9% Carl-Roth, 8388.1
Mitomycin-C Sigma-Aldrich, M4287
NP-40 Abcam, ab142227
Penicillin-Streptomycin Thermo Fisher Scientific, 15070063
Phorbol 12-myristate 13-acetate (PMA) Cayman Chemical Company,
Cay-10008014
Skim milk powder, blotting grade Carl-Roth, T145.2
Sodium chloride (NaCl) solution Sigma-Aldrich, S5150-1L
Trizma R© hydrochloride solution (Tris-HCl) Sigma-Aldrich, T2694
3.1.2 Buffers
Buffer Supplier and catalog number
Ammonium-Chloride-Potassium (ACK) lysing buffer Thermo Fisher Scientific,
A1049201
Laemmli buffer (4×) Biorad, 161-0747
Novex R© Tris-Glycine Transfer Buffer (25×) Thermo Fisher Scientific,
LC3675
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Buffer Supplier and catalog number
Rotiphorese R© 10× SDS-PAGE (Sodium dodecyl
sulphate-polyacrylamide gel electrophoresis) running
buffer
Carl-Roth, 3060.1
Tris/Borate/EDTA (TBE) Genaxxon bioscience,
M3206.1000
Roti R©-Stock 10× Tris-buffered saline-Tween
(TBS-T)
Carl Roth, 1061.1
3.1.3 Growth Media for Bacterial and Cell Culture
Medium Supplier and catalog number
Dulbecco’s Phosphate-Buffered Saline (D-PBS)
without calcium and magnesium
Thermo Fisher Scientific,
14190250
Dulbecco’s Modified Eagle Medium (DMEM) Thermo Fisher Scientific,
61965026
LB (lysogeny broth) medium Carl-Roth, X964.1
OptiMEM R© Thermo Fisher Scientific,
51985034
Roswell Park Memorial Institute medium 1640
(RPMI 1640)
Thermo Fisher Scientific,
61870044
SOC Outgrowth Medium (Super Optimal Broth
with glucose)
New England Biolabs (NEB),
B9020S
3.1.4 Oligonucleotides
Oligonucleotides were designed using Primer-BLAST210 and synthesized by Eurofins MWG
Operon. Primers for RT-PCR and RT-qPCR were designed to span an exon-exon junc-
tion. For primers binding in the measles genome (MeV) the genome position of the first
complementary nucleotide is given in the primer name. “+” or “rev” indicates primers
hybridizing to the “+” strand DNA/RNA; “for” indicates primers hybridizing to the “−”
strand DNA/RNA; m — murine; h — human. Restriction enzyme name is given if the
respective restriction site is present in the primer sequence.
Name Sequence 5’ → 3’
MeV ld-1 ACCAAACAAAGTTGGGTAAGGATAGT
MeV N-180+ CGGATCCTGATGTAATGGGTGGTT
MeV N-241 TTACCACTCGATCCAGACTTC
MeV N-988 CCACACTTGAGTCCTTGATGAACC
MeV N-1471 GGCCCAGCAGAGCAAGTGATG
MeV P-1967 GGCAGGCAGTTCGGGTCTCAG
18
3 Materials and Methods
Name Sequence 5’ → 3’
MeV P-2769 CTTGGCCAAAATACACGAGGATAA
MeV P-3023+ AGTGCTCGGCCTGAATCTCTGC
MeV P-3287 TTGCCAAGTTCCACCAGATGCT
MeV M-3478+ ATGTCCCATGCCGACTTGTCGAA
MeV M-3831 GGGAGTGTCTTCAACGCAAACCAA
MeV M-4271 GACCTTATGTTACCCGCTGATGGA
MeV F-5129 CACGGCAACCAAACCAGAACC
MeV F-5525+ CCGGTGGGTGTTTGGAGAGTTA
MeV F-5595 GACTCGTTCCAGCCATCAATCAT
MeV F-6094 ATCCTGTCATTATTTGGCCCC
MeV F-7100 GGTCGCTCTGATCCTCTACAACTC
MeV H-7480 CCATAAAAGCCTCAGCACCAATCT
MeV H-7583+ GGCCCACTTCATCACCGATGATT
MeV H-8233 CGTCAAGCTAGGTGTCTGGAAATC
MeV H-9018 GTGTGCTTGCGGACTCAGAATC
MeV L-9249+ CAGATAGCGAGTCCATAACGG
MeV L-9371 TCAGAACATCAAGCACCGCCTAAA
MeV L-9809+ TGTGTGTCTCCTCCTATGGCAAG
MeV L-10045 CACTCGGGAATCCAACTTATCAAA
MeV L-10713 GGTCACGGAGGCTTGTAGATGTT
MeV L-11585 CAGCACATGGCCCTACAACCTTA
MeV L-12004+ TTGTTTGTGAGGAGGGGTATGACT
MeV L-12574 GGATGGTGCTATTGACAGGAAGAA
MeV L-12936+ AGGATCGACTTGGGGCTCTTA
MeV L-13242 ATGCTTCTAGGGTTGGGTGTTTTA
MeV L-13767 GAGCTGTTGTCATCGTTCCTTTCT
MeV L-14505 GGGTTGAACTCATCTGCTTGCTAC
MeV L-15008+ CAAAATCCCCGCTGAAAGGCATAAG
MeV L-15240 GCAATTGTGGGAGACGCAGTTAGT
pJET 1.2 for CGACTCACTATAGGGAGAGCGGC
pJET 1.2 rev AAGAACATCGATTTTCCATGGCAG
pCG for TTGTGCTGTCTCATCATTTTG
pCG rev GTCCCCATAATTTTTGGCAG
MeVac H-ATU SpeI
XbaI for
CTAGTCATCCATCATTGTTATAAAAAACTTAGGAACCAGGTCCACACAGCTC
GAGTCGCGCGCGTT
MeVac H-ATU SpeI
XbaI rev
CTAGAACGCGCGCGACTCGAGCTGTGTGGACCTGGTTCCTAAGTTTTTTATA
ACAATGATGGAGTA
saPD-L1 SalI rev TTGTCACAAGATTTGGCCTCGTCGAC
m IP10 MluI for CCCTTTACGCGTGCCACCATGAACCCAAGTGCTGCCGTC
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m IP10 AscI rev CCCTTTGGCGCGCCTATTAAGGAGCCCTTTTAGACC
m IL12p40-477 rev GGAACTGCTACTGCTCTTG
m CD80 for TTTACGCGTGCCACCATGGCTTGCAATTGTCAGTTG
m CD80-Fc SalI rev TTGTCACAAGATTTGGCCTCGTCGACTTCTCTGCTTGCCTCATTTCTTCTGA
IgG Fc SalI for GTCGACGAGGCCAAATCTTGTGACAA
m CD80-Fc AscI rev AAAGGGGGCGCGCCTAATTCAGATCTTTTTCTGAGATGAG
hsCEA MluI for TTTACGCGTGCCACCATGGAGTCTCCCTCGGCCCCTCC
hsCEA AscI rev TTTGGCGCGCCTATTATGCAGAGACTGTGATGCTCTTGAC
m β2m for CTGCTACGTAACACAGTTCCACCC
m β2m rev CATGATGCTTGATCACATGTCTCG
m PD-L1 752 for GATCATCCCAGAACTGCCTG
m PD-L1 908 rev TTCAACGCCACATTTCTCCA
m CTLA-4 var1 for AGGTGGAACTCATGTACCCA
m CTLA-4 var1 rev CTTCTTTTCTTTAGCATCTTGCTC
m CTLA-4 var2 for GACGCAGATTTATGTCATTGCTAA
m CTLA-4 var2 rev AACGGCCTTTCAGTTGATGG
m CXCR3 for GCCATGTACCTTGAGGTTAGT
m CXCR3 rev CCAGCAGAACATCGGCTACA
m GAPDH for TTCACCACCATGGAGAAGGC
m GAPDH rev GGCATGGACTGTGGTCATGA
m Foxp3 for GGCCCTTCTCCAGGACAGA
m Foxp3 rev GCTGATCATGGCTGGGTTGT
m T-bet for TAAGCAAGGACGGCGAATGTT
m T-bet rev TGCCTTCTGCCTTTCCACAC
m L13A for GGCTGCCGAAGATGGCGGAG
m L13A rev GCCTTCACAGCGTACGACCACC
m β-actin for AGAGGGAAATCGTGCGTGAC
m β-actin rev CAATAGTGATGACCTGGCCGT
m 18S for CTTAGAGGGACAAGTGGCG
m 18S rev ACGCTGAGCCAGTCAGTGTA
FhIL-12 p40 MluI for CCCGGGACGCGTGCCACCATGTGTCACCAGCAGT
FhIL-12 p40 rev AGATCCGCCGCCACCGCCACCACTGCAGGGCAC
FhIL-12 p35 for GGTGGCGGTGGCGGCGGATCTAGAAACCTCCCC
FhIL-12 p35 PauI rev CCCGGGGCGCGCTCACTAGGAAGCATTCAGATAGCTC
h nectin-4 1065 for CAAAATCTGTGGCACATTGG
h nectin-4 1234 rev GCTGACATGGCAGACGTAGA
h A33 for CCTGTCTGGAGGCTGCCAGT
h A33 rev AGGTGCAGGGCAGGGTGACA
h Cytokeratin-20 for CAGACACACGGTGAACTATGG
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Name Sequence 5’ → 3’
h Cytokeratin-20 rev GATCAGCTTCCACTGTTAGACG
h Mucin-1 fw CACTTCTCCCCAGTTGTCTAC
h Mucin-1 rev GGGTACTCGCTCATAGGATG
h Villin for TGTTCCTTCCAGCACCTTTG
h Villin rev CCTGAGTCTCTCCATACGGG
h CEA-810 TTGGTTTGTCAATGGGACTTTC
h CEA-1288+ CTGGACGGTAATAGGTGTATGA
h β-actin Ex6 for TCATTGCTCCTCCTGAGCGCA
h β-actin Ex6 rev CTAGAAGCATTTGCGGTGGAC
A1SnaBI GCGCGCTACGTAAAAGCTGGGAATAGAAACTTCG
A2NotI TAGAGAGAGCGGCCGCTCTGGTGTAAGTCTAGTATCAGA
B1 ATGACAGATCTCAAGGCTAAC
3.1.5 Antibodies
Antibodies for western blot (WB), enzyme linked immunosorbent assay (ELISA) and flow
cytometry (FC) analyses, as well as in vivo immune cell depletions (D) are listed below. The
respective antigen and conjugate are given under “Antibody”, host, isotype and clone are
given under “Description”, application and dilution are given under “Application”, supplier
and catalog number are given under “Supplier”. Ab — antibody; PE — phycoerythrin;
PerCP-CyTM5.5 — peridinin chlorophyll protein complex with cyanine-5.5; APC — allophy-
cocyanin; CyTM7 — cyanine 7; FITC — fluorescein isothiocyanate.
Antibody Description Application Supplier
Anti-human
IgG-Fc-Biotin
Murine IgG2a, clone
HP-6017
WB 1:2000,
ELISA 1:500
Sigma-Aldrich,
B3773
Anti-HA Murine IgG1, clone HA-7 FC 1:1000 Sigma-Aldrich,
H9658
Anti-mouse Ig-PE Goat, polyclonal Secondary Ab,
FC 0.025µg/µl
BD Biosciences,
550589
Anti-mouse
CD45.2-PerCP-
CyTM5.5
Murine (SJL) IgG2a, κ,
clone 104
FC 1:100 BD Biosciences,
561096
Anti-mouse CD3
complex-Alexa
Fluor R© 700
Rat IgG2b, κ, clone 17A2 FC 1:100 BD Biosciences,
561388
Anti-mouse
CD8a-APC
Rat IgG2a, κ, clone 53-6.7 FC 1:100 BD Biosciences,
561093
Anti-mouse
CD4-APC-CyTM7
Rat IgG2b, κ, clone GK1.5 FC 1:100 BD Biosciences,
561830
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Antibody Description Application Supplier
Anti-mouse
CD335-FITC
Rat IgG2a, κ, clone 29A1.4 FC 1:50 Biolegend,
137606
Anti-mouse
CD69-PE
Armenian Hamster, IgG,
clone H1.2F3
FC 1:80 Biolegend,
104507
Mouse IgG2a, κ,
PerCP-CyTM5.5
Isotype control, clone
MOPC-173
FC 1:100 Biolegend,
400251
Rat IgG2b, κ,
Alexa Fluor R© 700
Isotype control, clone
RTK4530
FC 1:100 Biolegend,
400628
Rat IgG2a, κ, APC Isotype control, clone
R35-95
FC 1:100 BD Biosciences,
553932
Rat IgG2b, κ,
APC-CyTM7
Isotype control, clone
A95-1
FC 1:100 BD Biosciences,
552773
Rat IgG2a, κ,
FITC
Isotype control, clone
RTK2758
FC 1:50 Biolegend,
400501
Armenian
Hamster, IgG, PE
Isotype control, clone
HTK888
FC 1:80 Biolegend,
400907
Anti-mouse CD8 Rat IgG2a, κ, clone 53-6.7 D Biolegend,
100735
Anti-mouse CD4 Rat IgG2a, κ, clone GK1.5 D Biolegend,
100435
Anti-mouse NK1.1 Mouse IgG2a, κ, clone
PK136
D Biolegend,
108712
Anti-human
CD46-PE
Mouse IgG1, clone
TRA-2-10
FC 1:100 Biolegend,
352401
Anti-human
CD150-PE
Mouse IgG1, κ, clone A12 FC 1:25 BD Biosciences,
559592
Mouse IgG1, κ, PE Isotype control, clone
MOPC-21
FC 1:100 or 1:25 BD Biosciences,
555749
3.1.6 DNA Plasmids
Plasmid Description
pUC19 High copy number cloning vector211
pJET 1.2 Cloning vector, GenBank accession number:
EF694056.1 (Thermo Fisher Scientific)
pcDI dsRed Eukaryotic expression vector for a variant of the
Discosoma red fluorescent protein
pcDIMER-N Eukaryotic expression vector encoding Schwarz
measles vaccine strain N
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Plasmid Description
pcDIMER-P Eukaryotic expression vector encoding Schwarz
measles vaccine strain P
pcDIMER-L Eukaryotic expression vector encoding Schwarz
measles vaccine strain L
pJET 1.2 mIP-10 pJET 1.2 vector encoding a murine IP-10
(CXCL10) expression cassette
pCG FmIL-12 Eukaryotic expression vector encoding murine
IL-12 fusion protein212
pCG anti-CTLA-4 Eukaryotic expression vector encoding an anti-
body against murine CTLA-4 (CD152)213
pCG anti-PD-L1 Eukaryotic expression vector encoding an anti-
body against murine PD-L1 (CD274)213
pCG IgG1-Fc Eukaryotic expression vector an antibody con-
stant region IgG1-Fc213
pCG mCD80 Eukaryotic expression vector encoding murine
CD80
pCG MeVac Hbl Eukaryotic expression vector encoding Schwarz
measles vaccine strain H which is “blinded” for
binding to CD46 and CD150 with Y481, R533A,
S548L and F549S mutations
pCG NSe Hbl-αCEA Eukaryotic expression vector encoding the H
of measles Edmonston B derived measles vac-
cine strain vector which is “blinded” for bind-
ing to CD46 and CD150 with Y481, R533A,
S548L and F549S mutations and fused to a sin-
gle chain antibody against human CEA with a
six-histidine tag at the C terminus
pCG NSe Hbl-αCD20 Eukaryotic expression vector encoding the H
of measles Edmonston B derived measles vac-
cine strain vector which is “blinded” for binding
to CD46 and CD150 with with Y481, R533A,
S548L and F549S mutations and fused to a sin-
gle chain antibody against human CD20 with a
six-histidine tag at the C terminus212
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Plasmid Description
pCG MeVac Hbl-αCEA Eukaryotic expression vector encoding the H of
measles Schwarz vaccine strain vector which is
“blinded” for binding to CD46 and CD150 with
with Y481, R533A, S548L and F549S mutations
and fused to a single chain antibody against hu-
man CEA with a six-histidine tag at the C ter-
minus
pCG MeVac Hbl-αCD20 Eukaryotic expression vector encoding the H of
measles Schwarz vaccine strain vector which is
“blinded” for binding to CD46 and CD150 with
with Y481, R533A, S548L and F549S mutations
and fused to a single chain antibody against hu-
man CD20 with a six-histidine tag at the C ter-
minus
pcMeVac Measles Schwarz vaccine strain antigenome en-
coding plasmid214; allows rescue with the RNA
polymerse II dependent system215
pUC19 MeVac NarI -NarI pUC19 vector containing a part of the measles
Schwarz vaccine strain antigenome with F, H
and L ORFs between two NarI restriction sites
pcMeVac ld-ATU Plasmid with measles Schwarz vaccine strain
antigenome encoding an additional transcrip-
tion unit upstream of the measles leader
pcMeVac P-ATU Plasmid with measles Schwarz vaccine strain
antigenome encoding an additional transcrip-
tion unit downstream of the measles P ORF
pcMeVac H-ATU Plasmid with measles Schwarz vaccine strain
antigenome encoding an additional transcrip-
tion unit downstream of the measles H ORF
pcMeVac Hbl-αCEA Plasmid with measles Schwarz vaccine strain
antigenome in which the H is “blinded” for
binding to CD46 and CD150 and fused to a sin-
gle chain antibody against human CEA with a
six-histidine tag at the C terminus; allows prop-
agation on Vero-αHis cells
pcMeVac ld-eGFP Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for eGFP up-
stream of the measles leader
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pcMeVac ld-eGFP Hbl-αCEA Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for eGFP up-
stream of the measles leader and with measles H
“blinded” for binding to CD46 and CD150 and
fused to a single chain antibody against human
CEA with a six-histidine tag at the C terminus;
allows propagation on Vero-αHis cells
pcMeVac H-anti-CTLA-4 Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for an antibody
against murine CTLA-4 (CD152) downstream
of the measles H ORF
pcMeVac H-anti-CTLA-4 Hbl-αCEA Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for an antibody
against murine CTLA-4 (CD152) downstream
of the measles H ORF and with measles H
“blinded” for binding to CD46 and CD150 and
fused to a single chain antibody against human
CEA with a six-histidine tag at the C terminus;
allows propagation on Vero-αHis cells
pcMeVac H-anti-PD-L1 Plasmid with measles Schwarz vaccine strain
antigenome encoding an antibody against
murine PD-L1 (CD274) downstream of the
measles H ORF
pcMeVac H-anti-PD-L1 Hbl-αCEA Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for an antibody
against murine PD-L1 (CD274) downstream
of the measles H ORF and with measles H
“blinded” for binding to CD46 and CD150 and
fused to a single chain antibody against human
CEA with a six-histidine tag at the C terminus;
allows propagation on Vero-αHis cells
pcMeVac H-anti-PD-L1 Hbl-αCD20 Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for an antibody
against murine PD-L1 (CD274) downstream
of the measles H ORF and with measles H
“blinded” for binding to CD46 and CD150 and
fused to a single chain antibody against human
CD20 with a six-histidine tag at the C terminus;
allows propagation on Vero-αHis cells
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pcMeVac H-IgG1Fc Plasmid with measles Schwarz vaccine strain
antigenome encoding an antibody constant re-
gion IgG1-Fc downstream of the measles H
ORF
pcMeVac H-IgG1Fc Hbl-αCEA Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for an antibody
constant region IgG1-Fc downstream of the
measles H ORF and with measles H “blinded”
for binding to CD46 and CD150 and fused to a
single chain antibody against human CEA with
a six-histidine tag at the C terminus; allows
propagation on Vero-αHis cells
pcMeVac H-IgG1Fc Hbl-αCD20 Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for an antibody
constant region IgG1-Fc downstream of the
measles H ORF and with measles H “blinded”
for binding to CD46 and CD150 and fused to
a single chain antibody against human CD20
with a six-histidine tag at the C terminus; al-
lows propagation on Vero-αHis cells
pcMeVac H-mCD80-Fc Hbl-αCEA Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for a soluble form
of murine CD80 downstream of the measles H
ORF and with measles H “blinded” for bind-
ing to CD46 and CD150 and fused to a single
chain antibody against human CEA with a six-
histidine tag at the C terminus; allows propa-
gation on Vero-αHis cells
pcMeVac ld-mIP-10 Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for murine Ip-10
(Cxcl10 ) upstream of the measles leader
pcMeVac ld-mIP-10 Hbl-αCEA Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for murine Ip-10
(Cxcl10 ) upstream of the measles leader and
with measles H “blinded” for binding to CD46
and CD150 and fused to a single chain anti-
body against human CEA with a six-histidine
tag at the C terminus; allows propagation on
Vero-αHis cells
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Plasmid Description
pcMeVac ld-mGM-CSF Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for murine
Gm-csf upstream of the measles leader
pcMeVac ld-mGM-CSF Hbl-αCEA Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for murine
Gm-csf upstream of the measles leader and
with measles H “blinded” for binding to CD46
and CD150 and fused to a single chain anti-
body against human CEA with a six-histidine
tag at the C terminus; allows propagation on
Vero-αHis cells
pcMeVac P-FmIL-12 Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for murine IL-12
fusion protein downstream of the measles P
ORF
pcMeVac P-FmIL-12 Hbl-αCEA Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for murine IL-12
fusion protein downstream of the measles P
ORF and with measles H “blinded” for bind-
ing to CD46 and CD150 and fused to a single
chain antibody against human CEA with a six-
histidine tag at the C terminus; allows propa-
gation on Vero-αHis cells
pcMeVac P-FmIL-12 Hbl-αCD20 Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for murine IL-12
fusion protein downstream of the measles P
ORF and with measles H “blinded” for bind-
ing to CD46 and CD150 and fused to a single
chain antibody against human CD20 with a six-
histidine tag at the C terminus; allows propa-
gation on Vero-αHis cells
pcMeVac P-FhIL-12 Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for human IL-12
fusion protein downstream of the measles P
ORF
pcMeVac H-FhIL-12 Plasmid with measles Schwarz vaccine strain
antigenome encoding an ORF for human IL-12
fusion protein downstream of the measles H
ORF
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3.1.7 Cell Lines
Cell line Description Medium Source
Vero African green monkey Cercopitheus
aethiops kidney epithelial cell line
DMEM
+ 10% FCS
ATCC, Manas-
sas, VA
Vero-αHis Vero cells transduced with a lentivi-
ral vector for stable expression of a
single-chain antibody against a six-
histidine peptide (His6)
216
DMEM
+ 10% FCS
S. J. Russell,
Rochester, MN
MC38 Murine colon adenocarcinoma cell
line derived from a chemically in-
duced tumor in a C57BL/6 mouse217
DMEM
+ 10% FCS
R. Cattaneo,
Rochester, MN
MC38cea MC38 cells transduced with a lentivi-
ral vector for stable expression of
a human carcinoembryonic antigen
(CEA) variant218
DMEM
+ 10% FCS
R. Cattaneo,
Rochester, MN
B16 Murine melanoma cell line derived
from a spontaneous tumor of a
C57BL/6 mouse
RPMI 1640
+ 10% FCS
D. M. Nettelbeck,
Heidelberg,
Germany
B16-CD20 B16 cells transduced with a lentiviral
vector for stable expression of human
CD20212
RPMI 1640
+ 10% FCS
C. Großardt,
Heidelberg,
Germany
COLO 205 Human colorectal carcinoma cell line RPMI 1640
+ 10% FCS
A. Jassowicz,
Heidelberg,
Germany
DLD-1 Human colorectal carcinoma cell line RPMI 1640
+ 10% FCS
S. Fro¨hling,
Heidelberg,
Germany
HCT 116 Human colorectal carcinoma cell line DMEM
+ 10% FCS
S. Fro¨hling,
Heidelberg,
Germany
HT29 Human colorectal carcinoma cell line RPMI 1640
+ 10% FCS
C. Plass,
Heidelberg,
Germany
KM12 Human colorectal carcinoma cell line DMEM
+ 10% FCS
C. Plass,
Heidelberg,
Germany
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3.1.8 Recombinant Measles Viruses
Virus Description
MeVac Measles Schwarz vaccine strain virus214
NSe Measles Edmonston B derived vaccine strain
virus
MeVac ld-eGFP Hbl-αCEA Measles Schwarz vaccine strain virus encoding
eGFP in an additional transcription unit up-
stream the measles leader and with the H fully
retargeted to human CEA
MeVac H-anti-CTLA-4 Hbl-αCEA Measles Schwarz vaccine strain virus encoding
an antibody against murine CTLA-4 (CD152)
in an additional transcription unit downstream
the H ORF and with the H fully retargeted to
human CEA
MeVac H-anti-PD-L1 Hbl-αCEA Measles Schwarz vaccine strain virus encoding
an antibody against murine PD-L1 (CD274)
in an additional transcription unit downstream
the H ORF and with the H fully retargeted to
human CEA
MeVac H-IgG1Fc Hbl-αCEA Measles Schwarz vaccine strain virus encoding
a constant region of an antibody IgG1-Fc in an
additional transcription unit downstream the H
ORF and with the H fully retargeted to human
CEA
MeVac ld-mIP-10 Hbl-αCEA Measles Schwarz vaccine strain virus encoding
murine IP-10 (CXCL10) in an additional tran-
scription unit upstream of the measles leader
and with the H fully retargeted to human CEA
MeVac P-FmIL-12 Hbl-αCEA Measles Schwarz vaccine strain virus encoding
a murine IL-12 fusion protein in an additional
transcription unit downstream of the measles P
ORF and with the H fully retargeted to human
CEA
MeVac H-mCD80-Fc Hbl-αCEA Measles Schwarz vaccine strain virus encoding
a soluble form of murine CD80 in an additional
transcription unit downstream of the measles H
ORF and with the H fully retargeted to human
CEA
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Virus Description
MeVac ld-mGMCSF Hbl-αCEA Measles Schwarz vaccine strain virus encoding
murine GM-CSF in an additional transcription
unit upstream of the measles leader and with
the H fully retargeted to human CEA
MeVac P-FmIL-12 Hbl-αCD20 Measles Schwarz vaccine strain virus encoding
a murine IL-12 fusion protein in an additional
transcription unit downstream of the measles P
ORF and with the H fully retargeted to human
CD20
MeVac H-IgG1Fc Hbl-αCD20 Measles Schwarz vaccine strain virus encoding
a constant region of an antibody IgG1-Fc in an
additional transcription unit downstream the H
ORF and with the H fully retargeted to human
CD20
MeVac H-anti-PDL1 Hbl-αCD20 Measles Schwarz vaccine strain virus encoding
an antibody against murine PD-L1 (CD274)
in an additional transcription unit downstream
the H ORF and with the H fully retargeted to
human CD20
MeVac P-FhIL-12 Measles Schwarz vaccine strain virus encoding
a human IL-12 fusion protein in an additional
transcription unit downstream of the measles P
MeVac H-FhIL-12 Measles Schwarz vaccine strain virus encoding
a human IL-12 fusion protein in an additional
transcription unit downstream of the measles H
3.2 Methods
3.2.1 Standard DNA and RNA Molecular Biology Methods
Polymerase chain reaction
DNA fragments were amplified in a polymerase chain reaction (PCR) with OneTaq R© stan-
dard buffer (NEB, M0480L), 200 nM deoxynucleotide triphosphates (dNTPs, Thermo Fisher
Scientific, R0192), 200 nM respective forward and reverse primers, 0.625 U OneTaq R© DNA
polymerase (NEB, M0480L) and sterile water. For cloning, DNA fragments were amplified
in a PCR with Phusion HF buffer (NEB, M0530S), 200 nM dNTPs, 200 nM respective for-
ward and reverse primers, 0.01 U Phusion R© High Fidelity DNA polymerase (NEB, M0530S)
and sterile water. The PCR conditions are given in the Table 3.1. The PCR reactions were
perfomed in a T1 PCR cycler (Biometra, Go¨ttingen).
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Table 3.1: Polymerase chain reaction (PCR) conditions. Conditions for PCR with a
OneTaq R© DNA polymerase (OneTaq) or Phusion R© High Fidelity DNA polymerase (Phu-
sion). The annealing temperature (x) was determined individually for each primer pair. The
extension time (y) was calculated based on the size of the expected product — 60 s per kbp
for OneTaq and 15 s per kbp for Phusion. t◦C — temperature, degrees Celsius.
OneTaq Phusion
t◦C Time, s t◦C Time, s
Initial denaturation 94 120 98 30
Denaturation 94 30 98 10
 25 – 35×Annealing x 30 x 30
Extension 68 y 72 y
Final extension 68 120 72 120
Agarose gel electrophoresis
For separation in a gel electrophoresis, a DNA gel loading dye (Thermo Fisher Scientific,
R0611) was added to the DNA fragments and the mixture was loaded on a 1% agarose
gel with ethidium bromide. As a molecular weight standard, 100 bp or 1 kbp DNA Ladder
(SM0321 or SM0311, Thermo Fisher Scientific) was used. Horizontal electrophoresis was
performed in a 1× TBE buffer at 140 V for approximately 30 min and gels were visualized
under ultraviolet light of 265 nm wavelength.
DNA fragment cloning
DNA was fragmented via restriction enzyme digest in appropriate buffers as suggested by the
manufacturer (NEB or Thermo Fisher Scientific). Vector backbones were dephosphorylated
using the Rapid DNA Dephos & Ligation Kit (Sigma-Aldrich, 04 898 117 001) according to
instructions of the manufacturer. Inserts were separated in an agarose gel electrophoresis
as described above and the band of interest was excised from the gel with a scalpel. Sub-
sequently, the insert fragment was purified using the Qiaquick Gel Extraction Kit (Qiagen,
28704) according to the instructions of the manufacturer. Insert fragments generated via
PCR were purified using the Qiaquick PCR purification Kit (Qiagen, 28104). To generate
inserts from synthetic oligonucleotides, a double-stranded oligonucleotide (dsOligo) was cre-
ated by mixing 1 nmol (10µl) of each complementary oligonucleotide with 80µl 50 mM NaCl
in a buffer EB (Qiagen, 19086), denaturing the mix at 95◦C for 10 min and slowly cooling
to room temperature. The generated dsOligo was phosphorylated with T4 Polynucleotide
Kinase (Thermo Fisher Scientific, EK0031) as suggested by manufacturer. Vector and insert
ligation was performed using the Rapid DNA Dephos & Ligation Kit at a molar ratio 1:3 ac-
cording to the instructions of the manufacturer. Transformation competent Escherichia coli
(E. coli) (NEB, C3019H) bacteria were transformed with 2µl ligation products as described
further.
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Plasmid DNA preparation and quality control
Transformation competent E. coli bacteria were thawed on ice. DNA was added to the
bacterial suspension and incubated on ice for 30 min. Subsequently, a heat shock for exactly
40 s was performed and afterwards the suspension was incubated on ice for another 5 min.
Next, 450µl of SOC outgrowth medium was added and the cell suspension was incubated
at 37◦C with shaking at 900 rpm (rounds per minute) for 1 h. Further, 200 – 300µl of the
bacterial suspension was uniformely plated on an agar plate with selection antibiotics and the
plate was incubated at 37◦C overnight. On the next day, single colonies were picked with a
sterile toothpick and added to round bottom tubes with 2 – 8 ml LB medium. The inoculated
LB medium mini cultures were incubated at 37◦C with shaking at 800 rpm overnight. On the
next day, plasmid DNA was isolated from the mini cultures using the QIAprep Spin Miniprep
Kit (Qiagen, 27104) according to the instructions of the manufacturer. DNA concentration
in the resulting samples was determined using a Nano-Drop ND-1000 spectrophotometer
(Thermo Fisher Scientific) by measuring absorbance at 260 nm wavelength. Further, the
correct plasmid preparations were identified by restriction enzyme digestion analysis and
the sequence in the correct samples was finally controlled by Sanger sequencing (GATC
Biotech, Konstanz).
RNA isolation and quality control
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, 74104) according to the in-
structions of the manufacturer. To remove potential genomic DNA contamination, cleanup
with RNAse-free DNAse set (Qiagen, 79254) according to the instructions of the manufac-
turer was included. RNA concentration in the resulting samples was determined with a
Nano-Drop ND-1000 spectrophotometer by absorbance measurments at 260 nm wavelength.
The integrity of the isolated RNA was assessed in a horizontal agarose gel electrophoresis.
The RNA integrity was considered intact if two clear bands corresponding the 18S and 28S
ribosomal RNA could be detected.
Complementary DNA synthesis and reverse transcription PCR
Complementary DNA (cDNA) synthesis was performed using the Maxima H Minus First
Strand cDNA Synthesis Kit (Thermo Fisher Scientific, K1681) using 1µg total RNA and
oligo(dT) primers according to the instructions of the manufacturer. Subsequently, digestion
with Ribonuclease H (RNAse H, NEB, M0297L) for 20 min at 37◦C was included. Reverse
transcription PCR (RT-PCR) was performed using OneTaq R© DNA polymerase as described
before (subsection 3.2.1).
3.2.2 Cell culture
Cultivation of cell lines
All cell lines were cultivated at 37◦C in a humidified atmosphere with 5% CO2. Cells were
cultivated in Nunc cell culture treated flasks with filter caps (Thermo Fisher Scientific).
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When reaching confluency of 80 – 100%, cells were split for subcultivation. For that, medium
was removed, cell layer was gently washed with D-PBS, a 0.05% Trypsin-EDTA solution
with phenol-red (Thermo Fisher Scientific, 25300054) was added and the culture flask was
returned to incubator. After detachment of the cell layer (5 – 15 min), the respective cell
culture medium (see before subsection 3.1.7) was added and cells were split at a ratio 1:10
– 1:20. The subcultivation procedure was performed once or twice per week, depending
on the cell line. To determine cell number, cell suspension was mixed with 0.4% Trypan
blue solution (Sigma-Aldrich, T8154) for cell viability staining and cells were counted using
a Neubauer hemocytometer (Marienfeld, Lauda-Ko¨nigshofen). All cell lines were routinely
tested for Mycoplasma contamination using the Venor R© GeM mycoplasma detection kit
(Sigma-Aldrich, MP0025). Fetal calf serum (FCS) (Biosera) used for supplementation of the
cell culture media, was heat-inactivated at 56◦C for 30 min and filtrated through a 0.22µm
pore-size EMD Millipore StericupTM Sterile Vacuum Filter Unit (SCGPU05RE, Thermo
Fisher Scientific).
Cryopreservation and storage of cell lines
To prepare cells for cryopreservation they were pelleted at 300×g for 5 min and pellets were
resuspended with the respective cell culture medium supplemented with 20% (v/v) FCS and
10% (v/v) DMSO and aliquoted into Nunc R© CryoTubes R© (Thermo Fisher Scientific, 375418).
The tubes were kept into Stratagene Cryo 1◦C Freezing Container (Agilent, Waldbronn) at
−80◦C for 24 h and then transferred to liquid nitrogen. For resuscitation of frozen cell lines,
the vials were thawed in a 37◦C water bath and the cell suspension was transferred into a
cell culture flask with the respective culture medium. After cultivation at 37◦C 5% CO2 for
24 h the culture medium was removed and supplemented with a fresh respective medium.
3.2.3 Recombinant Measles Viruses
Rescue of viral particles
Rescue of recombinant measles virus particles was performed using the RNA polymerase
II-dependent system215. Vero-αHis cells were seeded into 6-well plates 6 – 12 h prior to
preparation of a rescue. Plasmid encoding a measles antigenome (5µg) and expression
plasmids encoding MeVac N, P and L proteins, pcDIMER-N (500 ng), pcDIMER-P (100 ng)
and pcDIMER-L (500 ng), respectively, were added to ≈180µl unsupplemented DMEM.
For use as a transfection efficieny control, 0.1µg of a plasmid encoding a red fluorescent
protein, pcDI dsRed, was added to the mix. Followingly, 3µl/µg FuGENE R© HD (Promega,
E2311) was slowly added to the plasmid mix and the mixture was incubated for 25 min at
room temperature to allow formation of transfection complexes. During incubation of the
transfection mixture, Vero-αHis cells were washed twice with unsupplemented DMEM and
afterwards cultivation medium was changed to DMEM + 2% FCS + 50µg/ml kanamycin.
Subsequently, the previously prepared transfection mixture was evenly distributed per one
well with Vero-αHis and cells were cultivated at 37◦C in a humidified atmosphere with 5%
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CO2. Cells were monitored daily for formation of syncytia.
Virus propagation and storage
After rescue, the recombinant virus particles were propagated on Vero-αHis cells. For first
two to three passages, 1.5×106 Vero-αHis cells were seeded into 10 cm cell culture dishes 8 –
16 h prior infection. Before the first passage, cells with the newly rescued viral particles in the
6-well plate well were scraped in the rescue medium with a cell lifter, the cell suspension was
transferred to a 2 ml tube and vortexed vigorously. In parallel, culture medium was removed
from the prepared 10 cm dish with Vero-αHis cells and replaced with 3 ml OptiMEM R©.
Followingly, the whole rescue cell suspension was added to the Vero-αHis in the 10 cm dish
and cells were cultivated at 37◦C. After 2 – 4 h 6 ml DMEM + 10% FCS was added to
the culture dish. Cultivation was continued at 37◦C for up to 96 h. Subsequently, culture
medium was removed, up to 1 ml OptiMEM R© was added, cells were scraped with a cell
lifter, transferred to a 2 ml tube, vortexed vigorously, snap-frozen in liquid nitrogen and
stored at −80◦C. Followingly, the initial virus preparations were thawed at 37◦C in water-
bath and centrifuged for 5 min at 6000×g 4◦C to remove cellular debris. The cleared virus
suspension was aliquoted and stored at −80◦C. For virus propagation in the second and
following passages, Vero-αHis cells were infected with a multiplicity of infection (MOI) of
0.03. For large scale virus propagation, 4.5 – 5×106 Vero-αHis were seeded into 15 cm cell
culture dishes 12 – 16 h prior to infection. Inoculation with virus suspension at MOI = 0.03
was performed in 8 ml OptiMEM. After 8 – 12 h of incubation at 37◦C, 8 ml DMEM + 10%
FCS was added per plate and cultivation at 37◦C was continued for up to 45 h. For harvest
of the viral particles, the culture medium was completely removed and cells were scraped
with a cell lifter. The cell suspension was collected and a clear virus suspension was further
prepared as described above.
Virus titration
The amount of viral particles in a virus suspension was determined in a serial dilution titra-
tion assay. Serial dilutions of the virus suspension stocks in octuplicates (virus propagation)
or quadruplicates (one-step growth curves) were performed at 1:10 with a DMEM + 10%
FCS in 100µl total volume per well in 96-well plates. Subsequently, 1×104 Vero-αHis cells
in 100µl were seeded in each well and plate was incubated at 37◦C. After 72 h, individual
syncytia were counted and titer was calculated as cell infectious units per milliliter (ciu/ml).
One-step growth curves
Vero-αHis (1×105) or MC38cea (1.5×105) cells were seeded into 12-well cell culture plates.
After 12 h cell culture medium was removed and cells were inoculated with the respective
viruses at an MOI = 3 in 300µl OptiMEM in triplicates for each time point. After allowing
adsorption for 2 h, the inoculum was removed and substituted with 1 ml DMEM + 10% FCS
per well. Cells were scraped in the culture medium at the designated time points, 300µl cell
suspension from each of the triplicate infections per time point was pooled in one 2 ml tube
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and snap-frozen in liquid nitrogen. The amount of viral particles was determined by serial
dilution titration assay as described above.
3.2.4 Cell Viability Assay
Target cells were seeded into 6-well plates and cultivated for 12 h to allow adherence of the
cells. Afterwards, the culture medium was removed and cells were inoculated with the re-
spective viruses at an MOI = 5 in 800µl total volume of OptiMEM. After adsorption for
2 h, the inoculum was removed and substituted with the respective cell culture medium. At
the designated time points cell viability was determined using an XTT (2,3-Bis-(2-Methoxy-
4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide) assay. The XTT assay allows to
monitor cell viability based on the ability of metabolically active cells to convert the water-
soluble XTT reagent into an orange-colored formazan product. The amount of of the con-
verted formazan product in the medium can be quantified with a spectrophotometer. XTT
assays were performed using the Colorimetric Cell Viability Kit III (PromoKine, PK-CA20-
300-1000) according to the instructions of the manufacturer.
3.2.5 Detection of MeVac Encoded Transgene Expression
Enzyme-linked immunosorbent assays
Expression of the MeVac encoded immunomodulators was detected by enzyme-linked im-
munosorbent assays (ELISAs). All samples were cleared of cellular debris by centrifugation
at 300×g prior to analysis. Commercially available ELISA kits were used for detection of
mGM-CSF, FmIL-12 (murine IL-12p70), mIP-10 (R&D Systems, MGM00, M1270, MCX100,
respectively), CD80-Fc (Boster Biological Technology, EK0708), murine IFN-γ (eBioscience,
88-7314-22) and FhIL-12 (human IL-12p70) (eBioscience, 88-7126-22) according to the in-
structions of the manufacturer. Anti-CTLA-4 and anti-PD-L1 were detected by binding to
the respective murine proteins by ELISA as described previously104. In detail, Nunc Max-
isorp 96-well plates (Thermo Fisher Scientific, 439454) were coated with 100µg recombinant
murine CTLA-4 or PD-L1 (Sinobological, 50503-M08H-100 and 50010-M08H, respectively)
in 100µl D-PBS by incubating 2 h at room temperature or over night at 4◦C. Protein solution
was removed and wells were washed twice with 200µl D-PBS per well. To block unspecific
binding, 200µl blocking buffer consisting of D-PBS + 5% FCS + 0.05% Tween20 (Biotium,
22002) was added per well and incubated for 1 h at room temperature. Subsequently, plate
was washed three times with 200µl D-PBS per well, 100µl of the cleared sample per well
was added and incubated for 2 h at room temperature or at 4◦C over night. After incu-
bation, samples were removed and plate was washed four times with 200µl washing buffer
per well consisting of D-PBS supplemented with 0.05% Tween20. Biotin-labeled antibody
against the HA-tag was diluted 1:500 in blocking buffer, 100µl of the prepared solution
was added per well and incubated for 1 h at room temperature. Afterwards, antibody so-
lution was removed and plate was washed four times with 200µl washing buffer per well.
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Horseradish peroxidase-coupled Streptavidin (Dianova, 016-030-084) (1 mg/ml) was diluted
1:500 in blocking buffer and 100µl of the solution was added per well. After incubation for
10 min at room temperature, the Streptavidin containing solution was removed and plate
was washed five times with 200µl washing buffer per well. Further, 100µl 1-StepTM Ultra
TMB-ELISA Substrate Solution (Thermo Fisher Scientific, 34028) was added and after in-
cubation for 5 – 20 min at room temperature the reaction was stopped with Stop Solution
for ELISA (Takara, MK021). Absorbance was read at 450 nm wavelength with an Infinite
M200 Plate reader and i-control Software (Tecan, Ma¨nnedorf).
Immunoprecipitation
To concentrate MeVac expressed anti-PD-L1 and IgG1-Fc from supernatants of transduced
cells, immunoprecipitation with Sepharose-A beads (Biocat, 6520-1-BV) was performed.
Approximately 20µl of the beads were prepared for 2 ml supernatant sample. The beads
were washed three times with D-PBS and following resuspension in D-PBS added to the
samples. The samples were incubated for 1 h at room temperature with constant rotation.
Afterwards, the beads were pelleted at 300×g for 5 min and washed twice with D-PBS.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
For further separation of the IgG1-Fc and anti-PD-L1 by sodium dodecyl sulphate-polyacryl-
amide gel electrophoresis (SDS-PAGE), the immunoprecipitated samples were supplemented
with 1× Laemmli buffer and incubated at 95◦C for 5 min. Subsequently, the samples were
loaded onto a 12% precast polyacrylamide protein gel (Mini-PROTEAN R© TGX
TM
; Bio-
rad, 4561041) in SDS-Running buffer. Prestained protein ladder (Thermo Fisher Scientific,
26616) was used as a molecular weight standard. The electrophoresis was performed for
≈ 30 min at 200 V.
Western blot analysis
After SDS-PAGE electrophoresis, the proteins were transferred onto a methanol activated
Immobilon-P polyvinylidene difluoride (PVDF) membrane, 0.45µm (Merck Millipore, IPVH-
07850) in a Mini-PROTEAN R© Tetra Cell wet-chamber with 1× Novex R© Tris-Glycin Transfer
Buffer. After the transfer, the PVDF membrane was incubated in a 5% skim-milk in a TBS-T
buffer for blocking of the unspecific binding sites. After blocking, the skim-milk was substi-
tuted with 10 ml of fresh 5% skim-milk, a biotin-coupled antibody against the human IgG-Fc
was added at a dilution 1:2000 and the membrane was incubated for 2 h at room tempera-
ture. Subsequently, the membrane was washed three times with 10 ml TBS-T buffer. After
washing, 10 ml fresh 5% skim-milk was added, 4µl (1 mg/ml) horseradish peroxidase-coupled
Streptavidin (Dianova, 016-030-084) was added and the membrane was incubated 10 min at
room temperature. Afterwards, the membrane was washed three times with 10 ml TBS-T
buffer. For detection of the bound antibodies, SuperSignal West PICO Chemiluminescent
Substrate (Thermo Fisher Scientific, 10177533) was added and signals were recorded using
a ChemiDOC XRS Imaging System (Biorad, Munich).
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3.2.6 Functional Assays for MeVac Encoded Immunomodulators
Production of MeVac encoded immunomodulators
Vero-αHis cells were seeded in 15 cm cell culture dishes and infected with MeVac encoding
the respective transgenes at MOI = 0.03. Supernatants were collected (15 ml per plate)
when syncytia had spread across the whole cell layer (ca. 36 h – 44 h post infection). Su-
pernatants were snap-frozen in liquid nitrogen, stored at −80◦C and sterile filtered before
use. Expression and concentration of the immunomodulators was determined by ELISA as
described before (subsection 3.2.5).
Anti-PD-L1 binding to MC38cea cells
To assess MeVac expressed anti-PD-L1 binding to the surface of PD-L1 positive cells,
MC38cea cell line was used. 1×106 MC38cea cells were incubated with anti-PD-L1 or
IgG1-Fc containing supernatant previously collected from a one fully infected 15 cm dish
for 1 h with rotation at room temperature. After incubation, cells were washed once with
1 ml D-PBS and resuspended in 100µl D-PBS. For detection of the bound anti-PD-L1, cells
were stained with an antibody against the HA-tag at a 1:1000 dilution and incubated for
30 min at RT. Afterwards, cells were washed with 1 ml D-PBS and pellet was resuspended
in 100µl D-PBS. Further, 2.5µg of a secondary PE-coupled antibody against the mouse
IgG1-Fc was added per sample and incubated for 30 min at RT in dark. After incubation,
cells were washed with 1 ml D-PBS and resuspended in 500µl D-PBS with 0.2µg/ml DAPI.
The samples were directly acquired on an LSRII flow cytometer (BD Biosciences) with
FACS Diva software version 8.0.1 (BD Biosciences) and at least 10000 events per sample
were recorded. Results were analyzed with FlowJo V10 (Tree Star Inc., La Jolla, CA).
Functional assay for anti-PD-L1, anti-CTLA-4 and CD80-Fc
MC38cea cells (2×105) were incubated with 15 ml medium containing MeVac-encoded anti-
PD-L1, anti-CTLA-4, mCD80-Fc or IgG1-Fc. The treated MC38cea cells were resuspended
in 100µl activation medium consisting of RPMI 1640 with 5% FCS, 1% Penicillin-Streptomy-
cin (P/S), 500 nM ionomycin and 5 nM PMA and seeded in a 96-well plate. 2×105 freshly
isolated splenocytes from a C57BL/6J mouse in 100µl activation medium were added per
well. After 24 h coculture of splenocytes with the treated MC38cea cells supernatants were
collected and IFN-γ concentration was determined by ELISA as described before (subsection
3.2.5).
IFN-γ induction assay for murine IL-12 fusion protein
To assess FmIL-12 functionality 2×106 freshly isolated splenocytes from a C57BL/6J mouse
were resuspended in RPMI 1640 supplemented with 10% FCS, 1% P/S and 50 U/ml re-
combinant murine IL-2 (mIL-2; Miltenyi, 130-094-05) and varying concentrations of MeVac-
encoded FmIL-12 or respective amounts of supernatant from cells infected with MeVac
encoding eGFP. Splenocytes were seeded in 12-well plates and incubated for 48 h at 37◦C
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5% CO2. Supernatants were collected and IFN-γ concentration was determined by ELISA
as described before.
Chemotaxis assay for murine IP-10
Freshly isolated C57BL/6J mouse splenocytes were cultivated for 48 h in a medium consisting
of RPMI 1640, 10% FCS, 1% P/S, 50 U/ml IL-2. The activated splenocytes were added to
the upper part and supernatants from cells infected with MeVac mIP-10 or MeVac eGFP
to the lower part of 24-well cell culture plate with transwell migration chambers (6.5 mm,
pore size 5µm) (Corning, 29442-118). Splenocyte migration was allowed for 3 h at 37◦C.
Supernatants from the lower part of the chamber were collected and cells were counted
using trypan blue staining for dead-cell exclusion and a Neubauer hemocytometer.
3.2.7 In vivo Experiments
All animal experimental procedures were approved by the Animal Protection Officer at
the German Cancer Research Center (Heidelberg, Germany) and by the regional council
according to the German Animal Protection Law. Six to eight weeks old C57BL/6J mice
bred in Harlan Laboratories (Rossdorf, Germany) or the Central Animal Laboratory of the
German Cancer Research Center were used in all experiments.
Implantation of tumor cells
Low passage (up to eight) tumor cells were detached and collected from the cell culture flasks
as described before (subsection 3.2.2) when reaching 70 – 80% confluency. The collected cells
were washed twice with D-PBS and resuspended in D-PBS to achieve a final concentration
of 1×107 cells/ml. The cell suspension was kept on ice until use. Right flanks of the animals
were shaved and subsequently 100µl (1×106 cells) of the prepared cell suspension per mouse
was implanted subcutaneously (s.c.) into the shaved region using 1 ml syringes (VWR,
720-2561) and 26 G needles (Neolab, 194211002).
Monitoring
Tumor volumes were determined every third day by measuring the largest and smallest diam-
eter with a caliper and calculating the volume using the formula: largest diameter×(smallest
diameter)2×0.5. Mice were sacrificed when tumor volumes exceeded 1500 mm3, ulceration
occurred or animals were moribund.
Treatment with recombinant measles viruses
Treatment was initiated when the average tumor volume reached 40 – 70 mm3 (efficacy
experiments) or 120 mm3 (immune profiling experiments). Before start of the treatment the
animals were allocated to the treatment groups as to ensure similar average tumor volume
and standard deviation in the groups. The respective virus suspensions were thawed only
directly before the treatment and diluted with OptiMEM R© to concentrations of 5×105 or
1×106 cell infectious units per ml depending on experiment. Mice received intratumoral
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(i.t.) injections with 100µl of the respective virus suspensions (1 ml syringes, 26 G needles)
on four or five consecutive days (see figure legends for treatment schedules). Mice in the
mock group received treatment with 100µl OptiMEM.
Collection of peripheral blood
Peripheral blood was collected via puncture of the vena saphena. The mouse was restrained,
the left hind leg was immobilized and shaved with an electrical trimmer until the saphe-
nous vein was visible. The vein was punctured with a 26 G needle and up to 100µl of the
blood was dropwise collected with a capillary blood collection tube. Microvette R© CB 300µl,
Lithium Heparin tubes (Sarstedt, 16.443) were used if further plasma separation was in-
tended, Microvette R© CB 300µl, K2 EDTA tubes (Sartstedt, 16.444) were used if analysis
of full blood was to follow. The site of the puncture was compressed with a cotton swab to
stop the bleeding.
Depletion of immune cell populations
For immune cell depletion experiments mice received intraperitoneal injections with anti-
bodies against CD4 (clone GK1.5), CD8 (clone 2.43) or NK1.1 (clone PK136). The CD4
and CD8 depletion groups received injections of 100µg antibody in 100µl three days be-
fore s.c. implantation of MC38cea cells, on the day of tumor cell implantation, three days
post tumor cell implanatation and followingly once a week. The NK1.1 depletion group
received injections with 200µg of the antibody in 200µl three and two days before tumor
cell implantation, on the day of tumor cell implantation, one and three days post tumor cell
implantation and followingly once a week. The depletion efficiency was controlled by flow
cytometry of peripheral blood in selected animals from each group once a week as described
further (subsection 3.2.8).
3.2.8 Experiments with Murine Tissues
Isolation of murine splenocytes
Aseptically isolated spleens were maintained in RPMI 1640 at 4◦C until further processing.
Spleens were passed through 100µm nylon cell strainers (Neolab, 352360) into 10 ml RPMI
1640 and pelleted. The pellets were resuspended in 1 ml ACK lysing buffer for red blood cell
lysis, incubated 10 min at room temperature and pelleted. Cells were resuspended in D-PBS
and kept on ice until further use.
Tumor-specific IFN-γ immune memory recall
MC38cea, MC38 and B16 cells were treated with 20µg/ml mitomycin-C for 2 h with shak-
ing at 37◦C. Subsequently, cells were washed three times with D-PBS and resuspended in
activation medium consisting of RPMI 1640 with 10% FCS, 1% P/S and 50 U/ml mIL-2.
Freshly isolated murine splenocytes were resuspended in activation medium. Cocultures were
prepared in 24-well plates by seeding 1×105 tumor cells with 1×106 splenocytes per well in
0.5 ml total volume of activation medium. As controls 1×106 splenocytes were cocultivated
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with Vero or DLD-1 cell lysates prepared by lysis of 1×106 cells per ml with one freeze-thaw
cycle. Cells were cocultivated for 48 h, supernatants were collected and IFN-γ concentration
was assessed by ELISA as described before (subsection 3.2.5).
Measurement of FmIL-12 concentration in peripheral blood of mice
Peripheral blood from animals was collected for serum separation as described before (sub-
section 3.2.7) and kept on ice until further use. Plasma separation was performed by cen-
trifuging the tubes at 2000×g for 15 min. The serum fraction was transferred to a sterile
tube by pipetting and stored at −80◦C until analysis. FmIL-12 concentration in the samples
was determined by ELISA as described before (subsection 3.2.5).
Flow cytometry of immune cell populations in peripheral blood
Freshly collected murine peripheral blood (up to 100µl) was eluted from the collection tubes
into 1.5 ml Eppendorf tubes with 700µl ACK lysing buffer, vortexed briefly and incubated
for 5 min at room temperature. Subsequently, 700µl D-PBS was added and the samples
were centrifuged at 300×g for 5 min at room temperature. Supernatant was removed, pellet
was resuspended in 700µl ACK lysing buffer, incubated for 5 min, 700µl D-PBS was added
and centrifuged at 300×g for 5 min. Supernatant was removed and pellet was resuspended
in 100µl D-PBS. Fluorescently labeled antibodies against murine leukocyte subpopulation
markers were added — 1µl anti-CD45.2-PerCP-CyTM5.5, 1µl anti-CD3 Molecular Complex-
Alexa Fluor R© 700, 1µl anti-CD4-APC-CyTM7, 1µl anti-CD8a-APC, 2µl anti-CD335-FITC,
and samples were incubated for 30 min in dark at room temperature. For washing, 1 ml
D-PBS per sample was added and samples were centrifuged at 300×g for 5 min. Pellets were
resuspended in 500µl D-PBS with 1µg/ml DAPI for dead cell staining and acquired directly
on a BD FACS AriaII instrument with FACS Diva software version 8.0.1 (BD Biosciences).
Results were analyzed with FlowJo V10 (Tree Star Inc., La Jolla, CA).
3.2.9 Immune Profiling of Tumor Environment
Quantification of transcription factor mRNA levels
Pieces of freshly explanted MC38cea tumors were immersed in RNAlater (Qiagen) and stored
at −20◦C until further processing. Total RNA was extracted and cDNA synthesis was
carried out as described before (subsection 3.2.1). RT-qPCR was prepared with 1µl cDNA,
200 nM respective forward and reverse primers, 10µl Power SYBR R© Green PCR Master
mix (Thermo Fisher Scientific, 4367659) and water up to 20µl total reaction volume. The
reaction conditions were as follows — 10 min initial denaturation at 95◦C, followed by 40
cycles of 15 s denaturation at 95◦C, 60 s annealing and extension at 55◦C (T-bet) or 60◦C
(Foxp3 and L13a), and 5 s fluorescence detection at 72◦C on a Roche LightCycler R© 480
System. Melting curve analysis was prepared to identify specific amplification. Minus reverse
transcriptase controls and no template controls were run in parallel with the cDNA samples.
Stable expression of the reference gene among treatment groups was validated using the
40
3 Materials and Methods
Normfinder Software219.
Intratumoral cytokine profiling
Protein extraction from freshly harvested MC38cea tumors was performed as described in220.
In brief, freshly isolated MC38cea tumors were snap-frozen in liquid nitrogen and stored at
−80◦C until processing. Samples were thawed on ice, minced in small pieces and homog-
enized with a pestle in lysis buffer with 10 mM Tris–HCl (pH 8.0), 150 mM NaCl, 10%
Glycerol, 5 mM EDTA, 1% NP-40 and one cOmplete Mini, EDTA-free Protease Inhibitor
Cocktail Tablet (Sigma-Aldrich, 05892791001). Lysates were incubated for 1 h at 4◦C with
rotation and sonicated afterwards with an intermittent (0.5 min) on and off sonication regi-
men for 7 min (High intensity) using Diagenode Bioruptor R© Standard with a cooling water
pump (Diagenode, Seraing, Belgium). Lysates were cleared by centrifugation at 13000×g
for 15 min and aliquots of supernatants were stored at −80◦C until analysis. Cytokine con-
centrations were measured with the Mouse Th1/Th2/Th17 Cytokine Bead Array Kit (BD
Biosciences, 560485) according to the manufacturer’s instructions.
Flow cytometry of tumor infiltrating lymphocytes
Single cell suspensions were prepared from freshly isolated MC38cea tumors. Tumors were
minced in small pieces in RPMI 1640 + 10% FCS + 200 U/ml Collagenase Type I and
incubated for 30 min at 37◦C with gentle vortexing every 10 min. The resulting cell sus-
pensions were passed through 100µm nylon cell strainers and cells were spun down and
resuspended in D-PBS. Subsequently 2×106 cells per sample were resuspended in 100µl D-
PBS and stained with the antibodies against murine leukocyte subpopulation markers — 1µl
CD45.2-PerCP-CyTM5.5, 1µl CD3 Molecular Complex-Alexa Fluor R© 700, 1µl CD4-APC-
CyTM7, 1µl CD8a-APC, 1.25µl CD69-PE, 2µl CD335-FITC. For dead cell staining samples
were resuspended in D-PBS with 1µg/ml DAPI before acquisition. Data were acquired on
a BD FACS AriaII instrument with FACS Diva software version 8.0.1 and analyzed with
FlowJo V10. Only samples with at least 3000 events were included in the analysis.
3.2.10 Statistical Analyses
Statistical analyses were performed using GraphPad Prism software (version 6.01; Graph-
Pad Software). Tumor volume differences in in vivo experiments, ELISA results in restimu-
lation experiments, RT-qPCR, flow cytometry and cytokine profiling results were analyzed
by one-way analysis of variance (ANOVA) with Tukey’s multiple comparison post-hoc-test.
Multiplicity adjusted p-values are reported for data analyzed with ANOVA. Results were
considered statistically significant if p-values were lower than 0.05. Tumor volume distri-
butions were analyzed for the last day when all animals where alive. Survival curves were
analyzed by log-rank (Mantel-Cox) test with Bonferroni correction for multiple comparisons.
Results were considered statistically significant if the p-value was lower than the corrected
threshold after Bonferroni correction.
41

4 Results
4.1 Construction and Characterization of Recombinant
MeVac in vitro
Measles Schwarz vaccine strain viruses (MeVac) encoding different immunomodulators were
developed to support establishment of an anti-tumor immune response by application of the
oncolytic MeVac vectors. Transgenes encoding the chosen immunomodulators were inserted
into different positions of the MeVac genome. Tropism of the novel vectors was modified by
displaying a single chain antibody variable fragment on the MeVac Hemagglutinin (H) to
allow transduction of target murine cells expressing the corresponding antigen. The novel
vectors were characterized in terms of replication kinetics, cytotoxic effects in the target
murine cells, expression kinetics of the inserted immunomodulators and their functionality
in vitro.
4.1.1 Additional Transcription Unit Behind the Hemagglutinin
Gene
Transgenes of interest can be inserted into the MeV genome in specifically designed addi-
tional transcription units (ATUs) with artificial gene-end/gene-start signals harboring unique
cloning sites. MeVac genomes with ATUs in the leader position (pcMeVac ld-ATU) and
downstream the P gene (pcMeVac P-ATU) have been previously constructed by S. Bossow
(unpublished). The ld-ATU contains an N→N gene-end/gene-start transit to transgene (Tg)
and a unique AscI cloning site. The P-ATU contains a P→P transit to Tg and a unique
MauBI cloning site. Transgenes inserted further upstream of the MeV genome are expressed
at higher levels than transgenes inserted further downstream due to the transcription gra-
dient characteristic for MeV151. Insertion of a transgene in a position as close as possible
to the MeV leader is therefore favorable for higher expression level. However, it is known
from previous work with Edmonston B vaccine strain MeV (NSe) that insertion of large
transgenes in the leader position may lead to severe inhibition of virus replication, e.g. NSe
ld-FmIL-12212, and rescue of viral particles from certain constructs can even be impossible,
e.g. NSe ld-anti-CTLA-4213.
To allow insertion of large transgenes and to avoid substantial attenuation of virus if
using existing MeVac constructs with ATUs closer to leader, a MeVac genome with an ATU
behind the H gene was constructed. The concept of the H-ATU was identical to that pre-
viously used in the Edmonston B genome104. The H-ATU was designed as a 66 nt fragment
harboring 5’-SpeI and 3’-XbaI sites. The gene-end/gene-start transit to Tg was designed as
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Figure 4.1: Schematic for cloning of MeVac with an additional transcription unit
(ATU) behind the Hemagglutinin gene. The SpeI -XbaI cassete containing H-ATU was
first inserted into a pUC19 cloning vector containing MeVac NarI -NarI subgenome. The
NarI -NarI fragment containing the H-ATU was then exchanged in the pcMeVac, thereby
generating pcMeVac H-ATU. Details in the figure are not depicted to scale. GE — gene-end
signal; GS — gene-start signal.
an N→P transit. The 5’ sequence in the ATU was slightly modified to exclude the “hidden”
start codons. The MeVac genome contains two SpeI sites in contrast to the Edmonston
B or NSe (“NarSpe eliminated”) vaccine strain. Therefore the 66 nt H-ATU cassette was
first inserted into a 11000 bp NarI -NarI MeVac subgenome in a pUC19 cloning vector as
a dsOligonucleotide SpeI -XbaI fragment via the SpeI site unique in the subgenome (con-
structed by C. E. Engeland). Subsequently, a PflFI -PmlI fragment containing the H-ATU
was excised from the generated subgenome and exchanged for the PflFI -PmlI fragment in
pcMeVac yielding pcMeVac H-ATU (Figure 4.1).
4.1.2 Construction of MeVac Encoding Immunomodulators
Transgenes coding for different immunomodulators were inserted into the MeVac genomes
with ATU downstream of the MeV leader, downstream the P gene or downstream the H gene.
Construction of the novel MeVac genomes was guided by two general considerations. Firstly,
MeV must have a genome length of a multiple of six (“rule of six”) to derive replication
competent virus particles188;221. Secondly, insertion of large transgenes (> 1 kbp) close to
the leader position of the genome should be avoided as it may severely impair replication of
the virus212;213.
Transgenes smaller than 1 kbp which included mGM-CSF, mIP-10 and eGFP as a con-
trol were inserted into the leader (ld) position of MeVac genome as MluI -AscI fragments
via the unique AscI restriction site (Figure 4.2). MeVac genomes encoding mGM-CSF and
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eGFP had previously been constructed by S. Bossow and C. Grossardt (unpublished). Murine
IP-10 encoding cassette was designed as an MluI -AscI fragment containing the 295 nt ORF
of mIP-10 preceded by Kozak sequence (GCCACC) and followed by a two nucleotide spacer
(TA) to obtain a 312 nt construct. The mIP-10 (mCxcl10 ) was amplified with primers flank-
ing the novel construct using cDNA obtained from murine splenocytes and cloned into a
pJET 1.2/blunt cloning vector. The mIP-10 cassette was excised from the cloning vector as
an MluI -AscI fragment and inserted into the MeVac ld-ATU via the unique AscI restriction
site (Figure 4.2.a).
The cassette encoding murine IL-12 was designed for expression of IL-12 as a fusion
protein (FmIL-12 – murine IL-12 fusion protein) consisting of the IL-12 p35 and IL-12 p40
protein subunits linked by a (Gly3Ser)4 linker which had previously been constructed for
insertion into the NSe genome by C. Grossardt212 based on results of Lieschke et al.222.
Systematic experiments with MeV Edmonston B vaccine strain viruses encoding FmIL-12 in
ld-ATU, P-ATU and H-ATU positions revealed that P-ATU is the most suitable, ensuring
high expression of FmIL-12 without significant attenuation of the virus212. The P-ATU
was therefore considered the most appropriate position for FmIL-12 insertion also into the
MeVac genome. The FmIL-12 cassette was excised from a pCG expression vector as a PauI -
MluI fragment and inserted into the pcMeVac P-ATU via the unique MauBI cloning site
(Figure 4.2.a).
Cassettes encoding antibodies against the negative regulators of murine T cells, CTLA-4
and PD-L1, as well as a soluble form of the murine T cell costimulatory molecule CD80
were inserted into the MeVac H-ATU. Also, a cassette encoding the respective antibody
constant region in these constructs, IgG1-Fc, for use as a control, was inserted into the MeVac
H-ATU. Cassettes encoding antibodies against murine CTLA-4 and PD-L1 and human
IgG1-Fc fragment, previously constructed by C. E. Engeland104, were used as templates. The
respective constructs were excised from pCG expression vectors as MluI -PauI fragments and
inserted into pcMeVac H-ATU via the unique MauBI cloning site (Figure 4.2.a).
The murine CD80 molecule, which under physiological conditions is expressed on the
cell surface, was inserted for expression from MeVac in a soluble form. CD80 is a known
T cell costimulatory molecule participating in activation of T cell receptor (TCR) signaling
through interaction with the TCR co-receptor CD28223. CD80 has also been shown to
interact with the negative T cell regulator PD-L159. Recent data have shown that a soluble
form of CD80 constructed from the extracellular domain of the CD80 molecule fused to an
IgG-Fc region (CD80-Fc) is functional and can counteract the PD-1/PD-L1 suppression even
more efficiently than blockade with anti-PD-1/PD-L1224. CD80-Fc was therefore considered
a more promising candidate for insertion into the MeVac genome than the native, membrane-
bound form of CD80. CD80-Fc was constructed by fusing the extracellular part of murine
CD80 with the same human IgG1-Fc region as used in both anti-CTLA-4 and anti-PD-L1
constructs via fusion PCR. The first PCR fragment consisting of the MluI restriction site
followed by a Kozak sequence (GCCACC), the murine CD80 signal peptide, the extracellular
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Figure 4.2: Schematics of the constructed recombinant MeVac genomes and retar-
geting strategy. a — transgenes encoding different immunomodulators as well as eGFP
and IgG1-Fc as controls were inserted into additional transcription units (ATUs) in different
positions of MeVac genome — ld-ATU (T1), P-ATU (T2), H-ATU (T3). b — retargeting of
the MeVac H protein was achieved by exchanging the authentic H gene in the novel con-
structs for an H gene with mutated attachment site to measles receptors CD46 and CD150
(“blinded” H — Hbl) and fused to a variable fragment of single chain antibody (scAb)
against human CEA (carcinoembryonic antigen) or CD20 to allow specific transduction of
murine MC38cea or B16-CD20 cell lines, respectively. The modified H gene contains a six
histidine tag (His6) to allow transduction of Vero cells expressing scAb for His6. A SpeI -SpeI
fragment encoding the modified H gene was cloned into an expression vector (pCG MeVac
Hbl-scAb SpeI -SpeI ) and inserted into the recombinant MeVac genomes (a) via exchange of
SpeI -SpeI fragments. ld — measles virus leader; tr — measles virus trailer.
part (up to the asparagine in position 246) of murine CD80 and the first 26 nucleotides of
the hinge of IgG1-Fc was amplified using a pCG vector encoding murine CD80 (constructed
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by C. E. Engeland, unpublished) as a template. The second PCR fragment consisting of the
human IgG1-Fc region followed by a myc tag, a stop codon and an AscI restriction site
was amplified using a pCG vector encoding human IgG1-Fc as a template. The obtained
PCR products were fused with flanking primers in an overlap PCR to obtain the mCD80-Fc
construct of 1614 bp. The resulting mCD80-Fc was inserted into the pcMeVac H-ATU as an
MluI -AscI fragment via the unique MauBI cloning site (Figure 4.2.a).
4.1.3 Retargeting of MeVac Hemagglutinin
An immunocompetent mouse tumor model is a prerequisite to study effects of immunovi-
rotherapy with the novel MeVac constructs encoding immunomodulators in vivo. MeV is
however able to naturally transduce only primate cells which express the specific receptors
CD150, CD46 or nectin-4225. Retargeting of the MeV attachment protein H to a defined
surface antigen is possible through different strategies with the most common being display
of single chain variable fragments of antibodies226, 227. Two immunocompetent murine tumor
models, syngeneic for C57BL/6 mice, expressing a defined antigen for targeting with a single
chain antibody (scAb) on MeV H have previously been created — murine colon adenocarci-
noma MC38 expresssing human carcinoembryonic antigen (CEA) (MC38cea)218, 190 and B16
murine melanoma expressing human CD20 (B16-CD20)212, 104. MC38cea was chosen as the
main tumor model for further use in this study. Expression of human CEA on mRNA level
by the MC38cea cell line maintained in laboratory was confirmed by RT-PCR (Figure 4.3).
In all the novel MeVac constructs the H protein was modified to allow transduction of
the target murine MC38cea cells via the human CEA antigen. The natural H attachment
sites to CD150 and CD46 were ablated by mutations in the coding region of the H gene
and a SpeI -SpeI subgenomic fragment with the mutated (“blinded”) H gene was cloned into
the pCG expression vector (pCG MeVac Hbl, generated by C. E. Engeland). MeVac Hbl
additionally contains a six-histidine (His6) tag at the 3’ end of the mutated H. The His6 tag
Figure 4.3: Human carcinoembryonic antigen (CEA) expression in MC38cea cell
line. Human CEA expression was assessed in MC38cea and MC38 cell lines by RT-PCR.
Murine beta 2 microglobulin (β2m) was amplified as a loading control. +RT – cDNA
samples; -RT – minus reverse transcriptase controls; NTC – no template control.
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allows rescue and propagation of the fully “blinded” MeVac on African green monkey kidney
Vero cells transduced for stable expression of a scAb against the His6 tag (Vero-αHis)
216.
Targeting of the “blinded” MeVac H protein (Hbl) to a desired antigen was further achieved
by displaying a respective scAb as an extension to the C terminus of the “blinded” H190. The
anti-hCEA scAb (clone MFE-23) with a 16 aa spacer between the VH and VL chains was used,
which had previously been developed in a context of retargeting the H protein of Edmonston
B vaccine strain MeV190. The scAb fragment was excised from the pCG vector encoding
the NSe H protein retargeted to CEA (generated by C. Grossardt) as an SfiI -NotI fragment
and inserted into pCG MeVac Hbl SpeI -SpeI via the respective restriction sites, yielding
pCG MeVac Hbl-αCEA SpeI -SpeI (Figure 4.2.b). The generated Hbl-αCEA fragment was
further inserted into the respective MeVac genomes encoding transgenes (Figure 4.2.a) by
exchange of the SpeI -SpeI fragment except for the FmIL-12 encoding construct. As the
second SpeI site is missing in the pcMeVac P-FmIL-12 construct due to the ATU inserted
downstream of P, in this construct the retargeting was achieved by exchanging the PflFI -
FspI fragment containing the fully retargeted H with pcMeVac ld-eGFP Hbl-αCEA. The
retargeting strategy allows a flexible change of the used model as a library of pCG MeVac
Hbl-scAb SpeI -SpeI fragments targeting different antigens can be created.
To assess the functionality of the retargeted H protein Vero, Vero-αHis, MC38 and
MC38cea cells were transduced with MeVac ld-eGFP Hbl-αCEA. No syncytia formation
was observed in Vero cells suggesting ablation of the natural tropism of the virus. Also no
spread of the infection could be observed in murine MC38 cells which lack the receptors
for MeV entry (Figure 4.4). In Vero-αHis syncytia had spread over the whole cell layer
within 48 h after infection and most of the cells were lysed 72 h after infection. In MC38cea
cells single eGFP positive cells were observed 48 h post infection and syncytia formation
was observed 72 h post infection (Figure 4.4). These results therefore illustrate that full
retargeting of the virus was achieved, ablating the natural tropism of MeVac and ensuring
targeted infection of murine MC38cea cells and Vero-αHis cells through the human CEA
and scAb against His6, respectively.
4.1.4 Replication Kinetics and Cytotoxic Effects
One step growth curves in the producer Vero-αHis and target MC38cea cell lines were gen-
erated to characterize replication kinetics of the novel MeVac constructs. In Vero-αHis cells
titers for viruses with transgenes in the leader position of the genome (eGFP, mGM-CSF,
mIP-10) and with FmIL-12 downstream of the P gene peaked 96 h post infection in the range
of 4×105 ciu/ml and 3.5×103 ciu/ml for FmIL-12 and mGM-CSF encoding viruses, respec-
tively (Figure 4.5). Viruses with transgenes downstream of the H gene reached highest titers
in Vero-αHis cells 36 – 48 h post infection in the range of 2×106 ciu/ml and 1×104 ciu/ml
for anti-CTLA-4 and IgG1-Fc encoding viruses, respectively (Figure 4.5). For the IgG1-Fc
encoding virus only a minimal increase in the amount of viral particles was observed in Vero-
αHis cells. This could be attributed to the fact that a very rapid destruction of the cell layer
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Figure 4.4: Targeted infection with MeVac. Cells were inoculated with MeVac ld-eGFP
Hbl-αCEA at a multiplicity of infection = 1 and fluorescence microscopy images were taken
at the depicted time points. Scale bars: 100µm.
was observed when using this virus (Figure A.1∗). Overall, viruses encoding smaller trans-
genes in the leader position reached lower titers in Vero-αHis cells than viruses with large
transgenes downstream of the H gene. Reason for this could be a faster spread and a rapid
destruction of cell layer by the less attenuated viruses with smaller transgenes which limits
production of viral particles. In the target MC38cea cells titers for all viruses peaked between
36 h and 48 h post infection in the range of 4×105 and 2.25×103 ciu/ml for anti-CTLA-4 and
mGM-CSF encoding viruses, respectively. In contrast to Vero-αHis cells, a steep decline
of the virus particle amount after 48 h post infection was observed (Figure 4.5). Maximum
titers in MC38cea for all viruses except for MeVac encoding IgG1-Fc were lower than in
Vero-αHis cells. The observed peak of virus particle production followed by the decline
and the lower amount of the produced viral particles in MC38cea cells in comparison to
Vero-αHis cells reflects the host restriction of MeV to primate cells and the inability of MeV
to efficiently counteract post-entry barriers in murine cells228.
Of note is that the mGM-CSF encoding virus reached the lowest titers in both cell
lines and it could be clearly observed that the spread of syncytia in Vero-αHis cell layer was
markedly slower than for the other viruses (Figure A.2). Also production of this virus to high
titers (>1×107 ciu/ml) was hindered in comparison to other vectors. Titers in the third and
fourth passage of the virus never exceeded 5×106 ciu/ml despite the complete fusion of the
cell layer in syncytia. Complete genome sequencing was performed for a fourth virus passage
of MeVac ld-mGM-CSF Hbl-αCEA and for a fourth virus passage of MeVac P-FmIL-12 Hbl-
αCEA construct. One silent mutation within the H ORF and three one nucleotide changes
∗Here and further, figures numbered as A.1, A.2, etc. are included in Appendix.
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Figure 4.5: One-step growth curves in Vero-αHis and MC38cea cells. Cells were
transduced with MeVac encoding the respective transgenes at a multiplicity of infection = 3.
Cell suspensions were collected by scraping in the culture medium and titers determined at
the depicted time points.
in the intergenic regions, that were identical in both constructs, were detected (Table A.1
in Appendix). Thus, mutations in the sequence of the mGM-CSF encoding construct were
excluded as the cause for its impaired replication. Accumulation of defective interfering
particles (DIs) could also explain an impaired replication of the mGM-CSF encoding vector.
DIs are defective, incomplete virus genomes, that arise if the virus polymerase prematurely
stops genome synthesis and subsequently, while still bound to the incomplete genome, re-
initiates genome synthesis in the opposite direction. In such a manner, a hybrid of a virus
genome and anti-genome with complementary ends is being generated. The DIs are known
to interfere with virus replication and the frequency of DI generation can depend on virus
strain, infected cell type, as well as the history of the virus passage229. To assess, if excessive
DI generation could explain the impaired replication of MeVac encoding mGM-CSF, a PCR
based assay was performed as described by Pfaller et al.230. Five other virus suspensions of
the third or fourth passage were assessed along with the mGM-CSF encoding virus. In all
of the tested virus passages, amplification with the two forward primers A1SnaBI /A2NotI
yielded two bands at approximately 600 bp and 800 bp, which could indicate either common
DIs species in all of the samples or an unspecific amplification. In the sample prepared from
the mGM-CSF encoding virus the common band at 800 bp was missing. Only in the sample
prepared from the mGM-CSF encoding virus suspension, a distinct band of approximately
300 bp was detected. This result indicates that, indeed, excessive DIs accumulation could
be the cause of the impaired replication of the mGM-CSF encoding MeVac. Furthermore,
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in addition to the mGM-CSF encoding MeVac, only in virus passages of MeVac encoding
a murine IL-15 protein agonist (FmIL-15) constructed in a different project, which also
demonstrated impaired replication, bands additionally to the two common bands could be
detected after DIs specific amplification.
Cytotoxic properties of the novel constructs were further assessed. Target MC38cea cells
were transduced with the respective viruses at an MOI = 5 and cell viability was determined
with an XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide)
assay. As expected based on the observed impaired replication in MC38cea cells, only mild
cytotoxic effects were detected. Cell viability decreased over the first 48 – 72 h and recovered
afterwards (Figure 4.6). The vector encoding anti-PD-L1 caused the greatest decline of cell
viability (Figure 4.6).
Figure 4.6: Cytotoxicity in target MC38cea cells. Cells were transduced with MeVac
encoding the respective transgenes at a multiplicity of infection = 5 and cell viability was
determined by XTT assay at the depicted time points. Mean results of triplicate infections
per time point with standard errors of the mean (not visible for some data points) are shown.
4.1.5 Transgene Expression and Functionality
To assess expression kinetics of the immunomodulators inserted into the MeVac genome,
MC38cea cells were transduced with the respective vectors and the concentration of im-
munomodulators was measured by ELISA at different time points. Expression of the control
transgenes eGFP and IgG1-Fc was determined by fluorescence microscopy (Figure A.2) and
western blot analysis (Figure A.4), respectively. Different patterns of expression kinetics were
observed for the MeVac encoded immunomodulators (Figure 4.7). Anti-CTLA-4 expression
reached a peak 36 h post infection and declined afterwards. Anti-PD-L1 and FmIL-12 con-
centration continuously increased over the course of the experiment reaching the highest
level 96 h post infection, but for mCD80-Fc and mGM-CSF the highest concentration was
measured in the inoculum at the time point of infection (0 h).
In case of mIP-10, an increase of the specific signal was observed also in the supernatants
collected from cells transduced only with the eGFP encoding vector. A barplot depicting
mIP-10 concentration in MC38cea transduced with both mIP-10 and eGFP vectors showed
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Figure 4.7: Expression of MeVac encoded immunomodulators. MC38cea cells were
transduced with MeVac encoding the respective immunomodulators and eGFP or IgG1-Fc
as control vectors at a multiplicity of infection = 3. Supernatant samples were collected
at the depicted time points and transgene expression was detected by ELISA. Unspecific
binding was controlled by IgG1-Fc (upper panels) or eGFP (lower panels) supernatants and
subtracted from the specific measurements. In case of mIP-10 an increase of the signal was
observed in the eGFP controls which was not subtracted from the specific measurements
and is depicted accordingly.
that there is a specific expression of MeVac encoded mIP-10 as a markedly higher mIP-10
concentration was detected in cells transduced with mIP-10 encoding vector (Figure 4.7).
However, the observed steady increase of the specific signal also in control samples suggested
that untransduced MC38cea constitutively express mIP-10. RT-PCR was carried out to
examine mIP-10 expression in untransduced MC38cea, parental MC38 and the unrelated
B16 murine melanoma cell line on mRNA level. Results confirmed that mIP-10 is expressed
in both MC38cea and MC38 cell lines and to a lesser extent also in B16 cells (Figure A.5).
Expression of the mIP-10 receptor CXCR3 was also further assessed by RT-PCR in all of
these cell lines. Weak bands for the specific product were detected in MC38cea and MC38
lines and a notably more intensive band in the B16 line (Figure A.5). Therefore, the MC38cea
model was considered unsuitable for evaluation of mIP-10 in the context of MeV therapy.
Functionality of MeVac-encoded immunomodulators was further evaluated in vitro.
Measles encoding mGM-CSF has been studied previously212. Functionality of MeVac-encoded
mIP-10 was assessed in a chemotaxis assay. Supernatants containing MeVac-encoded mIP-
10 attracted more splenocytes than supernatants from cells infected with MeVac encoding
eGFP (Figure A.6). Cell lines expressing CTLA-4 and PD-L1 were necessary to assess
the ability of MeVac encoded anti-CTLA-4, anti-PD-L1 and mCD80-Fc to counteract the
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Figure 4.8: Murine Ctla4 and Pd-l1 expression in MC38, MC38cea and B16 cell
lines. RT-PCR for murine Ctla4 variant 1 (v1) and variant 2 (v2), Pd-l1 (Cd274 ) and
Gapdh as a loading control was carried out using cDNA from the indicated cell lines. cDNA
from murine splenocytes activated with PMA and ionomycin served as a positive control.
+RT — cDNA samples; -RT — minus reverse transcriptase controls; NTC — no template
control; Act.splen. — activated splenocytes.
immunosuppressive signaling. The target MC38cea, parental MC38 and B16 cell lines were
tested for expression of both CTLA-4 and PD-L1 on mRNA level by RT-PCR. Neither of the
two murine CTLA-4 splice variants was detected in any of the tested cell lines (Figure 4.8).
PD-L1 expression was however detected in all of the cell lines (Figure 4.8).
Anti-PD-L1 binding to the PD-L1 positive MC38cea cells was assessed by flow cytome-
Figure 4.9: MeVac encoded anti-PD-L1 binding to MC38cea cells. MC38cea cells
were incubated with supernatants from Vero-αHis infected with MeVac encoding anti-PD-L1
or IgG1-Fc. For detection of bound anti-PD-L1 cells were stained with primary Ab specific
for the HA tag and secondary Ab coupled to PE. DAPI staining was used to exclude dead cells
and samples were analyzed by flow cytometry. Overlay histogram for PE of DAPI- MC38cea
populations from one of three independent experiments is shown in the left panel. Dashed —
untreated MC38cea; dotted — MC38cea treated with IgG1-Fc; solid fill — MC38cea treated
with anti-PD-L1. Average median fluorescence intensity (MFI) of PE for DAPI- populations
with standard error of the means from the three independent experiments is shown in the
right panel.
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try. An increase in the fluorescence signal was observed in samples treated with supernatants
from Vero-αHis infected with MeVac encoding anti-PD-L1 in comparison to untreated cells
or cells treated with supernatant from Vero-αHis infected with MeVac encoding IgG1-Fc
(Figure 4.9), indicating specific binding of MeVac encoded anti-PD-L1 to the surface of
PD-L1 positive cells.
The ability of MeVac encoded anti-PD-L1 and mCD80-Fc to counteract the immuno-
suppressive signaling of PD-L1 positive MC38cea cells was further assessed. Cocultivation of
activated murine splenocytes with untreated MC38cea cells markedly decreased IFN-γ con-
centration in culture medium, suggesting that immunosuppressive signaling is taking place.
However, IFN-γ concentration increased when activated splenocytes were cocultivated with
MC38cea cells treated with supernatants collected from cells infected with MeVac encoding
anti-PD-L1, mCD80-Fc or anti-CTLA-4 (Figure 4.10.a). IFN-γ concentration did not in-
crease if MC38cea cells were treated with supernatants containing MeVac encoded IgG1-Fc.
These results suggest that the examined MeVac encoded immunomodulators are able to
counteract immunosuppression mediated by PD-L1 positive tumor cells.
Functionality of MeVac encoded FmIL-12 was assessed by the ability to induce IFN-γ
production in murine splenocytes. Cultivation of murine splenocytes in medium containing
different concentrations of MeVac encoded FmIL-12 revealed that the increase in IFN-γ
production is dependent on FmIL-12 concentration in the range of 0.01 - 1 ng/ml. IFN-γ
concentration decreased when using FmIL-12 concentrations higher than 1 ng/ml, probably
due to over-stimulation of the cells and activation induced cell death (Figure 4.10.b).
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Figure 4.10: Functionality of MeVac encoded immunomodulators. a – MC38cea
cells were treated with supernatants from Vero-αHis cells infected with MeVac encoding
the respective immunomodulators and cocultured at a ratio 2:1 with murine splenocytes in
the presence of PMA and ionomycin. After 24 h supernatants were collected and IFN-γ
concentrations were measured by ELISA. Relative activation corresponds to the ratio of the
optical density (absorbance at 450 nm minus 570 nm) of the respective samples to activated
splenocytes. Mean relative activation values with standard errors of the mean from three in-
dependent experiments are shown; b – murine splenocytes were stimulated with recombinant
murine IL-2 and cultivated in the presence of medium from Vero-αHis infected with MeVac
encoding FmIL-12 or eGFP. After 48 h supernatants were collected and IFN-γ concentrations
were measured by ELISA. Mean IFN-γ concentrations with standard errors of the mean of
triplicate splenocyte cultures are shown for each FmIL-12 concentration. IFN-γ concentra-
tions in the eGFP controls were close to background (data not shown). Representative data
from one of two independent experiments are shown.
4.2 Evaluation of Therapeutic Efficacy in vivo
Therapeutic efficacy of the novel MeVac vectors encoding immunomodulators was evalu-
ated in the immunocompetent subcutaneous (s.c.) murine colon adenocarcinoma model
MC38cea226. First, screening experiments to identify the most promising vectors in terms of
reduction of tumor growth and extension of animal survival were performed. After the screen-
ing experiments a head-to-head comparison of the most promising vectors encoding FmIL-12
and anti-PD-L1 was performed in the s.c. MC38cea model. The potential for combination of
the MeVac vectors encoding FmIL-12 and anti-PD-L1 was also considered. Therapeutic effi-
cacy of the combination of these two vectors was evaluated in the s.c. MC38cea model and in
the more aggressive s.c. murine melanoma B16-CD20 model104. Finally, the establishment
of systemic anti-tumor immunity in long-term survivors of MeVac therapy was examined in
tumor rechallenge experiments in vivo and splenocyte restimulation experiments in vitro.
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4.2.1 Identification of the Most Promising Vectors
First, vectors encoding immunomodulators targeting the immunosuppressive tumor envi-
ronment (anti-CTLA-4, anti-PD-L1, mCD80-Fc) and selected combinations of these were
compared. Statistically significant differences in tumor growth or survival of the animals
could not be observed between the treatment groups (Figure 4.11.a). However, a trend to-
wards an extended survival of animals was observed in the group that received treatment
with the anti-PD-L1 encoding vector only. Two out of nine animals in the anti-PD-L1 group
experienced complete tumor remissions (Figure 4.11.a). It must be noted that a halted
tumor growth for a period of approximately 35 days was observed for one mouse receiving
treatment with the mCD80-Fc encoding MeVac, indicating a therapeutic effect of the applied
vector (Figure A.7).
Vectors encoding immunomodulators targeted at enhancement of antigen presenting cell
(mGM-CSF) and immune effector cell functions (FmIL-12 and mIP-10) as well as selected
combinations of these were compared in the next experiment. Due to the propagation
problems of the mGM-CSF encoding vector (see subsection 4.1.4), a lower virus dose (5×106
ciu/injection) was used, treatment was started earlier and carried out for five instead of four
consecutive days. Significantly delayed increase of tumor volume in comparison to mock was
observed in groups that received MeVac encoding FmIL-12 alone or in combination with
both, the GM-CSF and mIP-10 encoding vectors, as well as in the group receiving treatment
with the eGFP encoding vector (Figure 4.11.b). Survival of the animals was significantly
extended in the groups receiving treatment with the FmIL-12 encoding vector only or in
both combination groups in comparison to mock treatment (Figure 4.11.b). Notably, seven
out of nine mice in the FmIL-12 only group experienced complete tumor remissions as well as
six out of nine and five out nine mice in the combination groups with GM-CSF and mIP-10,
respectively. Thus, these screening experiments identified MeVac encoding FmIL-12 and
anti-PD-L1, respectively, as having the best therapeutic efficacy in each experiment.
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Figure 4.11: Therapeutic efficacy of immunomodulatory MeVac. MC38cea cells were
implanted subcutaneously (s.c.) into the right flank of C57BL/6J mice (6 – 9 animals per
group). When tumors reached an average volume of 40 – 70 mm3 mice received intratumoral
injections (black arrows) with 1×106 ciu (a) or 5×105 ciu (b) with MeVac vectors encoding
the respective transgenes on four (a) or five (b) consecutive days in 100µl virus suspen-
sion with carrier fluid (OptiMEM). Mice in mock groups received i.t. injections of 100µl
OptiMEM. Tumor volume distribution on day 19 (a) and day 16 (b) post implantation with
dots representing individual mice and Kaplan-Meier survival analysis are shown. Complete
tumor remission rates are shown for each group in Kaplan-Meier plots. ciu — cell infectious
units.
4.2.2 Therapeutic Efficacy of the Most Promising Vectors
Therapeutic efficacy of the FmIL-12 and anti-PD-L1 vectors was subsequently directly com-
pared in the s.c. MC38cea tumor model. MeVac encoding IgG1-Fc instead of eGFP was
included as a control vector due to more similar genome structure to both FmIL-12 and
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Figure 4.12: Comparison of therapeutic efficacy of MeVac encoding FmIL-12
and anti-PD-L1. MC38cea cells were implanted subcutaneously into the right flank of
C57BL/6J mice (10 animals per group). When tumors reached an average volume of 40 mm3
mice received intratumoral (i.t.) injections with 1×106 ciu of viruses encoding the respective
transgenes on four consecutive days in 100µl virus suspension with carrier fluid (OptiMEM).
Mice in the mock group received i.t. injections of 100µl OptiMEM. Tumor volume distribu-
tion on day 16 post implantation with median for each group and Kaplan-Meier analysis are
shown. Dots represent individual mice. Complete tumor remission rates are shown for each
group in the Kaplan-Meier plot. ciu — cell infectious units.
anti-PD-L1 encoding vectors. MeVac treatment led to a significant delay in tumor growth
and prolonged survival of the animals in comparison to mock treatment, but no significant
differences were observed between the virus treatment groups (Figure 4.12). However, fre-
quency of complete tumor remissions indicated differences in efficacy: Four out of ten animals
treated with MeVac IgG1-Fc experienced complete tumor remissions, in contrast to six and
nine out of ten animals treated with MeVac encoding anti-PD-L1 and FmIL-12, respectively.
This result suggested an added therapeutic benefit for anti-PD-L1 and especially FmIL-12
in the context of MeVac therapy.
Interleukin-12 is a known potent activator of immune cells with one of its main prop-
erties being induction of IFN-γ production by NK and T cells27. It is however also known
that IFN-γ upregulates expression of PD-L1 as a negative feedback loop mechanism231. This
property would warrant combination of IL-12 therapy with blockade of PD-L1 to impede the
immunosuppressive signaling upregulated through IFN-γ induction. Furthermore, although
application of MeVac encoding FmIL-12 even as a single agent demonstrated a highly benefi-
cial anti-tumor effect in the MC38cea model, the efficacy could be more modest in other less
immunogenic and more aggressive tumor models. Given this rationale, experiments evaluat-
ing efficacy of combining MeVac vectors encoding FmIL-12 and anti-PD-L1 were performed
in the previously used MC38cea model and the more aggresive immunocompetent murine
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melanoma B16-CD20 model104. Efficacy of the combination of vectors encoding FmIL-12 and
anti-PD-L1 was compared with combinations of both vectors with MeVac encoding IgG1-Fc.
In the MC38cea tumor model a significantly delayed increase of tumor volume in compari-
son to mock was observed in the groups receiving treatment with any combination of MeVac
vectors, but no differences were observed between the treatment groups (Figure A.10.a).
Survival of animals was significantly extended in the groups receiving treatment with the
FmIL-12 and anti-PD-L1 combination and the FmIL-12 and IgG1-Fc vector combination
in comparison to mock. However, more animals experienced complete tumor remissions in
the group receiving treatment with FmIL-12 and IgG1-Fc vector combination (nine of ten)
than in the FmIL-12 and anti-PD-L1 (six of ten) combination group (Figure A.10.a). In
the B16-CD20 tumor model significantly delayed increase of tumor volume in comparison
to mock was observed only in the group receiving treatment with FmIL-12 and IgG1-Fc
vector combination (Figure A.10.b). Survival of the animals was extended in comparison to
mock in all groups receiving treatment with MeVac vector combinations. The FmIL-12 and
anti-PD-L1 as well as the FmIL-12 and IgG1-Fc combination extended survival significantly
more than the anti-PD-L1 and IgG1-Fc vector combination. No clear benefit could however
be recognized comparing the FmIL-12 and IgG1-Fc with the FmIL-12 and anti-PD-L1 vector
combination. No complete tumor remissions could be achieved with the examined treatment
strategies in the B16-CD20 tumor model (Figure A.10.b). These results therefore suggested
that there is no added therapeutic benefit when applying this combination of MeVac vectors
encoding FmIL-12 and anti-PD-L1 over the FmIL-12 in combination with a control vector
in this setting.
A certain amount of MeVac encoded transgene that is produced during virus propagation
in Vero-αHis cells remains present in the MeVac virus suspension. A non-targeted MeVac
encoding FmIL-12 was evaluated in the MC38cea model in comparison to the targeted MeVac
FmIL-12 Hbl-αCEA to assess the effects of the FmIL-12 delivered with virus suspension.
FmIL-12 could be detected in the serum collected from peripheral blood of mice treated with
both non-targeted and targeted constructs on the second day of treatment and two days after
the last treatment. The maximal FmIL-12 concentration, 857.5 pg/ml, was detected in the
MeVac FmIL-12 Hbl-αCEA group on third day of treatment. Expressed as a dose per kg of
body mass, if assuming total blood volume of a mouse ≈1.7 ml and body mass ≈22 g, this
equals to ≈66 ng/kg. Mice that received the targeted virus had significantly higher serum
levels of FmIL-12 on the second day of treatment than the mice receiving the non-targeted
virus (Figure 4.13.b). The FmIL-12 serum level declined to baseline within a week after
the last treatment. This implies a de novo FmIL-12 production during virus replication in
MC38cea cells in vivo after treatment with the targeted virus. Regarding efficacy, treatment
with both non-targeted and targeted FmIL-12 vectors significantly delayed tumor growth and
extended survival of the animals in comparison to mock, but no significant differences could
be observed between the treatment groups (Figure 4.13.c, d). This result demonstrated that
the delivery of a virus unable to replicate in the tumor cells and containing immunomodulator
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Figure 4.13: Systemic levels of FmIL-12 after intratumoral application and thera-
peutic efficacy of a non-targeted MeVac FmIL-12. a — schedule of the experiment.
MC38cea cells were implanted subcutaneously (s.c.) into the right flank of C57BL/6J mice
(9 animals per group). When tumors reached an average volume of 40 mm3 mice received in-
tratumoral (i.t.) treatment with 1×106 ciu of the respective viruses on four consecutive days
(black arrows) in 100µl virus suspension with carrier fluid (OptiMEM). Mice in the mock
group received i.t. injections with 100µl OptiMEM. b — peripheral blood was collected from
3 – 4 animals per group from the vena saphena at the time points denoted with grey arrows
in a. Serum was collected, the concentration of FmIL-12 was measured by ELISA and the
results were analysed with one-way ANOVA. Mean values from 2 – 5 individual samples per
group with standard errors of the mean are shown. c — tumor volume distribution on day
13 post implantation. Dots representing individual mice and a median in each group are
shown. d — Kaplan-Meier plot. Complete tumor remission rates are shown for each group.
ciu — cell infectious units.
only in the virus suspension is sufficient to achieve similar therapeutic benefit as with the
replicating virus which ensures also de novo production of the immunomodulator in vivo.
4.2.3 Assessment of anti-tumor immune response in long-term
survivors of MeVac therapy
Animals experiencing complete tumor remissions after MeVac therapy were rechallenged
with MC38cea cells six months after the initial tumor cell implantation. Tumor engraftment
rejection rates were monitored to assess establishment of protective anti-tumor immunity.
All of the mice previously treated with FmIL-12 and anti-PD-L1 encoding vectors from
the experiment comparing efficacy of FmIL-12 and anti-PD-L1 encoding MeVac and three
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Figure 4.14: Systemic anti-tumor immunity in long-term survivors of MeVac ther-
apy. Animals experiencing complete tumor remissions after treatment with MeVac encoding
the respective transgenes were rechallenged with subcutaneous (s.c.) MC38cea implantation
six months after the initial tumor cell implantation. Naive mice served as a control group. a
– mice were monitored for tumor engraftment. Tumor rejection rates are shown. Splenocytes
were collected from the animals two weeks after rechallenge, stimulated with recombinant
murine IL-2 and cocultivated with MC38cea cells (b) or with MC38 and B16 cells and DLD-1
cell lysate (c) for one mouse from each group at a ratio 10:1. Supernatants were collected
after 48 h and IFN-γ concentration was measured by ELISA. Dots representing individual
mice and a median in each group are shown in b. Mean values with standard errors of the
mean from two replicate measurements per sample are shown in c.
out of four mice treated with the IgG1-Fc vector rejected secondary tumor engraftment,
in contrast to naive control mice, where tumor engraftment was observed in all animals
(Figure 4.14.a). The ability to reject secondary tumor engrafment in mice treated with
MeVac was confirmed also in other rechallenge experiments. In total, 64 of 71 mice (90.1%)
that experienced complete tumor remissions after treatment with different MeVac vectors
or vector combinations rejected secondary tumor engraftment in contrast to only 3 of 25
(10.7%) naive mice.
To assess specificity of the induced anti-tumor immune response, splenocytes from the
survivors in the experiment comparing efficacy of the FmIL-12 and anti-PD-L1 vectors were
stimulated with MC38cea in vitro two weeks after tumor rechallenge. A significantly higher
IFN-γ production was observed in the group receiving MeVac encoding FmIL-12 compared
to naive mice and the anti-PD-L1 group (Figure 4.14.b), suggesting more potent cell medi-
ated immune memory in animals treated with the FmIL-12 encoding MeVac. Stimulation
with parental MC38 cells induced a similar IFN-γ production pattern as with MC38cea
cells, demonstrating that the response is not CEA restricted (Figure 4.14.c). Only a slight
induction of IFN-γ production was detected after stimulation with an unrelated murine
tumor cell line, B16, and IFN-γ concentration was close to background after stimulation
with human DLD-1 cell lysate (Figure 4.14.c), showing that the observed response is specific
for MC38-derived tumor cells. Similarly, a higher IFN-γ memory recall after rechallenge
was demonstrated also from survivors of treatment with MeVac encoding FmIL-12 in com-
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bination with IgG1-Fc or anti-PD-L1 than from animals treated with the anti-PD-L1 and
IgG1-Fc MeVac combination and naive mice (Figure A.11), further strengthening the results
described above.
4.3 Analysis of MeVac induced Anti-Tumor Immune
Effector Mechanisms
Analysis of the immunological milieu in tumors after MeVac therapy was performed to
identify immune effector mechanisms associated with the mechanisms of action of MeVac
encoding FmIL-12 or anti-PD-L1. Assuming that FmIL-12 would exert its specific effects
earlier after expression than anti-PD-L1, two experiments with different schedules were car-
ried out. To analyze the effects of the vector encoding FmIL-12, tumors were explanted
24 h (Figure 4.15.a), but to analyze the effects of the vector encoding anti-PD-L1 tumor
were explanted four days (Figure 4.15.b) after the last treatment. Control group receiving
treatment with the IgG1-Fc encoding vector and a mock group were also included in each
experiment. After tumor explantation the material was divided for flow cytometry, cytokine
bead array and RT-qPCR analyses (Figure 4.15.c). Further, depletions of the main immune
effector cell populations were performed to identify their contribution for the therapeutic
efficacy of the most promising MeVac vector encoding FmIL-12.
Figure 4.15: Treatment schedules and schematic for preparation of tumor material
for analyses of MeVac induced immune effectors. MC38cea cells were implanted
subcutaneously into the right flank of C57BL/6J mice (12 animals per group). When tumors
reached an average volume of 120 mm3 (a) or 100 mm3 (b) mice received intratumoral (i.t.)
treatment with 1×106 ciu of MeVac encoding FmIL-12 or IgG1-Fc (a) or anti-PD-L1 or IgG1-
Fc (b) on four consecutive days in 100µl virus suspension with carrier fluid (OptiMEM).
Mice in the mock group received i.t. injections with 100µl OptiMEM. Tumors were explanted
one (a) or four (b) days after the last treatment and tumor material was divided for further
analyses as depicted in c.
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4.3.1 Quantification of Transcription Factor Expression
The mRNA levels of the transcription factors Foxp3 and T-bet were quantified in the tumors
after MeVac therapy to assess changes in immunosuppressive and cell mediated immune re-
sponse mediators, respectively. Complete RNA was extracted from the freshly explanted
tumor material (Figure 4.15) and reverse transcriptase quantitative PCR (RT-qPCR) analy-
sis was carried out. RNA integrity was assessed by electrophoresis on an agarose gel and only
samples with clear 18S and 28S ribosomal RNA bands were included in the analysis (Fig-
ure A.12). mRNA levels of different potential reference genes in representative samples from
all treatment groups were evaluated before the analysis. The reference gene L13a (Rpl13a)
had the lowest variation of the mRNA levels between the samples and the treatment groups
and was, thus, chosen for further use (Figure A.13).
In the “early” experiment, including the group with the FmIL-12 encoding vector, anal-
ysis indicated an increased level of T-bet mRNA in the tumors treated with the FmIL-12
encoding vector in comparison to the IgG1-Fc encoding vector and mock groups (Fig-
ure 4.16.early). In the “late” experiment, including the treatment group with the anti-PD-L1
encoding vector, only a slight shift towards elevated amount of T-bet mRNA in comparison
to the IgG1-Fc encoding vector and mock groups could be detected, but the differences were
Figure 4.16: Changes in T-bet and Foxp3 mRNA levels after MeVac therapy.
MC38cea cells were implanted subcutaneously into C57BL/6J mice. When tumors reached
an average volume of 120 mm3 (early) or 100 mm3 (late) mice received intratumoral treat-
ment with MeVac encoding the respective transgenes or the respective amount of OptiMEM
(mock). Reverse transcription quantitative PCR (RT-qPCR) analysis was carried out using
RNA from tumors explanted one (early) or four (late) days after the last treatment. Dots
representing samples from individual mice and median values are shown. Cq — quantification
cycle.
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not statistically significant (Figure 4.16.late). No statistically significant differences could be
detected in FoxP3 mRNA levels in either of the experiments between any of the treatment
groups.
4.3.2 Cytokine Expression Profiling
Intratumoral cytokine profiles after therapy with MeVac encoding FmIL-12 or anti-PD-L1
were examined with cytokine bead array. Levels of seven different cytokines defining po-
larization towards Th1 (IL-2, IFN-γ, TNF (tumor necrosis factor)-α), Th2 (IL-4, IL-10)
or Th17 (IL-17) associated immune response types were simultaneously measured in tu-
mor samples prepared as described before (Figure 4.15). Significantly higher IFN-γ and
TNF-α concentrations were detected in the group receiving treatment with MeVac encod-
Figure 4.17: Intratumoral cytokine profiles after MeVac therapy. MC38cea cells were
implanted subcutaneously into C57BL/6J mice. When tumors reached an average volume
of 120 mm3 (early) or 100 mm3 (late) mice received intratumoral treatment with MeVac
encoding the respective transgenes or the respective amount of OptiMEM (mock). Cytokine
bead arrays were performed using protein extracts from tumors explanted one (early) or four
(late) days after the last treatment. Dots representing tumor samples from individual mice
and a median value in each group are shown.
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ing FmIL-12 than in the groups receiving treatment with the IgG1-Fc encoding vector and
mock (Figure 4.17.early). Also a slightly, but not significantly, higher IL-6 concentration
was observed in both the MeVac IgG1-Fc and FmIL-12 treatment groups in comparison to
mock (Figure 4.17.early). In the experiment including the treatment group with the anti-
PD-L1 encoding vector, no significant differences in cytokine expression could be observed
between the treatment groups, except for a slightly higher IFN-γ and TNF-α concentration
in the group receiving treatment with the anti-PD-L1 encoding vector in comparison to the
IgG1-Fc and mock groups (Figure 4.17.late). The cytokines IL-2, IL-4, IL-10 and IL-17 were
close to background in all samples tested (data not shown).
4.3.3 Analysis of Tumor Infiltrating Lymphocyte Subpopulations
Further, changes in tumor infiltrating lymphocyte (TIL) subpopulations after MeVac therapy
were evaluated. Single cell suspensions were prepared using tumor material explanted in the
previously described experiments (Figure 4.15) and flow cytometry analysis was carried out.
The gating strategy for a representative sample is shown in Figure 4.18.
Significant differences in the total amount of the CD45+ cells could not be observed
between the treatment groups. Treatment with MeVac encoding FmIL-12 led to a massive
decrease of the amount of natural killer (NK) cells (CD335+) (Figure 4.19.early) in compar-
ison to treatment with IgG1-Fc encoding vector and mock. The amount of activated NK
cells (CD335+CD69+) however was significantly higher after treatment with FmIL-12 vector
in comparison to the IgG1-Fc and mock groups (Figure 4.19.early). A significant decrease
in the amount of NK cells was observed also after treatment with both the IgG1-Fc and
anti-PD-L1 encoding vectors in comparison to mock with a slightly greater decrease in the
anti-PD-L1 group, but the amount of activated NK cells did not differ between the groups
(Figure 4.19.late). The proportion of TIL T cells increased significantly in the “early” exper-
iment after treatment with the FmIL-12 encoding vector in comparison to the IgG1-Fc and
mock groups and also in the “late” experiment after treatment with IgG1-Fc and anti-PD-L1
encoding vectors in comparison to mock (Figure 4.19). The size of the cytotoxic T cell sub-
population (CD3+CD8+) did not differ significantly between treatment groups in neither of
the experiments. A slight, but not significant increase of the activated cytotoxic T cell pop-
ulation (CD3+CD8+CD69+) could be observed after treatment with the FmIL-12 vector in
the “early” experiment. However, treatment with MeVac encoding anti-PD-L1 and IgG1-Fc
led to a significant decrease in the activated cytotoxic T cell population in comparison to
mock (Figure 4.19). The size of the T helper cell population (CD3+CD4+) did not differ
between treatment groups in the “early” experiment, but in the “late” experiment a slight
and significant increase of the population could be observed after treatment with anti-PD-L1
encoding MeVac (Figure 4.19).
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Figure 4.18: Gating strategy for analysis of tumor infiltrating lymphocyte sub-
populations after MeVac therapy. The cell population of interest was identified using
forward (FSC-A) and side scatter (SSC-A) parameters. Dead cells were excluded by gating
on the DAPI negative cell population. Within the live cell population the leukocyte pop-
ulation was identified as the CD45+ cells. Within the CD45+ cell population the natural
killer (NK) (CD335+) and the T cell (CD3+) populations were identified. Within the T
cell population the cytotoxic T cell (CD8+) and the helper T cell (CD4+) populations were
discriminated. Activated NK cells and CD8+ cells were identified as CD69+ cells in each
population.
To assess the involvement of intratumoral immune effector populations in the therapeu-
tic effect of the MeVac vectors, a relationship between the amount of certain TIL subpopu-
lations with the change of tumor volume after MeVac therapy was examined. The time span
of the experiment evaluating effector mechanisms of the anti-PD-L1 and IgG1-Fc encod-
ing vectors (Figure 4.15.b) was considered sufficient to meaningfully compare the impact of
treatment on changes in tumor volume. The differences of the tumor volume before the be-
ginning of the treatment and on the day of tumor explantation was calculated and correlated
with the size of TIL populations significantly differing between the treatment groups. The
proportion of NK cells in the tumor correlated significantly with a smaller increase in the
tumor volume in the mock group (Figure 4.20). In the IgG1-Fc group the same correlation
was not significant, but in the anti-PD-L1 group a smaller proportion of NK cells signifi-
cantly correlated with a greater decrease in tumor volume (Figure 4.20). In the mock group
66
4 Results
a larger size of the T cell population significantly correlated with a greater increase in tumor
volume, while in the IgG1-Fc group there was no significant correlation of these parame-
ters. However, in the anti-PD-L1 group a larger T cell population correlated significantly
with a greater decrease in tumor volume (Figure 4.20). The size of the activated cytotoxic
T cell population did not correlate significantly with change in tumor volume in the mock
group, but in both the IgG1-Fc and anti-PD-L1 groups a smaller activated cytotoxic T cell
population correlated significantly with a greater decrease in tumor volume (Figure 4.20).
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Figure 4.19: Tumor infiltrating lymphocyte subpopulations after MeVac therapy.
MC38cea cells were implanted subcutaneously into C57BL/6J mice. When tumors reached
an average volume of 120 mm3 (early) or 100 mm3 (late) mice received intratumoral treat-
ment with MeVac encoding the respective transgenes or the respective amount of OptiMEM
(mock). Single cell suspensions from the tumors were prepared and flow cytometry analysis
was performed one (early) or four (late) days after the last treatment. Dots representing
tumor samples from individual mice and the median value in each group are shown.
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Figure 4.20: Correlations of the amount of certain tumor infiltrating lymphocyte
subpopulations and a change in tumor volume after MeVac therapy. MC38cea
cells were implanted subcutaneously into C57BL/6J mice. When tumors reached an average
volume of 100 mm3 mice received intratumoral treatment with MeVac encoding the respective
transgenes or the respective amount of OptiMEM (mock) on four consecutive days. Tumors
were explanted four days after the last treatment and flow cytometry analysis was carried
out. Differences between the tumor volume on the day before the treatment and four days
after the last treatment were calculated and plotted against the proportion of the respective
immune cell populations. Pearson product-moment correlation analysis was carried out to
assess the correlation between the two factors. Results for significant positive correlations
are depicted in red, significant negative correlations in blue and no correlation is shown in
black. Dots represent samples from individual mice. r — Pearson’s correlation coefficient; n
— number of data points; p — p value.
4.3.4 Identification of Immune Effectors Crucial for the Efficacy
of the MeVac encoding FmIL-12
Contribution of the main immune effector cell populations to the therapeutic effect of the
most effective immunomodulatory vector in the MC38cea tumor model, the MeVac encoding
FmIL-12, was further assessed. The NK cells or the CD8+ cytotoxic T cells or the CD4+ T
helper cells, were depleted by intraperitoneal antibody injections prior to s.c. implantation of
the MC38cea cells and i.t. treatment with the MeVac encoding FmIL-12. Depletion efficiency
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Figure 4.21: Impact of the main immune effector cell population depletions on the
therapeutic efficacy of the MeVac encoding FmIL-12. C57BL/6J mice were depleted
of natural killer cells or CD4+ T cells (minus NK or minus CD4+ in a) or CD8+ T cells (minus
CD8+ in b) by intraperitoneal antibody injections. Two separate experiments are shown in a
and b. Mice with no immune cell depletions served as controls (mock, undepleted). MC38cea
cells were implanted subcutaneously and established tumors were treated with intratumoral
(i.t.) injections of 1×106 cell infectious units MeVac P-FmIL-12 Hbl-αCEA in 100µl on four
consecutive days. Mice in the mock groups received i.t. injections with 100µl OptiMEM in
parallel. Kaplan-Meier survival analyses are shown.
was controlled by flow cytometry in peripheral blood of selected animals from each group
(Figure A.15, Figure A.16, Figure A.17). Depletions of the NK and CD4+ T cell populations
did not have a significant impact on the survival of animals in comparison to the treated
animals with no depletions of the immune cells (Figure 4.21.a). However, depletion of the
CD8+ T cell population almost completely abrogated the therapeutic effect of the MeVac
encoding FmIL-12 (Figure 4.21.b).
4.4 Consideration of the Translational Potential
The previous chapters described the development of oncolytic measles virus vectors encoding
different immunomodulators and the assessment of their immunomodulatory properties in
murine tumor models. Experiments in immunocompetent mouse models can give valuable
information about the role of immune responses in the mode-of-acion of the oncolytic vectors.
However, the previously described MeVac vectors encode only the murine analogs of human
immunomodulatory molecules and development of vectors encoding transgenes for the re-
spective human proteins is a prerequisite for development of clinically relevant therapeutics.
As MeVac encoding the murine IL-12 fusion protein demonstrated the highest therapeutic
efficacy in the previously described experiments in murine tumor models, MeVac vectors
encoding human IL-12 fusion protein were further constructed and characterized in vitro.
Furthermore, as most of the experiments described previously focused on a murine colorectal
adenocarcinoma model, colorectal cancer was highlighted as a possible target for oncolytic
measles virus. A panel of human colorectal cancer cell lines was evaluated in terms of MV
receptor expression levels as well as replication kinetics and cytotoxic properties of both
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measles Edmonston B (NSe) and Schwarz (MeVac) vaccine strain viruses were examined in
vitro.
4.4.1 MeVac Encoding a Human IL-12 Fusion Protein∗
MeVac encoding the murine IL-12 fusion protein FmIL-12 demonstrated the highest ther-
apeutic efficacy in the experiments in the MC38cea murine colon adenocarcinoma model
described in the previous chapters. Further, the ability to establish a long-term anti-tumor
immune response and favorably modulate the tumor immune milieu was revealed, which
taken together allows to consider MeVac encoding IL-12 fusion protein a promising candidate
for translation into clinical application. MeVac encoding a human IL-12 fusion protein222
was therefore further developed and characterized in vitro.
The cassette encoding a human IL-12 fusion protein (FhIL-12) was designed analo-
gously to FmIL-12 with the exception of using a different linker, as the (Gly4Ser)3 used
in the murine construct had previously been found to be unstable in a human IL-12 con-
struct222. The IL-12p40 subunit was fused with the IL-12p35 subunit lacking the secretory
leader sequence (∆p35) via a Gly6Ser linker as in Lieschke et al.
222. The fusion protein was
preceded by a Kozak sequence and an extra stop codon was introduced behind ∆p35 to
obtain a construct complying with the “rule of six” for insertion into the MeVac genome
as an MluI -PauI fragment. The FhIL-12 cassette (1614 bp) was inserted downstream of
the MeVac P ORF or H ORF yielding MeVac P-FhIL-12 and MeVac H-FhIL-12 genomes,
respectively (Figure 4.23). It must be noted that two point mutations in the p40 subunit,
both G to C transversions, were revealed when controlling the final FhIL-12 construct by
Sanger sequencing. The mutation in the position 717 of the FhIL-12 construct was a mis-
sense mutation that has been described as a sequence conflict previously232, but the second
mutation in position 873 did not change the amino acid sequence.
One-step growth curves in the producer Vero cell line were performed to compare repli-
cation kinetics of the two novel MeVac constructs encoding FhIL-12. Replication kinetics of
both vectors were similar, with titers peaking 48 h post infection and declining only slightly
until 96 h post infection (Figure 4.23.a). MeVac H-FhIL-12 reached slightly higher titers
than MeVac P-FhIL-12. Expression kinetics of the MeVac encoded FhIL-12 was further as-
sessed in Vero cells transduced with both constructs. The FhIL-12 concentration in the cell
culture medium steadily increased after infection over the course of the whole experiment
until 96 h post infection. The FhIL-12 concentration after infection with MeVac H-FhIL-12
was markedly lower than when using MeVac P-FhIL-12 at all time points, reaching the
maximum difference 96 h post infection (Figure 4.23.b).
Cytotoxic properties of both MeVac constructs encoding FhIL-12 were compared with
the parental MeVac vector in the producer cell line, Vero, and a human colorectal adenocar-
cinoma cell line, DLD-1. In Vero cells MeVac H-FhIL-12 displayed similar cytotoxic activity
∗Experiments described in this subsection were carried out by L. Hartmann during a laboratory internship
supervised by R. Veinalde.
71
4.4 Consideration of the Translational Potential
Figure 4.22: Schematic of human IL-12 fusion protein (FhIL-12) and MeVac
genomes encoding FhIL-12. A human IL-12 fusion protein (FhIL-12) was constructed by
fusing the IL-12 p40 and a IL-12 p35 subunit lacking the secretory leader sequence (∆p35)
via a Gly6Ser linker. The fusion protein was preceded by a Kozak sequence and a second
stop codon was introduced behind ∆p35. The FhIL-12 cassette was inserted into the MeVac
genome as an MluI -PauI fragment (1614 bp) either downstream of the measles P ORF or
H ORF.
Figure 4.23: Replication kinetics of MeVac encoding human IL-12 fusion protein
(FhIL-12) and expression of FhIL-12. a – one-step growth curves were constructed by
transduction of Vero cells with the respective viruses at a multiplicity of infection (MOI) =
3. Cells were scraped in their medium at the depicted time points and titers were assessed
by serial dilution titrations and expressed as cell infectious units (ciu) per ml; b – Vero
cells were transduced with the respective vectors and with MeVac A as a control at an MOI
= 3. Supernatants were collected from the infected cells at the depicted time points and
concentrations of FhIL-12 were assessed by ELISA. Supernatants from cells infected with
MeVac A served as background controls and were subtracted from the respective specific
measurements. Mean values from triplicate infections per time point with standard errors
of the mean are shown.
as the parental MeVac vector. However, the MeVac P-FhIL-12 showed a notably lower cyto-
toxicity, being able to reduce cell viability to 56% compared to mock at 96 h post infection
in contrast to 15% and 7% for MeVac and MeVac H-FhIL-12, respectively (Figure 4.24).
However, in the DLD-1 cell line all constructs displayed similar cytotoxic properties and at
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Figure 4.24: Cytotoxic properties of MeVac encoding human IL-12 fusion protein.
Vero or DLD-1 cells were infected at multiplicity of infection = 1 with the respective MeVac
constructs. An XTT cell viability assay was carried out at the depicted time points. Results
are presented as a percentage of viable cells compared to mock (= 100%). Mean values from
triplicate infections with standard errors of the mean are shown.
96 h post infection cell viability was reduced to a range of 0.74% – 11% compared to mock
(MeVac – MeVac P-FhIL-12, respectively) (Figure 4.24).
4.4.2 Potential of Oncolytic MV for Treatment of Colorectal
Cancer∗
A panel of colorectal cancer cell lines was chosen to examine the expression of MV receptors
and to compare MeVac and NSe measles vaccine strain viruses in terms of their replication
kinetics and cytotoxic properties. The chosen cell lines were validated by assessing expression
of several colon cell specific markers (Figure A.18). Further, expression of the known MeV
receptors CD46, CD150 and Nectin-4 (PVRL-4) was examined. All of the tested cell lines
expressed CD46 on their surface as determined by flow cytometry (Figure 4.25.a). However,
the results indicated differences in the expression intensity of the CD46, as the lowest median
fluorescence intensity of the PE labeled antibody was detected on HCT 116, but the highest
on DLD-1 cells (Figure 4.25.b). However, none of the tested cell lines were positive for CD150
expression in flow cytometry (data not shown). Expression of the Nectin-4 was assessed by
RT-PCR and three of the cell lines, COLO 205, DLD-1 and HT-29, were positive for Nectin-4
on mRNA level (Figure 4.25.c).
MeVac and NSe vectors were tested in terms of replication kinetics and cytotoxic effects
in the previously characterized colon cancer cell lines by performing one-step growth curves
and XTT assays. In one-step growth curves titers for both vectors reached a peak 36 – 48 h
post infection in all cell lines, but the amount of the viral particles produced differed between
the vectors and cell lines. As a general pattern, at almost all time points lower titers were
∗Experiments described in this subsection were carried out by V. Mitesser during a laboratory internship
supervised by R. Veinalde.
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Figure 4.25: Expression of MV receptors by human colon cancer cell lines. a, b —
expression of CD46 by the respective colon cancer cell lines was assessed by flow cytometry.
Cells were stained with a PE labeled antibody against human CD46 (anti-hCD46) and DAPI
staining was used for exclusion of dead cells. Histograms showing PE signal intensity of the
live cell population (DAPI-) of cells stained with the anti-hCD46 (solid fill) in comparison
to an isotype control (dashed lines) by the respective cell lines is shown in a. Median
fluorescence intensity (MFI) of PE (anti-hCD46) by the live population of the respective cell
lines is shown in b. c — mRNA level of Nectin-4 (PVRL-4 ) was assessed by RT-PCR. Beta
actin (β-actin) was amplified as a loading control. +RT — cDNA samples; -RT — minus
reverse transcriptase controls.
reached after infection with the MeVac vector than with the NSe vector in the same cell line
(Figure 4.26). Cell lines in which the highest and lowest titers were reached differed between
both vectors. After infection with MeVac the highest titer (1.75×106 ciu/ml after 48 h) was
reached in KM12, but the lowest (8.75×104ciu/ml after 36 h) in the COLO 205 cell line.
After infection with the NSe vector the highest titer (5×106 ciu/ml after 48 h) was reached
in DLD-1, but the lowest (7.25×105 after 48 h) in the HT-29 cell line (Figure 4.26). Of note,
the differences between the peak titers after infection with MeVac were much higher and
more dispersed between the cell lines than after infection with the NSe vector.
Cytotoxic effects of MeVac and NSe vectors were assessed in all of the chosen cell lines
by XTT assay. Both vectors were able to reduce cell viability in a range of 35 – 0.25% viable
cells compared to mock 96 h post infection. The most resistant cell line with the lowest
reduction of cell viability after infection with both vectors was the HT-29, with MeVac
reducing cell viability to 21.5%, but NSe to 35.5% viable cells compared to mock 96 h post
infection (Figure 4.26). For the other cell lines the sensitivity to each of the vector was
different. After infection with MeVac the greatest and most rapid decline in cell viability
was observed for COLO 205 and KM12, but after infection with NSe for DLD-1 and HCT 116
cell lines (Figure 4.26).
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Figure 4.26: Replication kinetics and cytotoxic effects of measles Schwarz (MeVac)
and Edmonston B (NSe) vaccine strain viruses in human colon cancer cell lines.
Upper panels — one-step growth curves were performed by transducing the respective cell
lines at a multiplicity of infection = 3. Cells were collected by scraping in their own medium
and titers were determined at the depicted time points; lower panels — the respective cell
lines were transduced with MeVac or NSe vectors at a multiplicity of infection = 1 and
cell viability was determined by XTT assay at the depicted time points. Mean results of
triplicate infections per time point with standard errors of the mean are shown (not visible
for some data points). ciu — cell infectious units.
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5.1 Perspectives of Immunovirotherapy
Oncolytic viruses (OVs) are emerging as a class of clinically relevant cancer therapeutics and
declaring their place among current cancer immunotherapy strategies. The immunomodu-
latory properties of the OV therapy have been recognized to be an integral part of their
mechanism of action, allowing to coin the term “immunovirotherapy”75. Early studies of
oncolytic properties of different viruses focused on identification and generation of viruses
with enhanced cytotoxic potential in malignant cells233, 234. Since then, the focus in the
field of OV research has shifted considerably, with most of the current studies concentrating
on the immunomodulatory aspects of virotherapy and development of strategies to sup-
port the induction of an anti-tumor immune response93. OVs provide a unique mechanism
of action among the currently known immunotherapeutics. In virotherapy, the abilities of
OVs to selectively infect, replicate and destroy malignant tissues synergize with the im-
munostimulatory aspects, supporting establishment of a tumor-specific immune response235.
Furthermore, modification of the immunostimulatory properties of OVs and combination
with other immunotherapeutic strategies can result in a significantly enhanced therapeutic
efficacy236, 237, 107, 103. Particular interest has been given to development of OVs as vehicles
for delivery of different immunomodulators to tumor tissues93. Such oncolytic vectors en-
coding immunomodulators frequently demonstrate therapeutic benefits in pre-clinical tumor
models123, 126, 129. However, most importantly, this strategy has also been translated into
clinical application. The only oncolytic vector currently approved for clinical use in the U.S.
and European Union, T-VEC, encodes an immunomodulator, GM-CSF, targeting antigen
presenting cell functions71, 238. Although T-VEC has demonstrated enhanced therapeutic
efficacy for patients with advanced malignant melanoma in terms of increased response rates
and overall survival in comparison to administration of GM-CSF alone, the majority of pa-
tients do not experience benefits from the therapy100. Thus, further studies focusing on
identification of the most effective immunomodulators for combination with oncolytic vec-
tors as well as elucidation of immune effector mechanisms supporting the therapeutic effects
will be important for advancement of immunovirotherapy.
This study focused on the oncolytic measles vaccine strain vectors (MV), which are
emerging as promising virotherapeutics in clinical trials206, 207, 208. A great immunostimula-
tory potential associated with MV-mediated oncolysis has been demonstrated. In vitro stud-
ies have confirmed induction of immunogenic cell death in MV-infected tumor cells239, 240, 241.
More importantly, activation of tumor antigen specific T cell responses after MV therapy
has been demonstrated in a clinical trial for treatment of ovarian cancer208. Several pre-
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clinical studies have demonstrated that the therapeutic efficacy of oncolytic MV vectors
can be enhanced by combination with different immunomodulators, including GM-CSF,
IFN-β and antibodies against the negative regulators of T cell activation CTLA-4 and
PD-L1200, 114, 131, 104. However, advantages of different immunomodulation strategies in com-
bination with oncolytic MV vectors have not been compared before. Thus, this study aimed
at systematic evaluation of MV vectors encoding immunomodulators from different classes.
Furthermore, analyses of the tumor immunomicroenvironment following the most promising
MV immunovirotherapy strategies were carried out to deepen understanding of the determi-
nants of therapeutic efficacy.
5.2 Construction and Characterization of Recombinant
Oncolytic Measles Vectors
In contrast to the Edmonston B measles vaccine strain derivatives used in previous measles
oncolysis studies226, 114, 104, this study introduces recombinant Schwarz (MeVac) strain vec-
tors. The measles cloning platform was developed based on an Edmonston B-derived vec-
tor188. However, probably due to mutations that have occured during cloning process and
adaptation to propagation in Vero cells, the sequence of the Edmonston B-derived vectors
has deviated significantly from the initial vaccine seed214. The recombinant MeVac vectors
have been developed based on the commercially available measles vaccine Rouvax, which
is used for measles immunization in Europe214. It has been shown that the MeVac vectors
retain an immunogenic potential similar to that of the commercial vaccine, while the recom-
binant Edmonston B strain is poorly immunogenic214. The reduced immunogenicity of the
Edmonston B vaccine strain is most probably associated with its lost ability to counteract
interferon (IFN) signaling, which, in contrast, is preserved in the MeVac vectors148. These
properties strongly suggest recombinant MeVac vectors as candidates for further clinical
development and, thus, they were chosen for this study to deepen understanding of their
immunomodulatory properties in the context of oncolysis.
A panel of MeVac vectors encoding previously selected immunomodulators targeting
distinct phases in the establishment of an anti-tumor immune response was created. Addi-
tionally, MeVac encoding the enhanced green fluorescent protein (eGFP) and the constant
region of an antibody (IgG1-Fc) were generated for use as controls in further experiments.
Measles encoding IgG1-Fc has been used as a control vector for anti-CTLA-4 and anti-PD-L1
encoding Edmonston B measles vectors104. Thus, the IgG1-Fc encoding MeVac was used
as a control in experiments with MeVac encoding anti-CTLA-4, anti-PD-L1, as well as the
soluble form of CD80 (CD80-Fc). Measles encoding eGFP has been used as a control vector
in a previous study examining therapeutic effects of an Edmonston B strain virus encoding
mGM-CSF114. Thus, MeVac encoding eGFP was chosen as a control vector for experiments
with MeVac vectors encoding cytokines, mGM-CSF, IL-12 fusion protein (FmIL-12) and
mIP-10. To appropriately control experiments with oncolytic vectors encoding immunomod-
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ulators, an ideal control vector should have a similar genome structure, replication kinetics
and cytotoxic potential in the target cells as the vectors in question. Furthermore, it should
ensure expression of an immunologically inert molecule from the transduced cells. It must
be noted that, mainly in regards to the replication kinetics, selection of such a vector is very
challenging. The main factors influencing replication kinetics of recombinant measles vectors
are the size and position of the inserted transgene cassette as well as the structure of the
inserted sequence itself. Vectors with large transgene inserts (>1 kbp) in genome positions
close to the measles leader can be severely attenuated or even impossible to rescue212, 213.
Nevertheless, previous studies have demonstrated that generation of recombinant measles
vectors encoding single transgenes up to 3 kbp and multiple transgene cassettes with a total
size up to 5 kbp is feasible242, 243. The sizes of the transgene cassettes for immunomodulators
chosen in this study differed significantly (from 312 bp for mIP-10 to 1650 bp for FmIL-12).
Thus, to balance attenuation of the generated vectors, it was necessary to insert the trans-
gene cassettes into different positions of the measles genome. A further concern is that the
size of the transgene cassettes in control vectors in most cases differed significantly from
the size of the cassettes encoding immunomodulators. For instance, the IgG1-Fc cassette
was only approximately half of the size of anti-CTLA-4, anti-PD-L1 and CD80-Fc encoding
cassettes and the eGFP cassette was more than 1.5 times the size of mIP-10 encoding cas-
sette. It must also be noted that a codon optimization process to exclude sequences that
could cause premature interruption of RNA synthesis by measles polymerase during repli-
cation (repetitive sequences and sequences resembling regulatory elements in the measles
genome) was performed only for the anti-PD-L1 encoding cassette213. Nevertheless, as will
be discussed further, the replicative potential of the vector plays a secondary role in the
models used in this study. Therefore, despite the possibility of different replication efficien-
cies, the generated vectors encoding immunomodulators and the respective control vectors
were considered suitable for further experiments.
Measles replication is restricted to primate cells as hosts and therefore natural trans-
duction of murine cells with MV vectors is not possible. Measles hemagglutinin (H) however
tolerates insertion of foreign sequences. This allows alteration of the natural measles tropism
at the entry level by, for instance, display of single chain antibodies (scAb) on the C termi-
nus of H190. The retargeted vectors are able to enter murine cells expressing the respective
antigen via binding of the scAb. Until now, two immunocompetent murine models have
been developed in studies with oncolytic Edmonston B strain vectors — MC38cea226, 114
and B16-CD20104. To allow further use of both of them, the H protein in the novel MeVac
vectors encoding immunomodulators was retargeted by insertion of scAb sequences against
CEA or CD20. Full retargeting was achieved by using vectors with point mutations in the H
protein that ablate binding to the natural measles receptors CD46 and CD150. The STAR
system was used for propagation of the viruses216. From a clinical perspective, modifica-
tion of measles vector tropism is not an absolute necessity, as in most cases measles vaccine
strain vectors have a natural oncotropism due to the overexpression of CD46 in many tu-
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mor types179. The modification of measles tropism would be appealing only in cases with
CD46-negative tumors and as a safety measure, to detarget the virus from CD46, which at
low levels is expressed also on normal nucleated cells244, and to ensure targeting of only a
specific tumor-associated antigen as an entry receptor. However, until now, clinical trials
for measles oncolysis have successfully used only vectors with unmodified tropism. In these
trials no critical safety concerns arose207, 208.
Replication kinetics of the novel retargeted MeVac vectors in the producer cell line
Vero-αHis differed significantly, with differences in the maximum measured titers reaching
up to two log10. Overall, vectors with smaller transgene inserts tended to reach lower titers
than the vectors with larger transgene cassettes. A plausible explanation for this observation
would be that, as the vectors with shorter inserts are less attenuated and replicate faster,
the virus life cycle is completed more rapidly, resulting in cell lysis. The fast destruction of
the cell layer restricts the capacity for production of novel infectious particles and therefore
the in fact more attenuated vectors, with the large transgene inserts, are able to produce
more infectious particles in a cell before its destruction. Despite this, propagation of the
retargeted vectors to high titers (>107 ciu/ml) in the Vero-αHis cell line was feasible for
all of the novel retargeted vectors except for MeVac encoding mGM-CSF. In the previous
study with the Edmonston B-derived vector encoding the same mGM-CSF construct in
leader position of the genome, the replication of the vector was not impaired114. To exclude
that mutations introduced during the cloning or propagation process could be the cause of
the impaired replication of MeVac encoding mGM-CSF, the whole genome of the construct
was sequenced and compared to MeVac encoding FmIL-12. Since only one silent mutation
within the H ORF and three non-coding sequence variants in intergenic regions that were
identical in both constructs were detected, this was excluded as a reason for the impaired
replication. Further analysis for accumulation of defective interfering particles (DIs)230 was
carried out in which a distinct, DI amplification-specific band was detected only in samples
from the mGM-CSF encoding vector. This indicates that excessive accumulation of the DIs
could have caused the impaired replication of the mGM-CSF encoding MeVac. This could
probably be associated with the alteration of the genome structure through the insertion of
this specific mGM-CSF transgene cassette. As a solution, a vector encoding the mGM-CSF
cassette with an alternative codon usage could be assessed or the cassette could be inserted
further downstream in the MeVac genome.
Retargeted MeVac vectors were able to transduce the murine target cells, MC38cea, as
demonstrated by syncytia formation. Comparison of the replication kinetics in the MC38cea
cells in vitro confirmed the ability of all vectors to productively replicate in the target cells.
The results indicated one productive replication cycle as observed by a peak in the amount of
infectious cell units 36 – 48 h post infection. Furthermore, in general all vectors demonstrated
only mild cytotoxic effects in the MC38cea cells. Taken together, these results illustrate the
limitations for measles studies in mouse cells. Although the retargeted vectors are able to
enter murine cells, replication and subsequent oncolytic effect is hindered by the inability
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to efficiently counteract post-entry barriers in murine cells226. The oncolytic efficiency of
measles vectors in immunocompetent mouse tumor models can therefore be considered to
be of secondary importance, but the models are suitable for evaluation of the immunological
aspects of the therapy.
Further, it was demonstrated that after transduction of the MC38cea target cell line
with the respective vectors, the MeVac-encoded immunomodulators are expressed and re-
tain their biological activities. However, patterns of expression kinetics differed considerably
between the vectors. The expression kinetics of the inserted transgenes of the immunomod-
ulators can be expected to depend on a complex set of properties, including the replication
efficiency of the respective vector in a given cell line and properties of the resulting molecule.
Concentration of MeVac expressed FmIL-12 and anti-PD-L1 was observed to accumulate
constitutively in the cell culture medium over the course of the experiment. As for both of
these vectors a peak of viral particles followed by a decline until the end of the experiment
was measured in the one-step growth curve, the transgene expression result suggests both
molecules to be relatively stable, allowing their accumulation during the experiment. In
contrast to these results, the expression of anti-CTLA-4 presented a peak with a decline at
the end of the experiment, consistent with the pattern of virus particle production in the
growth curve. Thus, anti-CTLA-4 appears to be less stable than FmIL-12 and anti-PD-L1.
MeVac-encoded mCD80-Fc and mGM-CSF appeared to be produced inefficiently in the tar-
get cell line, as the highest concentration for both was measured in the inoculum. In case of
MeVac-encoded mGM-CSF, this result is in line with the impaired replication of the vector.
In the case of mCD80-Fc encoding virus, replication was comparable to the other vectors. It
is therefore possible that other factors might play a role in the observed CD80-Fc expression
pattern, for instance, instability of the molecule or inefficient secretion from the infected
cells.
During vector characterization in vitro it was discovered that the untransduced MC38cea
cell line as well as the parental cell line MC38 constitutively express mIP-10 and its recep-
tor CXCR3. It has been recognized that in the context of human cancer, IP-10 can either
exert an anti-tumoral effects or support tumor growth and formation of metastasis245. This
controversy can possibly be explained by involvement of different splice forms of the IP-10
receptor CXCR3. Several studies in different human tumor types have indicated that up-
regulation of the CXCR3-A splice variant and down-regulation of the CXCR3-B variant on
tumor cells is associated with increased metastatic potential246, 247. However, in murine cells
no alternative CXCR3 forms are known248. Many studies in murine tumor models, including
MC38-derived models, have reported involvement of IP-10 in a variety of anti-tumor actions
through its support of immune cell recruitment or its angiostatic activities40, 249, 250, 251. Re-
ports of the pro-tumorigenic IP-10 properties in murine tumor models are scarce, but it
has recently been demonstrated that the CXCR3/IP-10 interaction in a B16-derived murine
melanoma tumor model is associated with increased metastatic potential252. It is possible
that CXCR3/IP-10 engagement also supports the tumorigenic properties of the MC38cea
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cell clone used in this study. Given this, the MC38cea model used in this study cannot be
considered suitable to evaluate the therapeutic potential of the MeVac encoding mIP-10.
Nevertheless, the in vitro characterization data suggested that the MC38cea tumor model
will be suitable for evaluation of the properties of all the other novel immunomodulatory
MeVac vectors.
5.3 Immunomodulation for Enhanced Efficacy of
Oncolytic Measles Virus
For identification of the most promising immunomodulation strategies in the context of
oncolytic measles virus, therapeutic potential of the novel MeVac vectors encoding im-
munomodulators, as well as their combinations was assessed in the fully immunocompetent
subcutaneous (s.c.) MC38cea murine tumor model. First, two screening experiments indi-
cated vectors encoding anti-PD-L1 and FmIL-12 to have the best therapeutic efficacy. In
a further head-to-head comparison of these most promising vectors, the FmIL-12 encoding
vector demonstrated a superior efficacy, reproducibly leading to complete tumor remissions
in 90% of the treated animals. Such a high rate of complete tumor remissions has never
been achieved in previous pre-clinical measles oncolysis studies in immunocompetent tumor
models226, 114, 104.
Based on its potent anti-tumor activities in different animal tumor models, IL-12 has
long been considered a candidate for application in cancer therapy253. Clinical translation,
however, has been hampered by the modest efficacy and high toxicities observed in early
clinical trials. However, given its robust immunostimulatory potential, the studies of IL-12
as a cancer immunotherapeutic have not been abandonded, with recent efforts being fo-
cused on finding approaches for more targeted administration strategies to minimize toxicity
and increase therapeutic efficacy. The challenge for IL-12 delivery lies in its heterodimeric
structure, as expression of both protein subunits, p35 and p40, at a comparable level in
the same cell is necessary for generation of the biologically active IL-12 molecule27. Several
oncolytic vectors encoding both IL-12 protein subunits separated by an internal ribosomal
entry site have been previously studied122, 121, 123. Administration of both IL-12 subunits
separately creates a potential for formation of p40 homodimers which are natural inhibitors
of IL-12 functions27. Generation of a biologically active single chain IL-12 has previously
been demonstrated to be feasible222. Furthermore, an optimally designed IL-12 fusion pro-
tein has been shown to have even more pronounced anti-tumor activity than the natural
heterodimeric molecule, which could be a result of an increased stability of the fusion pro-
tein or an increased affinity for the IL-12 receptor222. Thus, MeVac encoding a murine IL-12
fusion protein which was developed in this study presents a novel approach for a targeted
delivery of this potent cytokine.
The anti-tumoral effects of IL-12 have previously been demonstrated also in MC38-
derived murine tumor models. For instance, local administration of a recombinant IL-12
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(rIL-12) has been shown to suppress growth of intracutaneous MC38 tumors and systemic
rIL-12 administration has reduced formation of liver metastases254. Local IL-12 adminis-
tration with a non-replicating adenovirus (AdV) has demonstrated high efficacy in a s.c.
MC38 tumor model, leading to complete tumor remissions in 80% of the treated animals255.
Evaluation of the transgene expression kinetics from the MeVac vectors used in this study
revealed that a large amount of FmIL-12 produced during virus propagation remains present
in the virus preparations and is, therefore, administered with initial virus injections. Given
the known IL-12 therapeutic benefits in MC38-derived tumor models, an obvious question
was, whether the administration of FmIL-12 present in the virus suspension is sufficient for a
therapeutic effect. A further experiment including an FmIL-12 encoding MeVac vector with
an unmodified tropism which is, thus, not able to enter the MC38cea cells, revealed induction
of complete tumor remissions at a rate comparable to that of the targeted FmIL-12 encod-
ing MeVac. This result indicated that the FmIL-12 administered with the virus suspension
might be sufficient for the observed therapeutic effect and the de novo FmIL-12 production
from the transduced MC38cea cells and oncolytic effect might not be essential in this model.
Nevertheless, it must be noted that although the non-targeted vector is not able to mediate
an oncolytic effect, the virus suspension can still potently activate innate immune responses
which could contribute to the therapeutic effect. The administered virus suspension contains
a large amount of cellular debris and components of different stages of measles virus replica-
tion. Particularly important could be the presence of different RNA species that arise during
the virus replication cycle. These can be recognized by RIG-I-like receptors RIG-I (retinoic
acid-inducible gene I) and MDA5 (melanoma differentiation-associated protein 5)256, lead-
ing to a potent upregulation of I type IFN expression257. IFN-α induction could potentially
synergize with the immunostimulatory effects of IL-12, as demonstrated in the MC38 tumor
model before258. Thus, for a clear dissection of the relative contribution of the oncolytic
effect, immunostimulatory properties of FmIL-12 and the virus to the therapeutic efficacy,
a further comparison of a recombinant FmIL-12, a non-replicating MeVac and a replicating
MeVac encoding FmIL-12 would be needed.
An important concern regarding any new therapeutic approach is safety. After intra-
tumoral injections of MeVac encoding FmIL-12, a peak of FmIL-12 concentration could be
observed also in peripheral blood of the treated animals. However, the highest peripheral
FmIL-12 dose assessed in this experiment, 66 ng/kg, would be relatively low in comparison
to the highest tolerated dose, 500 ng/kg, frequently reported in clinical studies with systemic
IL-12 administration32, 33. Therefore, this result indicates a rather insignificant leakage of
FmIL-12 into the periphery after a local administration with the MeVac vector. However, the
impaired measles replication in murine cells and, consequently, the relatively low de novo pro-
duction of FmIL-12 in vivo must be noted here. It is possible that FmIL-12 leakage into the
periphery might be an issue in a clinical situation where FmIL-12 production would increase
as the virus would have the ability to constitutively replicate into tumor cells. Further vector
optimization strategies could be applied to avoid this. First, the transcription gradient in
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the measles genome151 offers a possibility to modulate the amount of protein produced from
an inserted transgene cassette. Thus, the amount of FmIL-12 produced by the transduced
cells could be reduced by inserting the FmIL-12 cassette further downstream in the MeVac
genome. Second, a system providing a control of virus replication could be introduced in the
vector. A feasible approach for conditional control of measles virus replication has previously
been developed using artificial riboswitches based on aptazymes259. Aptazymes consist of a
ribozyme, a self-cleaving RNA sequence and an aptamer, a ligand binding RNA domain260.
Upon binding of the aptamer-specific ligand, the catalytic activity of the ribozyme can be
activated260. Thus, insertion of an aptazyme sequence into the measles genome provides an
opportunity to induce conditional cleavage of the virus genome by providing the respective
aptamer ligand. Ketzer et al. demonstrated that activation of aptazyme sequences flanking
the measles F gene results in inhibition of measles virus gene expression, replication and
spread259. Furthermore, since the aptazyme sequences are relatively short, around 100 bp,
insertion of this safety system should not considerably attenuate the vector259, and, thus,
should be compatible also with recombinant vectors already carrying such large transgene
inserts as the IL-12 fusion protein.
Although MeVac encoding PD-L1 was less efficient than the FmIL-12 encoding vector,
it also demonstrated a slight therapeutic benefit over the control vector in terms of the fre-
quency of induced complete tumor remissions. Measles encoding anti-PD-L1 was previously
studied in the aggressive murine melanoma B16-CD20 model, where the anti-PD-L1 encod-
ing vector treatment extended survival of animals in comparison to control vector, but no
complete tumor remissions could be achieved104. Therefore, in comparison to the study in the
B16-CD20 model, the MC38cea model appears to be more manageable with measles virother-
apy. Both MC38- and B16-derived tumor cells, have previously been reported to express
PD-L1261, 262. Thus, both models theoretically represent favorable targets for PD-1/PD-L1
blockade. In a clinical situation, the PD-L1 expression in the tumor microenvironment was
revealed as an indicator for a response to the PD-1/PD-L1 blockade already in one of the
first clinical studies using the PD-1 blocking antibody nivolumab263. Consequently, a lot of
effort has been invested in the development of a reliable test for PD-L1 expression to identify
patients with the highest chances of benefit from this therapeutic approach264. An immuno-
histochemistry test to accompany the decision for application of PD-1/PD-L1 blockade in
non-small-cell lung cancer and melanoma has been approved by the U.S. FDA71. However,
it must be noted, that stratification of patients for PD-1/PD-L1 blockade according only
to PD-L1 expression most probably cannot be considered an absolute measure. There are
still many other immune checkpoints and factors that could contribute to resistance against
PD-1/PD-L1 blockade265. Since only slightly more than half of the animals with MC38cea
tumors responded to MeVac encoding anti-PD-L1, this model would be interesting for further
study of factors determining resistance to the PD-L1 checkpoint blockade.
In some tumor types PD-L1 expression can be driven by constitutively active oncogenic
signaling pathways65. In other cases PD-L1 expression on the tumor cell surface can be
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induced as a result of an active immune response, in particular in response to IFN-γ, a
mechanism that is known as adaptive immune resistance44. It has been demonstrated that,
upon treatment with IFN-γ, PD-L1 expression is upregulated also in MC38- and B16-derived
cell lines266, 262. Thus, an increase of PD-L1 expression on the tumor cell surface would be
expected during treatment with IL-12, which is a well-known inducer of IFN-γ production27.
The synergy of PD-1 blockade and an IL-12 encoding Semliki Forest virus vector has been
demonstrated in a B16-OVA tumor model231. Given these results, therapeutic efficacy of
the combination of MeVac vectors encoding anti-PD-L1 and FmIL-12 was also examined.
However, synergistic effects could not be observed either in the MC38cea, or the B16-CD20
tumor model. The FmIL-12 encoding vector in combination with a control vector demon-
strated slight therapeutic benefit over the combination with the anti-PD-L1 encoding vector
in both models. It is possible that the therapeutic efficacy of the combination strategy could
be greatly influenced by the administration schedule. Based on the proposed mechanism
of synergy, a sequential treatment schedule with administration of the FmIL-12 encoding
vector followed by application of the anti-PD-L1 encoding MeVac could be advantageous.
It would be expected that treatment with the FmIL-12 encoding vector leads to strong im-
mune activation, inducing IFN-γ production and increasing PD-L1 expression on the tumor
cell surface. The following PD-L1 signaling blockade would antagonize the remaining im-
mune suppression. For optimization of the treatment schedule, an experiment assessing the
PD-L1 increase on the tumor cells following treatment with MeVac encoding FmIL-12 over
time would have to be carried out. After identification of the optimal treatment schedule
this combination might offer therapeutic advantages, especially in tumor types that do not
respond well to MeVac encoding FmIL-12 alone.
Due to the observed limited efficacy in the initial screening experiments, the poten-
tial therapeutic value for other previously developed MeVac vectors encoding anti-CTLA-4,
mCD80-Fc, mGM-CSF and mIP-10, as well as the initially examined vector combination
strategies, was not further assessed. However, efficacy of these vectors in the current study
was compared in only one tumor model. The efficacy of a particular immunovirotherapeutic
approach is expected to depend on interactions between the immunostimulatory properties
of the used oncolytic vector, the chosen immunomodulation type and the immune environ-
ment of the particular tumor. Therefore, in tumors with different immune signatures than
the MC38cea, MeVac vectors encoding anti-CTLA-4, mCD80-Fc, mGM-CSF or mIP-10
might offer therapeutic benefits. To this end, the developed panel with MeVac encoding
immunomodulators can be considered a flexible platform which could be used for targeted
delivery of immunomodulators most suitable for treatment of a certain type of malignancy.
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5.4 Immune Effector Mechanisms in Measles
Immunovirotherapy
Challenge of the long-term survivors of MeVac therapy with the tumor cells used in initial
tumor implantations demonstrated establishment of a protective long-term immune response
in most of the treated animals. The anti-tumor vaccination effect following MV immunovi-
rotherapy has been demonstrated before114. Further in vitro restimulation experiments
showed a higher IFN-γ production by splenocytes from mice treated with MeVac encoding
FmIL-12, indicating a larger or more potent immune memory response. This result would be
in line with the previously reported enhanced memory T cell survival in presence of IL-12267.
To further explore the immune effector mechanisms associated with response to MeVac ther-
apy in detail, analyses of the tumor immune micorenvironment following treatment were
performed. Previous studies of measles vectors in immunocompetent murine tumor models
have focused on few immunological parameters and highlighted the role of T cell responses.
An increase of CD3+ T cells in the tumor and invasive margin of the MC38cea tumors has
been observed after treatment with an mGM-CSF encoding measles vector114. Increase in
the total amount of T cells and decrease in the amount of Treg cells has been demonstrated in
B16-CD20 tumors after treatment with measles encoding anti-CTLA-4 and anti-PD-L1104.
In the present study, intratumoral cytokine profiling, analyses of the main intratumoral im-
mune cell subpopulations and their activation status as well as validation of the contribution
of the immune effector cells to the therapeutic efficacy of measles immunovirotherapy were
carried out. Thus, this is the first study providing a broader overview of the immune effector
mechanisms associated with measles immunovirotherapy.
Two separate experiments were performed to assess the impact of treatment with MeVac
encoding FmIL-12 and anti-PD-L1 on the tumor immune environment. It was expected that
MeVac-expressed FmIL-12 would exert its effect early after the expression due to the known
IL-12 ability to directly stimulate immune effector cells27. Thus, the effects of FmIL-12
encoding MeVac were examined 24 h after the last treatment (“early”). In contrast, the
impact of MeVac encoding anti-PD-L1 was examined four days after the last treatment
(“late”). The effects observed in the “early” experiment seemed mainly associated with
the actions of the MeVac-encoded FmIL-12, as the changes in T-bet mRNA level, cytokine
profile and the amount and activation status of TIL subpopulations were observed only in
the group receiving treatment with the FmIL-12 encoding vector, but not in both control
groups. In the “late” experiment changes in immunological parameters were observed in both
groups that received treatment with MeVac vectors, the anti-PD-L1 as well as the control
IgG1-Fc group, but not in the mock group, suggesting also vector-mediated immunostimu-
latory effects. The most significant change in cytokine profile after treatment with MeVac
encoding FmIL-12 was an increase in IFN-γ and TNF-α concentration. These changes in
the cytokine profile are in line with the well-known ability of IL-12 to induce IFN-γ and
TNF-α expression, mainly from NK and T cells27. Consistently, also an increase of T-bet
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mRNA level was observed after treatment with MeVac encoding FmIL-12. Taken together
these results indicate polarization towards a Th1-associated immune response, which is also a
well-described characteristic of IL-1227. Notably, in the “early” experiment a slight increase
in IL-6 concentration was observed in both virus treatment groups, which could represent
an acute inflammation induced by application of the MeVac vector. It is possible that also
infected tumor cells are among the IL-6 producers in the given model. It has been demon-
strated that IL-6 is among the cytokines released from measles-infected human mesothelioma
and melanoma cells239, 241. In the “late” experiment, an increase in the mRNA level of the
Th1 response-associated T-bet was observed in both groups receiving virus treatment with
no significant differences between the anti-PD-L1 and control vectors. Given that in the
“early” experiment no increase in T-bet mRNA level could be observed after treatment with
the control vector, the increase in “late” experiment in both treatment groups could be
associated with activation of adaptive immune cell responses as a result of oncolysis. Al-
though one of the best-known functions of T-bet is to determine CD4+ T cell differentiation
towards a Th1 phenotype, this transcription factor is also involved in regulation of many
more immunological processes, including regulation of development and effector functions
of innate immune cells268. Thus, the increase of T-bet mRNA level alone only indicates
activation of an immune response following MeVac treatment, but the specific meaning of
this result needs to be considered in the context of the TIL subpopulation analysis that will
be discussed further.
After treatment with the FmIL-12 encoding MeVac, a decrease in the total amount of
NK cells and an increase of the early activation marker CD69 on the remaining NK cell
population was observed. IL-12 was initially discovered as an NK cell stimulatory factor269.
The ability of IL-12 to stimulate human NK cell responses, inducing expression of activa-
tion markers, including CD69, and increasing the target cell killing capacity has often been
reported subsequently270, 271 272. It is possible that the observed decrease in the NK cell pop-
ulation following treatment with MeVac encoding FmIL-12 was caused by NK cell death due
to powerful direct IL-12 stimulation. It is known that a prolonged exposure of human NK
cells to IL-12 in vitro in combination with IL-2 or IL-15 induces cell death, with higher IL-12
concentrations causing apoptosis in a higher number of NK cells273. This effect is considered
a control mechanism for excessive NK cell activation273.
The total number of intratumoral T cells increased after treatment with MeVac en-
coding FmIL-12. This could result either from proliferation of T cells within the tumor
or from de novo T cell infiltration. Involvement of both mechanisms would be plausible.
Although tumor-infiltrating T cells become functionally suppressed, most of them have been
pre-activated and would express the IL-12 receptor274. Therefore, IL-12-induced T cell pro-
liferation should be possible. No significant differences were observed between treatment
groups in the amount of CD4+ and CD8+ T cell subpopulations from the amount of all T
cells. Thus, the extent of the induced proliferation on the CD4+ and CD8+ T cells should
have been similar in this experiment. This is in agreement with similar IL-12R expression
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level on activated CD8+ and CD4+ T cells274. Recruitment of novel T cells to the tumor site
following treatment with MeVac encoding FmIL-12 could be supported by the chemokines
IP-10 and Mig, which are expected to be upregulated in response to IFN-γ which is induced
by IL-12275. Both chemokines are known to attract cells expressing the specific receptor
CXCR3, mainly activated T and NK cells275. It has been demonstrated that blockade of
IP-10 and Mig in the murine renal adenocarcinoma model, RENCA, dramatically reduces
the amount of CD8+ T cell infiltration observed after systemic treatment with recombinant
IL-12276. However, further experiments are needed to assess if this mechanism is relevant in
the model used in this study.
As the TIL subopulation analysis indicated activation of both NK and T cell popula-
tions, both could contribute to therapeutic efficacy of MeVac encoding FmIL-12. Depletion
experiments revealed that the NK and CD4+ T cell subpopulations do not significantly in-
fluence therapeutic efficacy of MeVac encoding FmIL-12, but that the CD8+ T cells are
essential. Discrepant results have been reported regarding the relative contribution of the
TIL subpopulations to the therapeutic efficacy of IL-12 in pre-clinical tumor models. The
essential role of the CD8+ subpopulation, but not CD4+ or NK cells, for efficacy of IL-12 has
been reported in a B16F10 murine melanoma model253. In contrast, both CD8+ and CD4+ T
cell subpopulations have been shown to contribute to IL-12 efficacy in a methycholanthrene-
induced murine sarcoma model, MCA-207277. Furthermore, NK cell activity has been shown
to be important for the therapeutic effect of IL-12 in a B16 lung metastasis model28. These
discrepancies can most probably be explained by differences in the dose, treatment schedule
and the used tumor model. Smyth et al. demonstrated that in the B16F10 lung metastasis
model the therapeutic effect of high-dose IL-12 relied on the activity of NK cells, while at
low doses the relevance of NKT cells increased278. The present study did not specifically
assess the effects of NKT cells. It was also suggested that the importance of an immune cell
population to the therapeutic efficacy of IL-12 is determined by its overall contribution to
tumor control in a given model278. Along this line, it could be hypothesized that the critical
role of CD8+ T cells in this model is determined by the central role of T cells in the control
of MC38 tumors. Furthermore, also the immunostimulatory effects of the vector and the
oncolytic effect might contribute to the mechanism of action of MeVac encoding FmIL-12,
adding a further layer of complexity.
In the “late” experiment, an increased T cell amount was observed in both MeVac
treatment groups, with a slightly higher increase in the MeVac anti-PD-L1 group. This
result indicates that treatment with MeVac without an immunomodulator is sufficient for
intratumoral T cell expansion or attraction with, as expected, a slight benefit for the anti-
PD-L1 group. The restoration of T cell activity and proliferation following PD-1/PD-L1
blockade is well-known and has been demonstrated for human and murine T cells279, 280.
Since a slightly increased amount of IFN-γ was also observed in the anti-PD-L1 group as
discussed before, it is possible that T cell attraction through upregulation of IFN-γ-induced
chemokine expression was also involved. It has indeed been shown that IP-10 determines
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increased trafficking of adoptively transfered T cells into tumor following PD-1 blockade in
a B16 tumor model249. Notably, a higher amount of intratumoral T cells in the anti-PD-L1
group correlated with a larger decrease in tumor volume. Increased intratumoral CD8+ T
cell proliferation and amount is known to be associated with tumor regressions also in a
clinical situation281. However, a decrease was observed in the amount of activated CD8+ T
cells in both virus treatment groups in the “late” experiment. This could reflect T cell death
in the contraction phase of the T cell response which follows target cell killing282. Only
small amount of T cells survive the contraction phase and form the memory T cell pool282.
As mentioned before, it must be noted that the differences in the amount of intratumoral
T cells after treatment with the control and anti-PD-L1 encoding MeVac vectors were not
significant. Activation of T cell responses after treatment with the control vector is probably
mostly associated with enhanced T cell priming as a result of immunological cell death of
infected tumor cells239.
In the “late” experiment, decreased amount of NK cells in comparison to mock treated
animals was observed after treatment with the control vector and an even slightly greater
decrease in the MeVac anti-PD-L1 group. In the MeVac anti-PD-L1 group, a lower amount
of NK cells also correlated with a greater decrease in tumor volume during the treatment.
This correlation was in a striking contrast to the mock treated animals where a lower amount
of NK cells correlated with a larger increase of tumor volume. However, it must be noted
that the NK and T cell populations were quantified as a percentage of the CD45+ cells and
an increase in one of them, would cause a decrease in the other one or vice versa. Since
the degree of the decrease in NK cell population was comparable to the increase in T cell
population, it is possible, that these results just reflect the relative change in one of these
populations in comparison to the other. However, with only these results, it is not possible
to explicitly determine which, the increase of the T cell amount or decrease of the NK cell
amount, is responsible for the observed effect. It is possible that NK cells contribute to the
control of tumor growth in the untreated animals, become activated after treatment with
MeVac, gaining a greater target cell killing capacity, but eventually undergo cell death after
completion of their effector functions. It has been demonstrated that activated NK cells
can engage in serial target cell killing283, but this capacity is most probably not unlimited.
Furthermore, there are also data demonstrating induction of apoptosis in activated NK cells
after engaging in their cytolytic function284, 285. Since recognition and destruction of virus-
infected cells is one of the main functions of NK cells286, solely the infection of the tumor
cells by MeVac could trigger their activation. This could explain the decrease of NK cell
numbers observed also in the control vector group. NK cells can recognize virus-infected cells
via several mechanisms, including recognition of MHC-I (major histocompatibility complex
I) class molecule downregulation on the surface of the infected cell, recognition of virus
proteins through natural cytotoxicity receptors, recognition of stress-induced ligands through
the NKG2D receptor and direct stimulation of TLR receptors on the surface of NK cells by
virus associated pathogen-associated molecular patterns286. If some of these mechanisms are
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relevant in the model used in this study should be assessed in further experiments. A trend
for a greater decrease in the amount of NK cells in the anti-PD-L1 group compared to the
IgG1-Fc group suggested that PD-L1 blockade could also be of a slight benefit for NK cell
activation. The PD-1/PD-L1 axis has indeed been shown to be relevant in regulation of NK
cell functions in the context of human multiple myeloma287. Clear dissection of the relative
contribution of T cells and NK cells to the therapeutic efficacy of the anti-PD-L1 encoding
vector would be possible in further immune cell depletion experiments.
The MC38cea tumor model used in this study has a specific immunological signature.
It was observed that tumors from animals in the mock group contain large amount of T and
NK cells, thus, suggesting an immunogenic environment under immunosuppression. Data
obtained in this study allow to propose a model in which the MeVac expressed FmIL-12
strongly activates the pre-existing tumor infiltrating immune effector cells, counteracting
the immunosuppressive signaling and inducing rapid killing of the surrounding tumor cells.
Therefore, tumors with similar immunological signatures as the MC38cea could be expected
to respond well to treatment with MeVac encoding the IL-12 fusion protein.
5.5 Translational Potential
This study revealed the potential to significantly increase therapeutic efficacy of oncolytic
MeVac vectors in combination with immunomodulators in a murine tumor model. In par-
ticular, MeVac encoding FmIL-12 demonstrated great efficacy in terms of complete tumor
remissions. Yet, the ultimate goal of the research of novel strategies for cancer treatment
is, of course, not the treatment of a murine, but a human disease. It is a disturbing fact
that most of the novel cancer therapeutics demonstrating promising effects in murine tu-
mor models, fail in clinical trials and never reach approvement for clinical use288. There
are many factors contributing to this unsettling statistic, including the burden of regula-
tory and financial issues, but frequently the cause of a failure is incompatibility of the used
pre-clinical model with the clinical situation. Testing of novel treatment strategies in vivo
is mandatory for initial assessment of safety and efficacy, but one must be aware of the
fact that the broadly used murine tumors models differ from situation in cancer patients
in many important aspects. These can include: age of the subject — use of young mice
in contrast to mostly elderly human cancer patients; minimal individual variation — use of
inbred mouse strains; time frame — use of tumor models that develop a malignancy within
days in contrast to human cancer development over decades; tumor microenvironment —
use of subcutaneous tumor models that can not be compared with physiology of tumors
arising in organs other than skin; immunobiology — differences between mice and humans
in functions of some components of the immune system. These limitations must be kept in
mind when interpreting the data obtained in this study in terms of implications for further
clinical development of MeVac encoding IL-12 fusion protein.
The biology of murine and human IL-12 does not differ significantly, with IL-12 from
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both species being involved in activation and enhancement of the cytotoxic potential of T
and NK cells27. The identity of murine and human IL-12 is 60% for the p35 protein subunits
and 70% for p40 protein subunits289. Furthermore, it has even been demonstrated that
mouse IL-12 remains active in human cells, but that human IL-12 is not active in murine
cells289. Nevertheless, given the differences in the protein sequence of IL-12 between both
species and the possibility for unknown interactions, the use of MeVac encoding FmIL-12
in a human system would not be desirable. Thus, a MeVac vector encoding a human IL-12
fusion protein (FhIL-12), which was constructed based on a previous study by Lieschke et
al.222, was generated. Insertion of FhIL-12 in genome positions downstream of the MeVac P
or H gene was demonstrated to be feasible. Replication and cytotoxic potential of the novel
vectors were not significantly affected. Expression of FhIL-12 from the inserted transgene
cassette could also be demonstrated. With these experiments an appropriate vector for
further clinical development of the oncolytic measles virus encoding an IL-12 fusion protein
has been generated. However, further functional in vitro and in vivo experiments would be
needed to further pursue a plan for clinical translation.
Most of the experiments performed in this study were carried out using the murine
colorectal adenocarcinoma model. However, as mentioned before, the subcutaneous model
used here can not be considered to reflect properties of human colorectal cancer (CRC).
Although currently no clinical studies for use of MV vectors in CRC therapy have been
performed, some pre-clinical data suggest that CRC could be a potential target for oncolytic
MV therapy290. To further examine CRC as a target for the vector used in this study, five
different human CRC cell lines were characterized for expression of MV receptors. Further,
replication kinetics and cytotoxic properties of the parental MeVac vector used in this study,
as well as the Edmonston B derived vaccine strain derived vector (NSe), used in most of the
current clinical studies with oncolytic MV, were assessed in these CRC cell lines. The main
MV receptor CD46 was expressed on all the cell lines, although the expression levels slightly
differed. Furthermore, three of the cell lines were found to be positive for the epithelial MV
receptor Nectin-4 on mRNA level. As expected based on the determined expression of CD46
by all of the cell lines, they were all susceptible to infection with MeVac and NSe viruses.
However, further experiments revealed that vector replication efficiency and cytotoxicity
differs between the cell lines and between the vectors. The available data set is not large
enough to draw any strong conclusions about the correlations of MV receptor expression with
the replicative or cytotoxic potential of the vectors or efficiency of virus particle production
and cytotoxic properties. Nevertheless, it could be distinguished, that receptor expression
is not the only factor influencing the cells’ susceptibility to MV infection. For instance, the
HT-29 cell line which was found to have one of the highest CD46 expression levels of the
tested cell lines and was also positive for nectin-4 on mRNA level, had the lowest decrease in
cell viability after infection with both MV vectors, but it was not the cell line with the lowest
viral particle production in the one-step growth curve. Differences, mainly in virus particle
production efficiency, were detected also between the two vectors, with MeVac reaching lower
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titers in most of the cell lines compared to the NSe vector. These data suggest that it would
be of further interest to systematically assess the properties of MeVac and NSe vectors in
different human CRC cell lines to identify host cell factors influencing replication efficiency
and cytotoxic properties. For such an analysis the U.S. National Cancer Institute 60 human
cancer cell line panel (NCI60), which includes comprehensively characterized cancer cell
lines, could be of interest291. Four of the CRC cell lines used in this study are included in
the NCI60. The replication efficiency and cytotoxic properties of MeVac and NSe vectors
could be screened on all seven of the NCI60 panel CRC cell lines and correlations with the
available gene and protein expression data could be performed. Such experiments could give
valuable indications about intrinsic host cell factors associated with efficacy of oncolytic MV
that could be used for selection of therapy targets and further vector modifications.
5.6 Conclusions and Outlook
This study compared advantages of different immunomodulation strategies in combination
with oncolytic MV. Novel MV vectors encoding six different immunomodulators to support
different phases in the establishment of an anti-tumor immune response were generated based
on the measles Schwarz vaccine strain vectors (MeVac). In vitro characterization demon-
strated that after transduction of the target cells with the novel MeVac vectors the encoded
immunomodulators are expressed and maintain their functionality. MeVac vectors, which
are more immunogenic than the Edmonston B derived MV used in previous measles oncoly-
sis studies, have not previously been engineered for expression of immunomodulators. Thus,
with the novel recombinant MeVac vectors the armamentarium of available immunomodula-
tory MV vectors has been significantly expanded. Therapeutic efficacy of the immunomod-
ulatory MeVac vectors was evaluated in vivo in a fully immunocompetent murine colon
adenocarcinoma model. MeVac encoding an antibody against murine PD-L1 (anti-PD-L1)
and a murine IL-12 fusion protein (FmIL-12) were identified as the most promising among
the novel vectors in terms of extended survival of animals. MeVac encoding FmIL-12 demon-
strated the highest therapeutic efficacy, inducing complete tumor remissions in 90% of the
treated animals. MeVac treatment induced a systemic anti-tumor immune response in most
of the long-term survivors of the therapy, as demonstrated by tumor engraftment rejec-
tions after tumor rechallenge. To analyze immune effector mechanisms contributing to the
therapeutic efficacy of the MeVac encoding anti-PD-L1 and FmIL12, analysis of the tumor
immune microenvironment following treatment was performed. Analysis four days after the
last treatment indicated that MeVac encoding anti-PD-L1 slightly enhances beneficial mod-
ulation of the tumor immune environment by supporting activation of cell-mediated immune
responses. In contrast, strong modulation of the tumor immune environment was observed
after treatment with MeVac encoding FmIL-12, as determined 24 h after the last treatment.
Activation of cell-mediated immune responses was indicated by an increase of the concentra-
tion of effector cytokines IFN-γ and TNF-α, as well as an increase in the intratumoral T cell
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amount and activation status and activation of NK cells. Immune cell depletion experiments
revealed that the cytotoxic CD8+ T cell subpopulation is essential for therapeutic efficacy
of the MeVac encoding FmIL-12, while CD4+ T cells and NK cells did not appear to be
crucial in the given model. The obtained data suggest MeVac encoding FmIL-12 as an effec-
tive therapeutic in tumors with high immune effector infiltration under immunosuppression.
However, tumors with different immune signatures might benefit from other immunomodu-
lation types and, thus, require vectors encoding other immunomodulators from the MeVac
vector panel developed in this study.
Based on the results of this study, rational development of measles immunovirotherapeu-
tic strategies is continued. A study to assess the properties of MeVac encoding murine IL-15
has been started (L. Hartmann, R. Veinalde, C. E. Engeland, unpublished). This project is
based on the hypothesis that MeVac encoding the cytokine IL-15 could be more beneficial
than the IL-12 encoding vector in tumors with lower immune effector infiltration. In contrast
to FmIL-12, along with the activation of immune effector cells, IL-15 is expected to have a
proliferative effect, particularly on NK cells292. The immunomodulatory effects of MeVac
encoding FmIL-12 and MeVac encoding IL-15 will be compared by performing an analysis of
the tumor immune environment post treatment, similarly as described in this study. Thera-
peutic efficacy of both vectors will be compared in the MC38cea tumor model and in a less
immunogenic tumor model. With regards to MeVac encoding anti-PD-L1, since only slightly
more than a half of the animals responded to the therapy in this PD-L1 positive MC38cea
tumor model, it could be used to further study mechanisms associated with resistance to
the PD-L1 blockade therapy. Furthermore, the therapeutic efficacy and immunostimulatory
properties of MeVac encoding anti-PD-L1 analyzed in this study, should be compared with
MeVac encoding anti-PD-1, which is a clinically more widely used approach for PD-1/PD-L1
blockade (C. E. Engeland, R. Veinalde, unpublished). Importantly, to facilitate further clini-
cal translation, development of mouse models with a humanized immune system for studies
of safety and efficacy of the immunomodulatory measles vectors, particularly MeVac encod-
ing the human IL-12 fusion protein, would be needed. Lastly, the MeVac vector system
can be envisioned as a flexible platform to allow targeted delivery of immunomodulators
based on the immune signature of the individual tumor. To approach this, tumor immune
profiling following oncolytic measles immunovirotherapy, similar as described in this study,
should be included in future clinical studies. Importantly, such an analysis of tumor immune
environment will be included in a Phase I clinical trial for oncolytic measles virus which is
currently in preparation in the National Center for Tumor Diseases in Heidelberg, Germany.
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Figure A.1: One step growth curves in Vero-αHis cells. Cells were infected with
MeVac encoding the respective transgenes at a multiplicity of infection = 3 and fluorescence
microscopy images were taken at the depicted time points. Scale bars 100µm.
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Figure A.2: One step growth curves in Vero-αHis cells. Cells were infected with
MeVac encoding the respective transgenes at a multiplicity of infection = 3 and fluorescence
microscopy images were taken at the depicted time points. Scale bars 100µm.
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Table A.1: Results for complete genome sequencing of MeVac GM-CSF
Hbl-antiCEA. ORF — open reading frame; H — measles hemagglutinin; F — measles
fusion protein; L — measles polymerase.
Position Region of genome Change Type of change
7812
Intergenic region between
F ORF and H ORF
A>G Change in a non-coding region
8875 H ORF C>T Silent mutation
10075
Intergenic region between
H ORF and L ORF
G>A Change in a non-coding region
10129
Intergenic region between
H ORF and L ORF
A>G
Change in a non-coding region
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Figure A.3: Assay for detection of the presence of defective interfering particles
(DIs). Total RNA was isolated from virus suspensions and RT-PCR analysis was carried
out for detection of DIs as described by Pfaller et al.230. 1 — MeVac Hbl-αCEA (VHp4),
2 — MeVac ld-mGM-CSF Hbl-αCEA (VHp4), 3 — MeVac ld-FmIL-15 Hbl-αCEA (VHp3),
4 — MeVac P-FmIL-12 Hbl-αCEA (VHp4), 5 — MeVac ld-eGFP Hbl-αCEA (VHp4), 6 —
MeVac ld-FmIL-15 Hbl-αCEA (VHp4). First six sample lines from the left were amplified
with two negative polarity primers A1SnaBI /A2NotI for DI specific amplification, second
six sample lines were amplified with a negative and positive polarity primers A1SnaBI /B1
as cDNA input controls. VHp3, VHp4 — third and fourth passage on Vero-αHis cells,
respectively; FmIL-12 — murine IL-12 fusion protein; FmIL-15 — murine IL-15 agonist.
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Figure A.4: Expression of MeVac encoded anti-PD-L1 and IgG1-Fc. Supernatants
were collected from Vero-αHis cells infected with MeVac encoding anti-PD-L1 (aP) and
IgG1-Fc (IgG) and western blot analysis was carried out. DMEM+10% FCS was used as a
negative control (N).
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Figure A.5: RT-PCR for murine Ip-10 (Cxcl10 ) and Cxcr3 in MC38, MC38cea
and B16 cell lines. RT-PCR for murine Cxcl10, Cxcr3 genes and Gapdh as a loading con-
trol was carried out using cDNA from the indicated cell lines. cDNA from murine splenocytes
activated with PMA and ionomycin served as a positive control. +RT — cDNA samples;
−RT — minus reverse transcriptase controls; NTC — no template control; Act. splen. —
activated splenocytes.
Figure A.6: Functionality of MeVac encoded mIP-10. Resting splenocytes or spleno-
cytes stimulated with a recombinant murine IL-2 were added in the upper part and super-
natants collected from Vero-αHis cells infected with MeVac encoding mIP-10 or eGFP in
the lower part of a transwell insert. Splenocyte migration was allowed for 3 h in 37◦C 5 %
CO2 incubator. Cells in the lower part of the chamber were counted using a hemocytometer
and Trypan Blue for dead cell exclusion. Mean values from three to four counts per sample
with standard errors of the mean are shown. Results were compared using Mann-Whitney
U test.
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Figure A.7: Individual tumor volume dynamics in the experiment comparing
MeVac encoding immunomodulators targeting the immunosuppressive tumor
environment. MC38cea cells were implanted subcutaneously (s.c.) into the right flank of
C57BL/6J mice (6 – 9 animals per group). When tumors reached an average volume of
70 mm3 mice received intratumoral injections with 1×106 ciu or with MeVac vectors encod-
ing the respective transgenes on four consecutive days in 100µl virus suspension with carrier
fluid (OptiMEM). Mice in the mock group received i.t. injections with 100µl OptiMEM.
Tumor volume dynamics for individual animals are shown. ciu — cell infectious units.
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Figure A.8: Individual tumor volume dynamics in the experiment comparing
MeVac encoding immunomodulators targeting antigen presenting cell and ef-
fector cell responses. MC38cea cells were implanted subcutaneously (s.c.) into the right
flank of C57BL/6J mice (6 – 9 animals per group). When tumors reached an average volume
of 40 mm3 mice received intratumoral injections with 5×105 ciu with MeVac vectors encod-
ing the respective transgenes on five consecutive days in 100µl virus suspension with carrier
fluid (OptiMEM). Mice in the mock group received i.t. injections with 100µl OptiMEM.
Tumor volume dynamics for individual animals are shown. ciu — cell infectious units.
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Figure A.9: Individual tumor volume dynamics in the experiment comparing
MeVac encoding FmIL-12 and anti-PD-L1. MC38cea cells were implanted subcuta-
neously into the right flank of C57BL/6J mice (10 animals per group). When tumors reached
an average volume of 40 mm3 mice received intratumoral (i.t.) injections with 1×106 ciu of
viruses encoding the respective transgenes on four consecutive days in 100µl virus suspension
with carrier fluid (OptiMEM). Mice in the mock group received i.t. injections with 100µl
OptiMEM. Tumor volume dynamics for individual animals are shown. ciu — cell infectious
units
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Figure A.10: Therapeutic efficacy of FmIL-12 and anti-PD-L1 encoding MeVac
combination. MC38cea (a) or B16-CD20 (b) cells were implanted subcutaneously into
the right flank of C57BL/6J mice (7 – 10 animals per group). When tumors reached an
average volume of 40 mm3 mice received intratumoral (i.t.) injections with 1×106 ciu of
targeted viruses (Hbl-αCEA in a or Hbl-αCD20 in b) encoding the respective transgenes
on four consecutive days in 100µl virus suspension with carrier fluid (OptiMEM). Mice in
the mock group received i.t. injections of 100µl OptiMEM. Tumor volume distribution on
day 13 (a) or day 15 (b) post implantation with median in each group and Kaplan-Meier
analysis are shown. Dots represent individual mice. Complete tumor remission rates are
shown in Kaplan-Meier plots. ciu — cell infectious units.
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Figure A.11: IFN-γ memory recall in long-term survivors of MeVac FmIL-12 and
anti-PD-L1 combination treatments. Splenocytes were collected from the animals two
weeks after a rechallenge with MC38cea cells, stimulated with recombinant murine IL-2 and
cocultivated with MC38cea cells (a) or MC38 and B16 cells and Vero-αHis cell lysate (b)
for one mouse from each group at a ratio 10:1. Supernatants were collected after 48 h and
IFN-γ concentration measured by ELISA. Dots representing individual mice and median in
each group are shown in a. Mean values with standard errors of the mean from two replicate
measurements per sample are shown in b
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Figure A.12: RNA integrity test. MC38cea cells were implanted subcutaneously into
C57BL/6J mice. When tumors reached an average volume of 120 mm3 or 100 mm3 mice
received intratumoral treatment with MeVac encoding murine IL-12 fusion proteim, antibody
against murine PD-L1 or antibody constant region IgG1-Fc. Mice in the mock group received
i.t. injections with a respective amount of OptiMEM. Tumors were explanted one or four
days after the last treatment. A part of the tumor was stored in an RNA stabilization reagent
(RNAlater) and total RNA was isolated subsequently. The RNA integrity was assessed by
loading 300 ng RNA on 1% agarose gel. Numbers denote the individual samples.
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Figure A.13: Validation of reference genes for reverse transcription quantita-
tive PCR (RT-qPCR) analysis. MC38cea cells were implanted subcutaneously into
C57BL/6J mice. When tumors reached an average volume of 120 mm3 (a) or 100 mm3 (b)
mice received intratumoral treatment with MeVac encoding the respective transgenes or the
respective amount of OptiMEM (mock). RT-qPCR analysis for different potential reference
genes was carried out using RNA from three tumors per group explanted one (a) or four (b)
days after the last treatment. Results were analysed using the NormFinder software219. The
gene having the lowest variation between conditions and samples was chosen for further use
as a reference.
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Figure A.14: Amplification and melting curves in RT-qPCR analysis of Foxp3
and T-bet mRNA levels. MC38cea cells were implanted subcutaneously into C57BL/6J
mice. When tumors reached an average volume of 120 mm3 (a) or 100 mm3 (b) mice received
intratumoral (i.t.) treatment with MeVac encoding murine IL-12 fusion proteim, antibody
against murine PD-L1 or antibody constant region IgG1-Fc. Mice in the mock group received
i.t. injections with a respective amount of OptiMEM. Reverse transcription quantitative PCR
(RT-qPCR) analysis for Foxp3, T-bet or L13a as a reference gene was carried out using RNA
from tumors explanted one or four days after the last treatment. Amplification curves (left
panels) and melting curves (right panels) for individual samples ar shown. +RT — cDNA
samples; −RT — minus reverse transcriptase controls.
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Figure A.15: Depletion efficiency of CD4+ T cells. Flow cytometry analysis of periph-
eral blood was carried out to assess the depletion efficiency of CD4+ T cells in selected mice.
a — example of ancestry gating for the plots in b. b — frequencies of the CD8+ and CD4+ T
cell populations for one selected animal on different time points prior to (day −3) and after
(day 3 and 9) subcutaneous implantation of MC38cea tumor cells. c — average percentage
with standard deviation of CD4+ cells from all T cells from two animals at different time
points.
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Figure A.16: Depletion efficiency of NK cells. Flow cytometry analysis of peripheral
blood was carried out to assess the depletion efficiency of NK cells in selected mice.
a — example of ancestry gating for the plots in b. b — frequencies of the NK and T cell
populations for one selected animal on different time points prior to (day −3) and after (day
3 and 9) subcutaneous implantation of MC38cea tumor cells. c — average percentage with
standard deviation of NK cells from all T cells from two animals at different time points.
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Figure A.17: Depletion efficiency of CD8+ T cells. Flow cytometry analysis of pe-
ripheral blood was carried out to assess the depletion efficiency of CD8+ T cells in selected
mice. a — example of ancestry gating for the plots in b. b — frequencies of the CD8+ and
CD4+ T cell populations for one selected animal on different time points prior to and after
subcutaneous implantation of MC38cea tumor cells (day 0). c — average percentage with
standard deviation of CD8+ cells from all T cells from two animals at different time points.
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Figure A.18: Validation of human colon cancer cell lines. Colon cell specific markers
in the respective cell lines were assessed by RT-PCR. +RT — cDNA samples; −RT — minus
reverse transcriptase controls; NTC — no template control.
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